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EXECUTIVE SUMMARY 
Colorectal cancer (CRC) is one of the most common cancers and is considered a 
highly lethal malignant tumour worldwide, with respect to its incidence and mortality 
rate (Bray et al., 2018). Early diagnosis of CRC can improve survival rate and be 
effectively cured (Simon, 2016). Current traditional diagnostic and treatment 
interventions for CRC such as colonoscopy, surgery, chemotherapy, and radiation, 
often have limitations, such as invasiveness, and are associated with various 
unwanted side effects (Mishra et al., 2013; Simon, 2016). As such, further research 
is required to enhance unconventional strategies, that can allow non-invasive 
diagnosis, alleviate adverse side effects, and offer improved treatment efficacies 
than when compared to conventional therapies.  
Unconventional diagnostic and treatment approaches, known as photodynamic 
diagnosis (PDD) and photodynamic therapy (PDT) are plausible candidates, since 
they offer a range of advantages which include minimal invasiveness, allow for 
multiple and repeatable dosages and with limited side effects (Naidoo et al., 2019). 
Furthermore, PDD and PDT innovative approaches can be localized and targeted 
to specific cancerous sites, to increase the specificity of this combinative diagnostic 
and therapeutic approach, without damaging normal surrounding tissues 
(Naidoo et al., 2019). Thus, PDD-PDT applications could likely allow for early CRC 
diagnosis, as well as serve as substitutes for chemotherapy and radiation, since 
they can be modified to target specific cancerous cells (Dos Santos et al., 2019). 
PDD is a diagnostic approach, which incorporates a photosensitizer (PS) and 
visible blue light to locally target tumours and is aimed at detecting malignant 
tumours and monitoring of PS accumulation within cancer cells prior to PDT 
treatment (Naidoo et al., 2019). The effect is achieved by the fluorescence emitted 
when a PS is activated with blue visible light (Naidoo et al., 2019). PDT is a 
clinically approved, tumour localizing unconventional treatment, which combines a 
photodynamic PS, laser light of a specific wavelength, and oxygen to exert 
selective cytotoxic destruction, on cancerous tissues (Agostinis et al., 2011). The 
concept of PDT is based on the specific photo-activation of a PS with red visible 
light, that has localized in the target cancer tissues to generate cytotoxic species 
in the presence of oxygen, which in turn leads to tumor cell death and ultimate 
destruction (Agostinis et al., 2011).  
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PS selectivity and sufficient absorption in cancer tissues are of critical importance 
in PDD-PDT applications, as to ensure optimal outcomes and this is a major 
challenge to overcome within these combinative applications (Shirasu et al., 2013). 
Tumor site specific and actively targeted PS uptake are highly advantageous to 
achieve ideal outcomes, in order to overcome undesirable PS off-targeting, which 
limits photo diagnostic sensitivity, as well as induces unwanted side effects in 
healthy tissues during treatment (Shirasu et al., 2013; Montaseri et al., 2020). 
Traditional PDD-PDT applications rely on the passive delivery and accumulation 
of PSs via the leaky tumour vascular and enhanced permeability retention (EPR) 
effect (Mokwena et al., 2018). However, this reliability of passive PS absorption in 
cancer tissues, is controversial, since various studies have noted that only small 
amounts of the PS actually accumulate in tumours and the rest diffuse into normal 
tissues adjacent to the cancerous tissue, resulting in off-target diagnostics and 
undesirable PDT side effects (Mokwena et al., 2018). 
This study investigated the development of a novel multi-component nanoparticle-
based system that could actively enhance targetability to cancerous cells, in order 
to facilitate enhanced preferential binding, uptake, and heighten the intracellular 
accumulation of PSs in order to enhance the efficiency and selectivity of PDD 
diagnostics, as well as improve the overall PDT therapeutic effectiveness CRC 
cells. The PS of choice in this study was Zinc sulfothiolphthalocynine (ZnPcS4), 
since it has three major Q bands of emission: 583, 634, 674 nm, within the far-red 
spectral range for maximum tissue depth penetration and PS excitation for 
effective PDT outcomes applications and it has additional short-blue absorption B 
band, between 330 to 350 nm, which is ideal for PDD applications (Brozek-Pluska 
2015; Abramczyk et al., 2017). Thus, the aim of this study was to incorporate an 
efficient singlet oxygen-generating hydrophilic ZnPcS4 PS, which is extremely 
soluble, due to its tetra sulphonation and chemical purity (Brozek-Pluska 2015), 
with specific CRC targeting antibodies (Anti-GC-C) on the surface of 
heterobifunctional amine-functionalized and PEG stabilized gold nanoparticles 
(AuNPs), to form a final actively targeted PS nanoconjugate (ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC  Ab). AuNPs were utilized as the PS nanocarrier of 
choice, since they enhance passive PS absorption is cancer tissues and within 
PDT applications, they can act as photothermal agents, which facilitates the 
conversion of light to heat, to promote tumour cell obliteration (Kim et al., 2018b). 
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In order to determine the optimal drug dose of ZnPcS4-mediated PDT, a dose 
response study was performed. Different concentrations of ZnPcS4 PS (0.0312, 
0.0625, 0.125 and 0.25 µM) were administered to various experimental and control 
groups and incubated for 24 hrs. Some groups were irradiated at 673.2 nm with a 
fluency of 10 J/cm2 and incubated for another 24 hrs. Cellular biological responses 
were analysed 24 hrs post PDT treatment to determine the lowest possible 
concentration of ZnPcS4 PS which could be administered to in vitro cultured CaCo-
2 to yield 50% cell viability, as well as induce a significant amount of cytotoxicity. 
This was performed in order to establish cell death induction potential (ICD50), but 
still allow cellular biological responses post PDT treatment to be determined. The 
optimal ICD50 dose response concentrations of ZnPcS4 post PDT treatment that 
induced approximately 50 % cytotoxicity was found to be 0.125 µM ZnPcS4, after 
observing the morphological changes, cellular viability, cellular proliferation and 
cellular membrane damage.  
Following the construction of the final actively targeted PS nanoconjugate (ZnPcS4 
– AuNP-PEG5000-SH-NH2 - Anti-GCC Ab) at the recommended 0.125 µM ZnPcS4 
PS PDT (IC50), which was then utilized throughout the study, it underwent a number 
of elementary characterization and stability analysis to confirm the efficient binding 
of the Ab and PS to the functionalized AuNPs’ surface. The molecular 
characterization results indicated that the final molecular PS conjugate was 
successfully synthesized. Furthermore, these assays revealed the final molecular 
conjugate’s structure, size, ROS generation and photostability. The final molecular 
conjugate displayed a UV-spectra showing a major Q band of emission at 674 nm 
within the far-red spectral range for maximum tissue depth penetration and PDT 
PS excitation, as well as noted a 340 nm Soret band for effective PDD applications. 
Moreover, this final NP PS delivery system demonstrated a mean Z-average 
diameter of 57.18 ± 3.04 nm, signifying that it was ideally small enough to embody 
an active nanodrug carrying system, with the definitive possibility of cellular uptake 
and absorption. 
In vitro cultured human CRC cells CaCo-2 and normal human fibroblasts (WS1) 
were treated with the final actively targeted PS nanoconjugate (ZnPcS4 – AuNP-
PEG5000-SH-NH2 - Anti-GCC Ab) in order to determine if the conjugated PS was 
able to actively localize more specifically in CRC tumour cells versus normal 
human cells. Immunofluorescent subcellular microscopy results validated that the 
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final actively targeted PS nanoconjugate was able to actively and specifically 
localize in target CRC cells only and had no affinity for normal human cells (such 
as fibroblasts). These findings demonstrated that this final actively targeted PS 
nanoconjugate exhibited an appreciable safety profile and posed no phototoxic 
effects or any unwanted side effects on normal human tissues pre and post laser 
irradiation. Immunofluorescent photodiagnostic results went on to confirm that 
when a ZnPcS4 PS is conjugated to a AuNP carrier, that is linked with an active 
targeting biomolecule (Anti-GCC Ab), the PSs active and specific uptake in CRC 
cells can be attained, in order to accommodate PDD cancer detection, due to the 
PSs highly specific and sensitive absorption in CRC cells only (with no affinity for 
normal human cells) and so can allow for precise identification and differentiation 
of in vitro CRC cells in comparison to normal tissues. 
The PDT effect of the final actively targeted PS nanoconjugate was then assessed 
within CaCo-2 (Cellonex Cat SS1402) and WS1 (ATTC CRL-1502) in vitro cultured 
cells. Post-irradiation, various biological and cellular responses assays were used 
to evaluate cellular morphology, cell death induction and DNA damage in order to 
assess the potency of the final actively targeted PS nanoconjugate, as well as its 
safety and tolerability profile in normal human cells. The cells were divided into 
various PDT experimental groups, which received 0.125 µM ZnPcS4 alone, 0.125 
µM ZnPcS4 – AuNP-PEG5000-SH-NH2 or 0.125 µM ZnPcS4 – AuNP-PEG5000-
SH-NH2 – Anti-GCC Ab and were irradiated at 673.2 nm with a fluence of 10 J/cm2. 
Post-irradiation, once the cellular responses were established these experimental 
groups were compared to various control groups, in order to establish a reference 
baseline of PDT induced cellular cytotoxicity or cell damage.  
All irradiated experimental group of cells demonstrated significant changes in 
morphology, viability, cell death and DNA damage, however the most prominent 
results were exerted by the final actively targeted PS nanoconjugate (0.125 µM 
ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti GCC Ab), whereby the cells changed 
from their initial morphological appearance, became distorted and round, some 
detached from the culture plate and emerged as free-floating cells in the culture 
medium. Furthermore, the final actively targeted PS nanoconjugate resulted in the 
most significant changes in the modes of cell death, when compared to any other 
experimental group post PDT, whereby only 31% of the cell population was viable, 
19% of the cells were undergoing early apoptosis, 34% were late apoptotic cells 
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and a staggering 16% of the cells were undergoing a necrotic mode of cell death. 
These findings indicated that the cells which received the final actively targeted PS 
nanoconjugate were unlikely to recover post PDT treatment, since most of CRC 
cells were in late apoptotic and necrotic mode of cell death. Moreover, following 
Hoechst 33258 immuno fluorescent staining, the cells which were PDT treated with 
the final actively targeted PS nanoconjugate noted nuclei shrinkage, with loss of 
cohesion between the cells and DNA chromatin fragmentation. In addition, when 
final actively targeted PS nanoconjugate was administered to normal human WS1 
cells, in comparison to control groups, no significant changes in the morphology 
nor in the modes of cell death induction were noted, suggesting that this form of 
PDT treatment exerted no phototoxic or cytotoxic side effects on normal human 
cells.  
In conclusion, the final actively targeted PS nanoconjugate actively and specifically 
enhanced PS uptake and retention within in vitro CRC cells, in comparions to 
ZnPcS4 administration alone and so augmented a significant PDT cytotoxic 
treatment, due to its high triplet singlet oxygen and ROS yield with a long triplet 
lifetime and noble metal photothermal energy. Furthermore, when the final actively 
targeted PS nanoconjugate was applied with PPD studies, it noted highly specific 
and sensitive absorption in only CRC cells (with no affinity for normal human cells) 
in comparison to singular ZnPcS4 administration and so allowed for the precise 
identification and differentiation of in vitro CRC cells in comparison to normal 
tissues. Thus, the simultaneous PDD and PDT-mediated treatment of in vitro 
cultured CRC cells is possible when utilizing the final actively targeted PS 
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1.1 Foreword  
In the recent decade, the prevalence of colorectal cancer (CRC) has steadily 
increased, and this aggressive tumor presents as the fourth leading cause of 
cancer-associated deaths worldwide (Arnold et al., 2017). In addition, the 
incidence is projected  to increase by 60% to more than 2.2 million new cases, and 
1.1 million cancer deaths by 2030 (Arnold et al., 2017). Therefore, there are 
ongoing efforts into the development of new techniques that will allow early, non- 
invasive diagnosis, as well as treat cancer. Diagnosing CRC at the earliest stage 
can provide the greatest chance for eradicating tumours, thus selection of a 
diagnostic and therapeutic modality that is safe, reliable, non-invasive, and tumour 
specific is crucial to improve patient survival rate (Kruger and Abrahamse, 2019).   
CRC is often asymptomatic and may only be apparent as the tumour progresses 
into advanced stages (Arnold et al., 2017).  When diagnosed early at a localized 
stage, CRC exhibits a 5-year relative survival rate of over 90% (Simon, 2016). 
However, CRC can be particularly difficult to diagnose as the absence of typical 
symptoms of CRC coupled with the semi-invasive nature of current diagnostic 
methods and suboptimal accuracy of these tests results in late diagnosis, at 
progressed stages, in a significant number of individuals (Gonzalez-Pons and 
Cruz-Correa, 2015). Some of the classical screening and diagnostic methods that 
are currently used for CRC, such as colonoscopy, are semi-invasive (Simon, 
2016). While some of the currently utilized screening programs of CRC have 
proven to be effective, there is still a need for affective, noninvasive detection 
methods for early CRC detection, and when coupled with appropriate treatment, 
can target, identify, and possibly enhance successful CRC outcomes (Kruger and 
Abrahamse, 2019).   
The photodynamic method is a promising technique for both fluorescent diagnosis 
(PDD-Photodynamic Diagnosis) and therapy (PDT-Photodynamic Therapy) for 
numerous cancer related diseases. PDD and PDT demands the presence of three 
basic elements: 1] photosensitizer (PS), 2] source of light causing fluorescence of 
PSs and 3] the presence of dissolved oxygen within the tissue / tumour being 
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treated (Kruger and Abrahamse, 2019). The effectiveness of either PDT or PDD is 
dependent on PS concentration in tumour tissues, as well as the wavelength of 
light applied (Kruger and Abrahamse, 2019). Generally, a lower wavelength of light 
is applied in PDD for illumination diagnosis, whereas higher wavelengths of light 
are utilized in PDT treatments to generate reactive oxygen species (ROS) and 
singlet oxygen (1O2) for tumour destruction (Kruger and Abrahamse, 2019). 
Upon entering the blood stream, the PS then accumulates either passively or 
actively within a tumour site, which is dependent on the type of PS delivery 
mechanism utilized (Kruger and Abrahamse, 2019). Activation of a PS in PDD and 
PDT applications is achieved through exposure to a specific wavelength of laser 
irradiation (Hodgkinson et al., 2017).  
PDT is an alternative method for the treatment of a cancer (Abrahamse et al.,  
2017). It involves the administration of PS to targeted tumour cells and the 
localization of light at an appropriate red wavelength (600 – 680nm) to excite the 
PS (Abrahamse et al.,  2017). This causes the production of cytotoxic reactive 
oxygen species (ROS), such as singlet molecular oxygen (1O2), hydroxyl radicals, 
and/or superoxide anions, which achieve photo-cytotoxicity through oxidatively 
stressing tumour cells and so damages their cellular macromolecules (Kruger et 
al.  2018). PDT has been applied to a variety of tissues that are accessible to light 
exposure, including the gastrointestinal tract for the treatment of CRC cells 
(Abrahamse et al.,  2017). 
PDD is similar to PDT, since it forms a part of photomedicine based diagnostics, 
which also incorporates a PS and light, however it induces no cellular damage - 
due to a shorter purple to blue wavelength of light being applied (Dobson et al.,  
2018). The development of new rapid diagnostic techniques is the basis for modern 
and effective treatments of cancer, as an early diagnosis allows physicians to 
rapidly initiate treatment and so substantially increases the chances of patient 
survival (Dobson et al., 2018). In comparison to PDT, PDD is based on 
fluorescence elicited by shorter purple to blue wavelength light (330 – 400 nm) 
(Oniszczuk et al.,  2016). Available literature indicates that most PDD methods are 
based on precursors of protoporphyrin IX (PpIX) or phthalocyanines (Pc) having a 
Soret band within the 300 – 400nm range (Oniszczuk et al.,  2016).  
Despite several main advantages of PDT and PDD, this modality is still not fully 
adapted in a clinical arena, due to some fundamental properties which PS lack 
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(Hong et al., 2016). Most first and second-generation PS drugs are hydrophobic 
and tend to aggregate under physiological conditions, drastically hindering 
cytotoxic species formation and abilities to illuminate, due to their limited uptake in 
tumour cells (Kruger and Abrahamse, 2018). In addition, another important 
drawback which hinders the wide application of PDD and PDT, is that conventional 
administrations of PS alone, without any further functionalization for active 
targeting, only rely upon passive accumulation in tumour cells and so inadequate 
PS absorption is often found, limiting overall diagnostic and treatments outcomes 
(Hong et al., 2016). Furthermore, within clinical applications it has been reported 
that PS cannot overcome immune system biological barriers and so their 
concentrated uptake in tumours is low (Kruger and Abrahamse, 2018). Thus, 
initiatives have been undertaken to circumvent these PS challenges in relation to 
the solubility, stability and target / concentrated absorption uptake (Kruger and 
Abrahamse, 2018). 
In recent years, the integration of nanoparticles (NPs) with PSs has gained a great 
deal of attention, since they can overcome the drawbacks conventional PS 
administration often faces (Hong et al., 2016). NPs can significantly enhance the 
solubility of PSs, improve either passive or active uptake in tumours, as well as 
make them more biocompatible to overcome immune system biological barriers 
(Kruger and Abrahamse, 2018). When PSs are combined with NPs, their passive 
uptake in tumour cells is improved via the enhanced permeability and retention 
effective (EPR), which is mediated by the leaky tumour vasculature and poor 
lymphatic drainage of tumour tissues (Hong et al., 2016; Mokwena et al., 2018; 
Kruger and Abrahamse, 2018). Furthermore, the active uptake of bound NP PS in 
tumour cells can be considerably improved, when the surfaces of NPs are modified 
with specific moieties, such as aptamers, monoclonal antibodies (mAb) and 
peptides, which are only overexpressed on tumour cells and so the specific and 
selective uptake of the PS is enhanced within targeted tumour cells only (Kruger 
and Abrahamse, 2019). Thus, NP PS active targeting allows for localized PDD and 
PDT treatments, since it increases the bioavailability of PSs to concentrate in 
tumour cells only and so reduces the possibility of uptake in other surrounding 
tissues, allowing for specific PDD diagnosis and limits any unwanted PDT side 
effects on neighboring healthy tissues (Hong et al., 2016). In relation to PDT 
various studies have been conducted, which support this treatment modality in 
CRC, however, drawbacks such as bioavailability and biocompatibility of PSs, as 
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reported above have been found and so in order to improve CRC PDT treatment 
outcomes PS actively targeted nanoconjugates require investigation (Sekhejane 
et al., 2014; Kruger and Abrahamse, 2018). Limited studies in relation to CRC and 
PDD have been performed.  
Thus, the effectiveness of CRC PDD and PDT treatment could possibly be 
achieved by exploring multicomponent synergistic combinations of active PS 
targeting strategies, combined with NP carriers, which can simultaneously evade 
the body’s immunological barriers, as well as allow PSs to be specifically absorbed 
by CRC tumour sites only to allow for specific diagnosis and localized PDT 
treatments.   
1.2 Problem Statement  
CRC remains an arduous disease to control, as it is often misdiagnosed and 
usually detected at an advanced stage, due to its asymptomatic nature and so 
tumour cell dissemination of this disease is often eminent (Lin et al., 2015). The 
efficacy of PDT and PDD in cancer treatment is highly dependent on the quality of 
the PS used, and therefore, it remains essential to investigate the development of 
novel PSs with enhanced delivery and uptake efficacy (Schmidt et al., 2018). 
For effective PDT treatment a wavelength above 600 nm is applied to ensure 
human tissue penetration and high yield PS ROS generation, whereas for PPD a 
much shorter wavelength (usually above 330nm) is applied to cause PS 
fluorescence (Staicu et al.,  2013). 
Research into the potential use of phthalocyanines (Pcs) as PSs in PDT and PDD 
is well advanced due to the interesting photo-physical properties they possess 
(Wood et al.,  1997). Pcs are photostable and most display a strong red absorption 
band for PDT, as well as a weak blue band for PDD applications (Staicu et al.,  
2013). Additionally, the incorporation of diamagnetic metal ions such as zinc ions 
(Zn2+) ensures that the Pc PSs have a high triplet ROS yield with a long triplet 
lifetime (Maksimov et al.,  2015). Studies by Sekhejane et al.  (2014) reported 
notable zinc phthalocyanine sulfonated mix (ZnPcSmix) PS PDT induced apoptotic 
cell death within in vitro treated CRC cell lines (DLD-1 and CaCo-2). However, 
studies by Broekgaarden et al., (2016) suggested that this PS drug should be 
further modified within its sulphide groups for improved solubilization, as well as 
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be considered for targeted cellular uptake and absorption to enhance PDT 
treatment.  
Studies by Chiarante et al.,  (2017) have shown the successful PDT treatment of 
2D and 3D CRC cell cultures when ZnPcS was encapsulated into poloxamine 
polymeric micelles. Thus, ZnPcS is an ideal PS for chemical modification into an 
active targeting nano drug delivery system for CRC PDD and PDT treatment. 
However, within this study it was decided to use a chemically pure form of Zinc 
sulfothiolphthalocynine (ZnPcS4), since it is a tetrasulphide derivative and so has 
4 SH / thioacetate groups, which enhances solubility, as well as allows for chemical 
modification enhancements in order to promote passive tumour uptake 
(Siriwandana et al., 2014). Additionally, ZnPcS4 has three major Q bands of 
emission (583, 634, 674 nm) within the far-red spectral range for maximum tissue 
depth penetration and PS excitation for effective PDT treatment, while notes an 
additional short-purple/blue absorption B band between 330 to 350 nm, which is 
ideal for PDD (Abramczyk et al., 2017).  
Moreover, conjugates of zinc phthalocyanines (ZnPc) and gold nanoparticles 
(AuNPs) have been reported for enhanced passive cancer drug delivery 
applications and showed better PDT efficiency, with higher triplet lifetimes than 
unbound ZnPc PS drug treatment alone (Calavia et al.,  2018). This is due to the 
fact that ZnPc are lipophilic in nature and so tend to aggregate in aqueous medium, 
reducing their photodynamic activity (Nombona et al.,  2011). However, when ZnPc 
are purely sulphonated (such as ZnPcS4) they are easily solubilized and when 
conjugated to AuNPs they become hydrophilic (Da Volta et al.,  2011).  Thus, they 
are able to more efficiently cross lipophilic membranes via endocytosis and so can 
have a higher intracellular passive concentration uptake in tumour cells, enhancing 
the overall effectivity of PDT (Sukumar et al., 2013). Moreover, studies by 
Colombeau et al., (2016) have noted that when PSs are bound to AuNPs they are 
protected from biological barriers increasing their in vivo lifetime for improved and 
increased passive cellular uptake via the enhanced permeability and retention 
(EPR) effect. Lastly within PDT applications it has been reported that AuNPs 
actually contribute to overall treatment outcome since the generate photothermal 




However, studies by Sukumar et al. (2013) and Wakaskar (2017) have reported 
that a major drawback of NPs passive drug delivery systems is that they are not 
able to distinguish normal tissues from the tumorous ones, and so as a result, 
therapeutic drugs may accumulate to some extent in healthy tissues, disrupting 
their normal bodily functions. Thus, in an effort to enhance host PS accumulation 
specificity, and improve PDT PS safety and tolerability profile, great efforts have 
been devoted towards the synthesis of PS-nanoparticle bio-conjugates, to further 
enhance PSs active delivery, by specifically ensuring that PSs are only absorbed 
by tumour cells which overexpress the matching bio-conjugate antigenic 
determinate site (Kruger and Abrahamse, 2019). Studies by Danaee et al. (2017) 
noted that CRC tumour receptors tend to specifically overexpress GUCY2C protein 
genes and suggested that Anti-GCC mAbs could be utilized as a specific target to 
actively enhance therapeutic drug delivery. In vitro human colorectal 
adenocarcinoma cells (CaCo-2 Cellonex Cat SS1402) were chosen for this study 
as this common form of CRC overly expresses the most commonly found CRC 
tissue markers found in this type of cancer, including GUCY2C protein genes 
(Danaee et al. 2017). 
Thus, the linkage of targeting moieties such as Anti-GCC mAb to NP-PS 
conjugates, could possibly enhance the active delivery of PSs in CRC cells and so 
promote PDD and PDT treatment outcomes?   
Despite significant efforts to develop PS modified nanostructures for the efficient 
PDD and PDT treatment of CRC, it currently remains a challenge to develop a 
nanostructured drug delivery system that is based on surface-functionalized 
AuNPs, which combines CRC targeted tumour molecular recognition, for effective 
PS short wavelength illumination in PDD applications, as well as produces 
cytotoxic species production under red irradiation for PDT. 
1.3 Aims of the Study  
Therefore, the aim of this study was to combine an efficient cytotoxic oxygen 
generating hydrophilic tetra sulphonated metal based PS known as Zinc 
Phthalocyanine Tetrasulfonic Acid (ZnPcS4), with CRC specific targeting 
antibodies – Anti-Guanylate Cyclase Ab (Anti-GCC) on the surface of 
heterobifunctional PEG amine stabilized AuNPs, in order to enhance the active PS 
uptake specifically within in vitro cutured CRC cells (CaCo-2 Cellonex Cat 
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SS1402), so the PDD and PDT treatment of CRC tumours could be improved 
(Figure 1).  
The efficiency of the final actively targeted PS nanoconjugate PDD was assessed 
using immunofluorescent subcellular localization staining techniques within in vitro 
cultured CRC and normal fibroblast cells (WS1-ATTC CRL-1502). Whereas, the 
PDT effects of the final actively targeted PS nanoconjugate was evaluated post-
irradiation, by assessing the cellular uptake, cellular morphology, viability, cell 
death, DNA damage and proliferation cytotoxic effects it had on in vitro cultured 
CRC in comparison to control groups and normal human in vitro cultured fibroblast 
cells. This approach allowed investigators to determine if when ZnPcS4 was 
applied alone in PDD and PDT applications, versus within it final actively targeted 
PS nanoconjugate, which was more effective for CRC diagnostic and treatment 
purposes, with negligible effect on healthy tissues, since this has not been 
accomplished to date. 
Objectives: 
• Chemical synthesis and characterization of final actively targeted PS 
nanoconjugate (ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC). 
• Assess sub-cellular localization and PDD targeting abilities of the final actively 
targeted PS nanoconjugate within in vitro cultured CRC and fibroblast cells. 
• Determine the lowest possible concentration of ZnPcS4 PS which could be 
administered to CRC cells to yield 50% cell viability, in order to establish cell 
death induction potential, but still be able to determine cellular responses. 
• Investigate the cytotoxic PDT abilities within in vitro cultured CRC and WS1 
cells, which received the final actively targeted PS nanoconjugate, versus 
those which received ZnPcS4 PS alone, by performing various cellular 





Figure 1 Hypothesised final actively targeted PS nanoconjugate (ZnPcS4 – 
AuNP-PEG5000-SH-NH2 – Anti-GCC) for the enhanced PDD and PDT 




LITERATURE REVIEW  
 
2.1  Cancer 
Cancer is a global burden, marked by an estimated 18.1 million new cancer cases, 
and associated with 9.6 million cancer-related deaths in 2018, worldwide (Bray et 
al., 2018). Breast, prostate, lung, and colon/rectum are the most common cancers 
reported (Bray et al., 2018).   
Cancer encompasses a group of heterogeneous diseases that are characterized 
by uncontrolled growth and acquisition of invasiveness and metastatic properties 
throughout the body (Cooper, 2000). Cancer is classified into benign and malignant 
tumours (Cooper, 2000; Lodish, 2000). Benign tumours are less aggressive and 
develop extensive masses slowly (Lodish, 2000). They are usually compacted and 
confined at the site of origin rather than spreading to adjacent normal cells or 
distant body sites (Cooper, 2000). In contrast, malignant tumours are a collection 
of many abnormal cells that tend to develop rapidly. Most of these tumours do not 
remain in their original site, instead they may start new tumours by infiltrating 
surrounding normal tissues, and other locations, within the body (Lodish, 2000). 
Generally, only malignant tumours are considered cancers since they can invade 
and metastasize rapidly, which makes cancer so lethal (Cooper, 2000).  
Studies have identified that several environmental factors and lifestyles contribute 
to developing cancer such as smoking, diet, and ionizing irradiation, thus, lifestyle 
changes can decrease the risk of developing cancer (Khan, 2010). Even though 
cancer-predisposing mutations could arise from environmental risk factors and 
lifestyle, studies have revealed that cancer is considered a genetic-related disease 
attributed to a series of DNA alterations that result in genetic mutations, such as 
oncogenes and tumor-suppressor genes (Lodish, 2000). 
2.1.1  Progression and Causes of Cancer 
The progression of nearly all cancers is largely determined by a sequence of 
events that results in the changes in the activity of normal cells, and a series of 
mutations within their genetic material that forces them to disregard signals that 
regulate their proliferation and gradually become malignant (Cooper, 2000). These 
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dysfunctions in cells make them proliferate rapidly, contributes to their escaping 
programmed cell death, and invading an array of other tissue sites (Hanahan and 
Weinberg, 2011).  
There are three types of genes that when mutated result in the transformation of 
normal cells into cancerous tumor cells: proto-oncogenes, tumour suppressor 
genes, and DNA repair genes (Figure 2) (Lodish, 2000). Progressive damage to 
proto-oncogenes results in them becoming oncogenes, which disrupts cellular 
processes such as cell division and growth (Cooper, 2000). The loss of function of 
tumour suppressor genes liberates the cell from growth constraints and contributes 
to malignant transformation. Irreparable damage can result in changes to the DNA 
sequence durign replication leading to mutations that can give rise to cancer (Basu, 
2018).  
Figure 2 Genetic alterations in proto-oncogenes, tumor suppressor genes, 
and DNA repair genes associated with cancer formation (Source 
https://images.app.goo.gl/DZ5L3qt9mu47J6Fb6). 
2.1.2  Characteristics of Cancer 
As shown in Figure 3 below, the transformation of tumour cells after an alteration 
within normal cells requires the tumour cells to adopt 6 characteristics of cancer 
that facilitate rapid tumour growth and ultimately metastasize to other tissues 
(Hanahan and Weinberg, 2011). According to the literature, over the past decades 
the 6 cancer hallmarks have been refined to 2 emerging hallmarks; reprogramming 
of energy metabolism and evading immune destruction (Hanahan and Weinberg, 
2011; Fouad and Aanei, 2017). 
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Figure 3 Therapeutic targeting hallmarks of cancer that capacitate cancer 
cells to grow and metastasize (Fouad and Aanei, 2017; Hanahan and 
Weinberg, 2011). 
 
• Sustaining proliferative signaling: normal cells release mitogenic growth factors 
that signal the regulation of cell proliferation to make an exact copy of DNA 
(Hanahan and Weinberg, 2011). According to Hanahan and Weinberg, (2011) 
cancer cells can deregulate the normal mitogenic growth signals and generally 
become less dependent on normal proliferating signals, resulting in unregulated 
growth (Cooper, 2000). Once unregulated, tumour cells produce their proliferation 
signals through autocrine secretion that stimulates cell growth (Cooper, 2000; 
Hanahan and Weinberg, 2011). 
• Evading growth suppressors: there are tumor suppressor genes and other 
multiple anti-proliferative signals in normal cells that are functionalized to regulate 
or limit cell growth, and cell proliferation, as well as regulate cellular quiescence 
and tissue homeostasis (Hanahan and Weinberg, 2011). The anti-proliferative 
tumour suppressor signals are regulated by the retinoblastoma protein and TP53 
protein; therefore, the loss of the tumor suppressor gene in cancer cells results in 
limitless replication (Hanahan and Weinberg, 2011).  
• Activating invasion and metastasis: is associated with the increased loss of E-
cadherin using proteases to potentiate metastasis (Martin et al., 2013). The 
extracellular matrix of surrounding cells is broken down, which consequently 
affects the enzymatic activity within the nearby cells (Martin et al., 2013).  
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Furthermore, a loss of cell-cell/matrix attachment proteins results in detaching of a 
cancerous tumour from the primary site and invading nearby cells (Hanahan and 
Weinberg, 2011). 
• Enable replicative immortality: human TERT gene (hTERT) increases 
telomerase activity in cancer cells upon activation, which independently enhances 
proliferative immortality (Jafri et al., 2016). However, hyperactivity causes cancer 
initiation and the survival of tumour (Jafri et al., 2016).  
• Avoidance of cell death: tumour cells can disable the apoptotic signal by 
decreasing the p53 tumour suppressor function responsible for inducing apoptosis 
(Hanahan and Weinberg, 2011).  
• Angiogenesis: the angiogenic switch in tumours is activated by the imbalance 
between angiogenic inducers and inhibitors that triggers vascular endothelial 
growth factor (VEGF) thereby stimulating angiogenesis and metabolism in 
cancerous cells (Hanahan and Weinberg, 2011).  
The enabling characteristic and emerging hallmarks are associated with 
orchestrating the acquisition of the 6 hallmark capabilities by the diseased cells 
(Hanahan and Weinberg, 2011). They include genome instability and mutation, 
tumor-promoting information, avoiding immune destruction, and dysregulating 
cellular energetics (Hanahan and Weinberg, 2011). 
2.2  The Human Colon 
The oral cavity, pharynx, esophagus, stomach, small intestine, and large intestine 
(colon) form part of organs that make up the gastrointestinal tract (GI tract) (Azzouz 
and Sharma, 2018). The walls of the GI tract have four layers called tunics, the 
mucosa, submucosa, musclaris externa layer, and serosa, which are connected 
by connective tissue, neural and vascular elements (Azzouz and Sharma, 2018; 
Tiwari et al., 2019). Even though each layer varies in structure, tissue type, and 
function, they all have roles in the coordinated digestion of food (Azzouz and 
Sharma, 2018). The colon is approximately 1.5 meters in length and hollow, in 
order to facilitate in the homeostatic reabsorption of electrolyte fluids and water, 
and in vitamin production and absorption (Azzouz and Sharma, 2018; Tiwari et al., 
2019). In addition, it functions in stool formation and removal of feces towards the 
anus for elimination (Azzouz and Sharma, 2018). Figure 4 shows the four different 
sections of the colon. The large intestine is composed of 4 parts; the caecum and 
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ascending colon, transverse colon, descending colon, and sigmoid colon (Azzouz 
and Sharma, 2018; Tiwari et al., 2019).  
 
Figure 4 The different sections of the colon (Blausen Medical, 2014).  
2.3  Colorectal Cancer (CRC) 
In the past decade, colorectal cancer (CRC) has become the most prevalent 
cancer and ranks as the third deadliest cancer in men and women worldwide 
(Schreuders et al., 2016). CRC has a rapidly accelerating diagnosis rate of 
approximately over a million new cases yearly (Schreuders et al., 2015). 
CRC arises from polyps in the mucosal layer of the large viscus (Figure 5) 
(Shussman and Wexner, 2014). These colon polyps are uncontrolled growth of 
masses that emerge when there are irregularities within the cells and project from 
the inner surface of the colon (Kumar et al., 2018). The protuberance of primary 
CRC polyps from the inner to outmost lining can subsequently grow into the blood 
vessels and metastasize to other organs (Kruger and Abrahamse, 2019).  
In general, colon-lining immature cells are programmed to proliferate, mature, and 
then die in a very coherent and timely manner. However, some genetic mutations 
can target oncogenes, tumour suppressor genes, and genes related to DNA repair 
mechanisms in the lining cells and halt cells from entering programmed cell death 
or maturation (Mármol et al., 2017). This results in the transformation of normal 
colorectal epithelium to immature, genetically altered cells that ultimately 
accumulate and lead to polyp formation which breaches the inner lining of the colon 
as well as metastatic neoplasm (Armaghany et al., 2012; Simon, 2016). Polyps are 
often non-cancerous growths or exhibit no malignant characteristics, however, as 
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the cells within the polyps proliferate, the size of the polyp increases, and abnormal 
mutation begins to accumulate, which develops some of the polyps into cancer 
(Simon, 2016).  
 
Figure 5 Illustration of CRC polyp origins (adapted from Ryan, 2016). 
The risk of developing CRC is linked to factors such as environmental and genetic 
predisposition, with an estimation of 75% and 25% of CRC cases respectively 
(Hodgkinson et al., 2017; Kruger and Abrahamse, 2019). The environmental 
factors include inappropriate lifestyle patterns, lack of active exercise, weight gain, 
alcohol drinking, and high fat and red meat diet (Hodgkinson et al., 2017). Kuipers 
et al. (2016) also reported that the rise in this aggressive disease in developed 
countries is associated with environmental factors through unfavorable modern 
dietary habits. 
Familial adenomatous polyposis (FAP) and Lynch syndrome (hereditary 
nonpolyposis colorectal cancer (HNPCC) are the most frequent predisposition 
syndromes (Armaghany et al., 2012; Kruger and Abrahamse, 2019). FAP consists 
of autosomal hereditary disorders that are usually observed when there is a loss 
of function mutation in the APC gene resulting in multiple adenomatous polyps and 
consequently in the incidence of CRC (Shussman and Wexner, 2014). The second 
most common inherited CRC cases consist of those diagnosed with Lynch 
syndrome (HNPCC) (Armaghany et al., 2012). HNPCC is a genetic defect in one 
of the DNA mismatch repair (MMR) genes that consist of MLH1, MSH2, MSH6, 
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PMS1, and PMS2 genes (Shussman and Wexner, 2014). One molecular pathway 
that has been associated with CRC carcinogenesis in both sporadic and hereditary 
CRC is the APC/Wnt/β-catenin pathway (Armaghany et al., 2012). Other signaling 
pathways have closely been associated with the oncogenesis of CRC, such as 
epidermal growth factor receptor (EGFR), STAT3 transcription factors, activation 
of Akt kinase, and the ras/RAF/MAPK cascade (Shussman and Wexner, 2014). 
The mortality rate of CRC is rising globally due to the common and nonspecific 
presentation of CRC symptoms such as abdominal pain, rectal bleeding, and 
weight loss, being misdiagnosed as other less serious conditions, therefore, result 
in its discovery at an advanced tumor stage (Mishra, 2013). Generally, if CRC  is 
discovered early, it can often be cured and improve patients’ lives (Mishra, 2013). 
CRC has a 5-year-survival rate of roughly 65%, which varies depending particularly 
on the stage of the disease (Kruger and Abrahamse, 2019). Regardless of recent 
advances in CRC diagnosis and treatment, significant research is still required to 
focus on early diagnosis concurrently with enhanced treatment outcomes (Simon, 
2016). 
2.3.1  Pathophysiology of CRC 
The neoplastic transformation of healthy, normal colon cells to colorectal polypoid 
lesions and ultimately to invasive CRC is associated with genetic abnormalities in 
oncogenes, tumour suppressor genes, and genes associated with DNA repair 
mechanisms (Mármol et al., 2017). Adenomatous polyps are solid suspicious 
growths considered to be the precursors of colon cancer that eventually become 
tumorous (Shussman and Wexner, 2014). CRC is classified into three distinctive 
groups according to the etiology and genetics of cancer:  sporadic, familial, and 
hereditary (Mármol et al., 2017). Almost 65% of CRC cases are sporadic with no 
family history or apparent inheritance disorder (Mishra, 2013). According to 
Nguyen and coworker (2018), there are three molecular pathway mechanisms of 
tumorigenesis associated with the progression of adenoma to carcinoma; 
chromosomal instability (CIN), microsatellite instability (MSI), and CpG island 
methylator phenotype (CIMP) (Nguyen and Duong, 2018). Colorectal malignant 
neoplasms could follow one of the three molecular mutational pathway 
mechanisms or even a combination of all of them. 
• Chromosomal Instability (CIN): is considered the most common type of genetic 
instability pathway observed in sporadic CRC (Nguyen and Duong, 2018). CIN 
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causes mitotic mutation such as centrosome mis regulation, which may trigger 
pathways essential for CRC initiation and progression. The accumulation of 
several mutations in the adenomatous polyposis coli (APC), such as micro-
deletions and frameshift mutations can activate specific oncogenes, such as KRAS 
proto-oncogene GTPase (KRAS) and B-Raf proto-oncogene serine/threonine 
kinase (BRAF), tend to inactivate tumor suppressor protein p53 (TP53) (Mármol et 
al., 2017; Nguyen and Duong, 2018). The accumulation of genetic anomalies in 
the APC is linked to the activation of the Wnt signaling pathway by increasing β-
catenin levels which subsequently triggers over activation of Wnt downstream 
effectors that, in turn, stimulates the proliferation, migration, invasion, and 
metastasis of cancerous cells (Mármol et al., 2017; Mishra, 2013). KRAS is a 
transductor GTP protein that is found in almost all human cells with intrinsic 
GTPase activity. However, when KRAS mutation accumulates, it inhibits the 
intrinsic GTPase activity of initiating the downstream proliferative signaling 
mechanisms (Nguyen and Duong, 2018). Several studies have reported a key role 
of KRAS mutation in terms of targeting its function and signaling pathways, such 
as direct targeting epidermal growth factor receptor (EGFR) and the ras/RAF / 
MAPK cascade. Thus, KRAS mutations are utilized as predictive markers (Porru 
et al., 2018). 
• Microsatellite Instability (MSI): The presence of MSI indicates abnormalities in 
the MMR such as the repetitive DNA sequences have replication errors due to the 
insertion/deletions of nucleotides in the microsatellite sequences (Nguyen and 
Duong, 2018; Nojadeh et al., 2018). MSI can be observed in both sporadic and 
hereditary groups of CRC and occurs in  15-20% of these cancers; such as Lynch 
syndrome (HNPCC). Hereditary non-polyposis colorectal cancer (HNPCC) which 
is associated with autosomal allele mutations in one of the various DNA mismatch 
repair (MMR) genes, such as MSH2 on chromosome 2p16, MLH1 on chromosome 
3p21, MSH6 on chromosome 2p16, and PSM2 on chromosome 7p22 (Mármol et 
al., 2017; Nojadeh et al., 2018).  MSI is a vital biomarker in CRC and has been 
associated with better prognosis in patients in the early stages of CRC, as well as 
used in early detection and diagnosis (Nojadeh et al., 2018). 
• CpG Island Methylator Phenotype (CIMP): is associated with the inactivation of 
gene transcription by the aberrant DNA hypermethylation situated at the promoter 
regions CpG islands (Mojarad et al., 2013). This mechanism of gene inactivation 
is facilitated by changes in the chromatin structure of a gene promoter that causes 
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gene silencing (Mojarad et al., 2013; Nguyen and Duong, 2018). Several studies 
have reported on the vital role of the CpG island methylator phenotype (CIMP) in 
CRC whereby it is considered to facilitate serrated colorectal tumorigenesis by 
deregulating gene expression of key genes (Mojarad et al., 2013). Two subsets of 
methylation; type A (for age-related) methylation, and type C (for cancer-specific) 
methylation are associated with progression and formation of CRC (Mojarad et al., 
2013). It was also highlighted that DNA hypermethylation in CpG-rich promoters 
was responsible for most CIMP CRCs with mismatch repair genes such as MLH1, 
MGMT (Puccini et al., 2017). Promoter DNA hypermethylation of specific CRC 
genes such as CDKN2A/p16, MGMT, THBS1, TIMP3, CDKN2A (p14ARF), and 
MLH1 can be found in urine and blood (Mojarad et al., 2013; Puccini et al., 2017). 
Ultimately, the potential application of epigenetic alterations to serve as diagnostic, 
prognostic, and predictive biomarkers of CRC has been evaluated (Mojarad et al., 
2013). 
2.3.2  Stages of CRC 
The severity of the disease and the appropriate therapeutic choices rely on the 
stages at which the tumour is diagnosed (Pandurangan et al., 2018). Currently, the 
tumor/node/metastasis (TNM) classification is adopted for different stages of CRC 
(Li et al., 2016). CRC is categorized into five stages based on the growth of cancer 
cells:  
• Stages 0:  It is the early phase of CRC, whereby the malignant cells are 
embedded within the innermost mucosal lining of the colon wall and are usually 
referred to as carcinoma in situ and they have the capacity to become cancerous 
and migrate to nearby normal cells (Simon, 2016). Generally, Stage 0 is considered 
to yield a 100% curative rate after surgical resection and the polyps can be fully 
eradicated during the polypectomy. (Gulbake et al., 2016). 
• Stage I: colon tumours have emerged in the innermost layer of the colon wall 
and grown to the submucosa and muscularis propria at this stage (Viswanath, 
2016). Normally, when CRC is diagnosed at this stage, the survival rate is about 
90% and surgery is the key treatment option for CRC treatment (Mishra et al., 
2013). 
• Stage II: This stage is subdivided into IIA, IIB, and IIC depending on the spread 
of CRC within the muscularis propria layer subdivision (IIA), the surface of the 
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outermost layer of the colon wall to the visceral peritoneum subdivision (IIB), or 
extension through the serosa and invasion of adjacent body site subdivision (IIC) 
(Viswanath, 2016). The treatment for this stage is similar to stage 0; surgical 
resection, with more than an 80% survival rate (Mishra et al., 2013). 
• Stage III: this stage is further categorized into three stages depending on the 
spread of CRC to the submucosa and muscle layer of the colon, the surface of the 
serosa within the visceral peritoneum, and the nearby lymph node (Viswanath, 
2016). The survival rate is between 30%-60% (Mishra et al., 2013). To treat CRC 
at this stage, surgery, chemotherapy and other treatment modalities are usually 
administered (Mishra et al., 2013). 
• Stage IV: with a survival rate of reduced to 6%, CRC at this stage has spread 
throughout the blood and lymph nodes to other distant body organs such as the 
liver, lung, and walls of the abdomen (Viswanath, 2016). Adjuvant chemotherapy 
after surgical resection, radiation therapy, and other treatment modalities are opted 
to treat at this stage of colon cancer, however patient survival rate is low (Mishra 
et al., 2013). 
2.3.3  Clinical Symptoms of CRC 
Generally, most patients have no initial clinical presentation of CRC in the early 
stages and can only become apparent at advanced stages of cancer (Kruger and 
Abrahamse, 2019). The presentation of CRC symptoms varies depending on the 
size and cancer location in the large intestine (Kruger and Abrahamse, 2019). CRC 
can be associated with a wide variety of symptoms that affect the patient, such as 
exudative diarrhea, constipation that arise after partial colonic obstruction, and 
disturbance in defecation (Viswanath, 2016).   Bleeding can also be caused by 
malignant growth and patients may present with the problems of abdominal 
cramping, lethargy, and gastrointestinal blood loss because of blood loss 
(Viswanath, 2016).    
2.3.4  Incidence and Mortality of Colorectal Cancer 
CRC still poses a significant challenge to global public health with 1.8 million new 
cases and nearly 861,000 deaths recorded in 2018 (WHO, 2018). Incidence and 
mortality rates for CRC have remained at a higher rate with distinct variation 
patterns geographically, as well as with the different age groups worldwide (Arnold 
et al., 2017). Although the CRC incidence and mortality rates have been reported 
to have decreased or stabilized in developed countries, the CRC rates have 
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remained the highest in these countries and trends have shown an alarming 
increase of CRC burden in low income and transitioning countries (Arnold et al., 
2017).  
Studies have reported evidence of increased CRC incidence among younger 
adults, where potential contributing risk factors such as poor diet, obesity, and 
social behavior (smoking) could be the cause (Siegel et al., 2019). Economically 
transitioning Sub-Saharan Africa countries have also reported an increase in CRC 
incidences and, in South Africa, CRC is identified as the fourth most common 
cancer and the six leading cause of cancer-associated fatality (Arnold et al., 2017; 
Brand et al., 2018). Crucially, preventative and early diagnosis interventions are 
needed to significantly reduce the number of CRC cases in the population and 
offering appropriate treatment protocols, timeously, in countries with increasing 
CRC incidence and mortality rate is a necessitation (Arnold et al., 2017). 
2.4  Conventional Diagnostic and Screening Modalities for CRC 
CRC diagnosis is made either from the evaluation of the patient's symptoms or 
traditional screening methods, such as a biopsy of the cancerous tissue. Although, 
tissue biopsy is sometimes difficult because tumours are in inaccessible in some 
body parts (Marrugo-Ramírez et al., 2018). In the absence of a biopsy, 
colonoscopy is the preferred method of diagnosis; however, other traditional 
methods can be used to investigate CRC (Viswanath, 2016). Several studies have 
indicated that early diagnosis could improve prognosis and decrease the mortality 
rate of CRC, however, only 40% of CRCs are diagnosed at an early stage (Simon, 
2016). Existing techniques for CRC screening are generally classified into the 
following three categories listed below. The advantages and disadvantages of 
each technique has been noted.  
2.4.1 Endoscopic Techniques 
• Flexible Sigmoidoscopy (FS): Flexible sigmoidoscopy detects colonic tumour 
cells that line the rectum and descending part of the colon (Viswanath et al., 2016). 
A sigmoidoscope is a long, hollow flexible tube with a tiny camera and light that is 
inserted through the rectum to provide a visual inspection of the rectum and lower 
part of the colon (Kuipers et al., 2016). However, it cannot detect polyps on the 
ascending parts of the colon, thus a colonoscopy is needed to observe the entire 
colon (Viswanath et al., 2016). 
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• Optical Colonoscopy: is an invasive standard method for diagnosis that uses a 
colonoscopy, which is similar to a sigmoidoscope, but longer (Kuipers et al., 2016). 
It consists of a flexible and fiberoptic instrument with a camera and a display screen 
that allows for direct observation of the entire lining of the colon, biopsy, and 
removal of identified polyps (Kuipers et al., 2016). A colonoscopy can detect almost 
all tumour growth with various sizes substantially providing a convenient single 
session detection and treatment hence, reducing the risk of the higher incidence 
and mortality of CRC. However, it can trigger bleeding of the intestinal wall 
(Viswanath et al., 2016). 
2.4.2 Imaging Techniques 
• Computed Tomographic (CT) Colonography: It is a visual technique that utilizes 
special X-ray instruments and computer software to provide CT images of about 2 
to 3-dimensional views of the entire colon to detect colorectal polyps (Kuipers et 
al., 2016). It is advantageous over traditional colonoscopy, because it is less 
invasive with minimal discomfort to patients.  It also yields highly diagnostic 
performance and sensitivity. However, it is costly and the patient has to endure a 
similar preparation as for the colonoscopy (Kuipers et al., 2016). 
• Magnetic Resonance (MR) Colonography: It is an evolved 3D imaging 
technique based on volume data, and it views the complete colon similar to CT 
technique allowing for fast acquisition of high-resolution images (Sambrook et al., 
2012). Furthermore, it is an advantageous technique over CT as it is associated 
with radiation exposure (Sambrook et al., 2012).  However, MRC can be costly and 
susceptible to signal artifacts (Sambrook et al., 2012). 
• Wireless Capsule Endoscopy (PillCam Colon): The Pillcam colon technique 
involves the ingestion of a double-headed capsule with two imagers that allow the 
device to obtain video images from both ends (Adler and Metzger, 2011).  
Compared with colonoscopy, its limitations include the inability to localize and 
obtain biopsies (Carter and Eliakim, 2016). 
• Double-Contrast Barium Enema (DCBE): It is a routine screening method that 
involves the injection of air and barium transrectally, followed up by an X-ray 
examination of the colon (Viswanath, 2016). However, some side effects such as 
constipation have restricted its application (Viswanath, 2016). 
2.4.3 Stool-Based Techniques 
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• Faecal Occult Blood Test and Faecal Immunochemical Test (FOBT and FIT): 
These involve the use of assay kits to detect abnormal blood or DNA markers in 
stool samples (Viswanath, 2016). FOBT relies on the concentration of guaiac to 
detect CRC DNA blood markers, while FIT uses globin specific antibodies to detect 
CRC DNA blood markers in stools (Viswanath, 2016). However, bleeding from 
other noncancerous tissues can result in false-positive results (Viswanath, 2016). 
• Stool DNA testing: The stool DNA test is a non-invasive screening tool that 
targets hemoglobin biomarkers and specific genetic alterations associated with 
colon neoplasm. Altered DNA material which is shed by CRC cells can be identified 
in faecal samples. However, the presence of abnormal DNA requires further 
investigation, such as colonoscopy to assess the inner lining of the colon. The 
inability to biopsy CRC upon detection is considered an obstacle in this technique 
(Simon, 2016). 
Overall, colonoscopy has been established as a mainstay for CRC diagnosis, 
nevertheless most of these conventional methods for CRC (including imagining 
and stool based techniques) have inevitable pitfalls as mentioned above (De Rosa 
et al., 2015). Most lack sensitivity within their detection methods and so most often 
patients are only diagnosed within late stages of this disease (Viswanath, 2016). 
Thus, it is imperative in order to improve CRC patients survival rates that more 
sensitive methods be developed to detect the earlier stages of CRC in order to 
prevent fatality.  
2.5  Conventional Treatment Approach’s for CRC 
Within medical oncology, there are several traditional treatments for CRC that 
include; surgery, radiation therapy, chemotherapy, targeted therapy, and 
immunotherapy (Viswanath, 2016). The selection of the CRC treatment modality 
relies upon several factors, including the wellness of the patient, the tumour type 
and its location, and the stage at which the cancer is diagnosed (Marley and Nan, 
2016; Kruger and Abrahamse, 2019). These different therapeutic options are 
intended to eradicate as many tumour cells as possible, while exerting minimal 
damage to the body, as well as to improve the overall survival rate of the patient, 
however they do present with limitations. A description of some of the therapeutic 
modalities are detailed below. 
• Surgery: surgical excision remains the main traditional modality that is 
extensively used for the treatment of solid tumours that are localized; such as CRC 
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if the cancer is diagnosed at an early stage (Mishra et al., 2013). This type of 
treatment is often carried out to remove tumours and some adjacent healthy 
tissues surrounding the tumours, to ensure that all the tumours are eradicated 
(Mishra et al., 2013). Surgery can also be considered during colonoscopy as the 
first line of treatment for polyps, this is known as polypectomy, as well as in 
combination with other treatments such as chemotherapy or radiation therapy 
(Viswanath, 2016). In addition to surgical excision, other surgical options for CRC 
include laparoscopic surgery, colostomy and radiofrequency ablation (RFA) or 
cryoablation (Oxenberg et al., 2014). Successful surgery treatment is highly 
dependent on the stage of cancer, the extent of local invasion, and the quality of 
surgery (Kuipers et al., 2016; Mármol et al., 2017). Surgery has shown several side 
effects such as pain, diarrhea, constipation, as well as triggering local and systemic 
inflammatory responses (Viswanath, 2016). Additionally, surgery carries the risk of 
increased shedding of tumor cells into the circulatory system, if the entire tumour 
is not excised properly, which in turn can influence the increased risk of metastasis  
(Viswanath, 2016; Tohme et al., 2017). Moreover, surgery may be less effective 
as a single treatment option for advanced cancers, but when used in combination 
with other treatment interventions, it can be more effective. 
• Radiation: This treatment approach is based on high-energy ionizing radiation 
X-rays that are used to impair DNA and inflict replicative stress resulting in the 
sudden death of the targeted cancer cells (Baskar, 2014). This form of treatment 
can be applied to shrink a tumour before surgery (neoadjuvant therapy) or after 
surgery to eradicate the remaining cancer cells on the lining of the colon 
(Viswanath et al., 2016). However, increased exposure to radiation poses a threat 
and potential DNA damage to healthy cells during high dose administrations 
(Viswanath, 2016; Mishra et al., 2013). Skin damage, nausea, diarrhea, anal 
discomfort, and irritated bladder are some of the undesired adverse reactions 
observed in radiation therapy for CRC (Kruger and Abrahamse, 2019). 
• Chemotherapy: is a therapeutic modality whereby cancer is treated singularly 
or in combination with cytotoxic antitumor drugs to suppress the unchecked growth 
of cancer cells, either by killing the cells or by discontinuing their division process 
(Mishra et al., 2013). The most widely used chemotherapy drugs for the treatment 
of CRC include; the combination of leucovorin, 5-fluorouracil (5-FU), and either 
oxaliplatin (FOLFOX régime) or irinotecan (FOLFIRI regime), capecitabine 
(Xeloda) and oxaliplatin (CAPEOX or CAPOX regime) and leucovorin, 5-FU, 
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oxaliplatin and irinotecan (FOLFOXIRI regime (Mishra et al., 2013). However, 
since these chemotherapeutic drugs have to circulate within the bloodstream to 
reach CRC cells, they assist in eradicate these cancerous tissue, but also cause 
severe damage to normal tissues (Senapati et al., 2018), as well as cause nausea, 
vomiting, and fatigue (Viswanath, 2016).  
• Immunotherapy: the basis of this treatment involves a biological boost to the 
immune system, whereby tumour specific antigens of the body are stimulated to 
fight and destroy cancer via the administration of various synthetic immune-system 
molecules, such as peptides and proteins (Koido et al., 2013). It also employs 
conjugated antibodies to target several checkpoint pathways to inhibit cancer 
growth processes (Koido et al., 2013). It also assists the immune system to 
eradicate cancerous cells and enhance the natural ability of the body to repair or 
replace cells damaged by cancer (Koido et al., 2013).  T-cell response stimulation 
(CTLA-4 and PD-1) against tumor-associated immune checkpoints blockades is 
another function of this modality (Mishra et al., 2013). However, fatigue, diarrhea, 
nausea, and dehydration are some of the demerits of this treatment (Mishra et al., 
2013). 
Overall, it can be stated from the above findings that conventional treatments for 
CRC such as surgery, chemotherapy, and radiotherapy are only effective at 
eliminating CRC in its early stages of diagnosis, suggesting that there is often poor 
prognosis, especially in patients with a late detection at an advanced stage with 
metastases (De Rosa et al., 2015). Immunotherapy is a promising treatment 
option, however, it requires completion of clinical trials and FDA approval before it 
can be administered safely. Given these shortcomings, early diagnosis and 
detection of CRC is imperative to improve patient survival rates and researchers 
need to start investigating more specific and unconventional treatment methods for 
CRC, in order to lessen the rates of a patients possible fatality.  
2.6  Unconventional Diagnosis and Treatment of CRC 
Current conventional diagnostic and therapeutic methodologies available for CRC  
have limitations such as lack of sensitivity, severe side effects, invasiveness, and 
inability to effectively treat late-stage CRC (Mishra et al., 2013). The main 
difficulties for conventional diagnosis of early CRC arise from lack of sensitivity 
these techniques have. The poor presentation, and pathological features of colon 
adenoma, which are mostly flat and depressed adenomas, can be possibly missed 
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by conventional diagnostic modalities (Kuipers et al., 2013; Zhao et al., 2018). 
Conventional diagnostic methods often fail to distinguish the boundary region, 
between healthy and cancerous tissues, as well as clearly define neoplastic 
transformations of carcinomas (Kuipers et al., 2013).  
Furthermore, despite effective advancements in conventional CRC treatments, 
there has only been a slight progress in terms of improved patients outcomes after 
treatment, especially in relation to the unwanted side effects, risk of spread and 
damage to healthy tissues, hence unconventional treatments need to be 
established to enhance patients survival rates post-treatment, with localized 
treatments (Mishra et al., 2013). Currently, the only conventional CRC therapy that 
seems promising is immunotherapy, however it still requires FDA approval (Mishra 
et al., 2013). 
These above conventional CRC diagnostic and treatment methods limitations have 
prompted researchers to investigate unconventional methods, such as the 
photodynamic diagnostic and treatment modality (Santos et al., 2019). A major 
advantage of photodynamic approaches over conventional methods is that they 
are inexpensive and less invasive (simply administered) (Santos et al., 2019). 
Furthermore, they can be designed to be highly selective in identifying, as well as 
combatively targeting and treating cancer cells, without damaging adjoining 
tissues, as well as allow for multiple dosage administration with negligible side 
effects (Santos et al., 2019). 
2.6.1  Photodynamic Diagnosis and Photodynamic Therapy  
Precise and early PDD of CRC can provide the greatest chance of a cure, since 
an effective method of treatment can be administered straight thereafter, 
increasing the rate of positive outcomes, as well as extended life expectancy 
(Kuipers et al., 2013). Thus, a photo diagnostic and treatment method needs to be 
developed that is minimally invasive, highly sensitive and selective to detect CRC 
(even within its early stages) in situ, as well as allow for its combinative treatment 
(Niedermaier et al., 2018). In this regard, studies by He et al. (2017), have reported 
that PDD and PDT have emerged as a promising unconventional method for the 
early diagnosis and treatment of CRC, since it is simple, cost-effective, and can 
directly detect cancer cells, with localized treatment outcomes and minimal side 
effects, however it requires intensive research and development.  
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2.6.1.1   Photodynamic Diagnosis (PDD) 
PDD is a simple, non-invasive, selective, sensitive and promising diagnostic 
method utilized for the detection of malignant tissues from healthy tissues (Kiesel 
et al., 2018). Naidoo and colleagues also reported that PDD is a non-destructive, 
fluorescent-based diagnostic tool that utilizes an intertumoral PS that is commonly 
used in PDT mediated therapy which emits light and so illuminates for diagnosis, 
when activated with a short blue wavelength of light (Naidoo et al., 2019).  
In PDD applications, when a low excitation of  blue laser light, which ranges from 
375 to 400 nm, is applied to the PS accumulated in cancerous tissues, the exposed 
PS is excited to produce fluorescence light, which can be effective in the diagnosis 
and visualization of the targeted cancerous lesions (Naidoo et al., 2019). PDD is a 
technical procedure that is dependent upon the selective accumulation of a PS in 
cancerous tissue, and this subcellular location of the PS is achieved through either 
passive or active targeting approaches (Kruger and Abrahamse, 2018). The 
excited PS which produces a fluorescence emission effect in PDD upon stimulation 
by blue light, is usually administered pre-operatively or intra-operatively (Kruger 
and Abrahamse, 2018). This is achieved by various routes of administration, such 
as topical, oral, or intravenous application, depending on where the tumour is 
located in the body (Kruger and Abrahamse, 2018). Moreover, when the excited 
PS (which has accumulated within the specific tumorous tissues) is illuminated by 
low blue light, the nearby healthy tissues have negligible fluorescence, allowing for 
the differential evaluation of cancerous tissues from healthy tissues for the 
accurate and early diagnosis, with the possibility of eradicating cancer if applied in 
combination with PDT, in a minimally invasive manner (Sieroń et al., 2013).  
PDD has been reported to be promising diagnostic tool when compared to other 
classical diagnostic protocols, despite its limited utilization in oncology (Xu et al., 
2020). Several studies have reported on the significant degree of specific tumour 
selectivity and uptake fluorescent PSs have, resulting in laser irradiation only at 
the tumour site, so this beneficial characteristic enables minimal toxicity to healthy 
tissues (Jendželovská et al., 2016; He et al., 2017). Evidence has been exploited 
and showed the promising potential of the PDD method to detect and distinguish 
malignant tumours such as CRC from healthy tissues (Sieroń et al., 2013). A study 
by Kato et al. (2012) reported that when a 5-ALA PS was administered to CRC 
models in vitro, it resulted in PpIX PDT red fluorescence emission, as well as 
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allowed for blue PDD fluorescent diagnosis. The preferential uptake of PpIX by the 
CRC tissue, as well as the ability to accumulate within the tumour could facilitate 
PDD modality, whereby the precise location of tumour could be visualized and, 
simultaneously, PDT treatment could be administered, when the tumour was 
exposed to red visible light, producing cytotoxic species which were lethal to the 
CRC cells (Kato et al., 2012). In another in vivo study, Kondo et al. (2014) reported 
on the improved diagnostic accuracy of PDD in patients with CRC using 5-ALA-
PDD, where a sensitivity of 53% was achieved.  
Overall, if a PS is able to produce a fluorescence intensity signal they can be 
utilized to visualize and distinguish cancer lesions from healthy tissues promptly 
for early stage PDD, as well as all a therapeutic intervention to be monitored (He 
et al., 2017). PDD is a comparatively easy, repeatable, non-invasive method which 
can be utilized for the more efficient diagnosis of cancer, when compared to 
conventional colonoscopy (Kuipers et al., 2016). 
2.6.1.2   Photodynamic Treatment (PDT) 
PDT is an unconventional, minimally invasive, localizing treatment modality for 
cancer, which uses near-infrared (NIR) laser light to activate a PS, which has 
accumulated in tumour tissues, to react with surrounding molecular oxygen to 
produce lethal cytotoxic species (Agostinis et al., 2011; Allison and Moghissi, 2013) 
(Figure 6). 
 
Figure 6 The principle of PDD and PDT. PSs selectively accumulate in the 
target tumour, following PS administration. Laser irradiation at a low 
wavelength of light, at the target site will induce fluorescence 
emission (PDD) and irradiation at a high wavelength of light generate 
cytotoxic species which destroy tumours (PDT) (Sansaloni-Pastor et 
al., 2019). 
The lethal cytotoxic species produced are ROS and 1O2, which are phototoxic to 
tumour cells, resulting in either apoptotic or necrotic cell death mechanisms (Deda 
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and Araki, 2015; Sansaloni-Pastor et al., 2019) (Figure 6). A PS can accumulates 
in tumorous cells by either passive or active targeting mechanisms, depending on 
the type of drug delivery system applied (Kruger and Abrahamse, 2018). 
Depending on the tumour site, various PS administration modes are used, 
including local application, intravenous, and topical administration (Kruger and 
Abrahamse, 2018).  
Thus, PDT is a promising treatment modality which has successfully demonstrated 
various treatment responses, in clinical oncology (Kwiatkowski et al., 2018). 
Generally, PDT is an advantageous therapeutic modality compared to 
conventional chemotherapy (which possess a low therapeutic index and has harsh 
side effects on healthy tissues), since only the cancerous site absorbs the 
administered PS and so receives localized PDT mediated treatment (Van Straten 
et al., 2017). Furthermore, Spring and colleagues (2015), reported that PDT based 
cancer treatments are less invasive, when compared to conventional treatments 
and can be repeated many times as required, opposed to radiation and 
chemotherapy, which are dose limiting (Zhang et al, 2014). Other studies by 
Kawczyk-Krupka et al. (2015) have demonstrated the effectiveness of applying 
PDT, as a promising alternative to eradicate CRC. Additionally, another attribute 
associated with PDT, is that this modality has the capability to provoke cancer 
killing immunogenic response, which can further promote the destruction of tumour 
cells (Hong et al., 2016). 
Currently, in relation to PDD and PDT applications, researchers are trying to 
investigate and improve PS subcellular uptake in cancer cells, accumulation, and 
localization by developing PS conjugates, which can specifically identify and target 
cancer cells only, via actively targeted ligands or mAbs. This is done as to ensure 
selective and specific identification of cancer cells, as well as enhance treatment 
outcomes within PDD and PDT applications, for a far more effective cancer 
management modality (Kruger and Abrahamse, 2018; Naidoo et al., 2019). 
 
2.6.2 PDD and PDT Mechanism of Action 
Both PDD and PDT incorporate the use of an administered PS photochemical, 
which can function as a molecular contrast agent when illuminated by blue light for 
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diagnosis purposes, or function as a cytotoxic species generator when activated 
with red light for localized tumor destruction (Naidoo et al., 2019). Moreover, the 
PS may accumulate passively or actively within a cancerous cells or tissues 
depending on the drug delivery system involved (Kruger and Abrahamse, 2018).  
2.6.2.1  PDD Mechanism of Action 
With respect to  PDD, it relies on the specific excitation of PS fluorophores, at short 
blue wavelength of light (330 to 400 nm), to cause a rapid spin-allowed 
fluorescence emission of light from singlet excited state PS (Figure 6) (Celli et al., 
2010).  
 
Figure 7 The principle of different types of photodynamic methods; 
photodynamic therapy and photo diagnosis (PDD) dependent on the 
appropriate wavelength of light to activate a PS after accumulation in 
cancerous tissues. 
The underlying principle of fluorescence relies upon light excitation of a 
diamagnetic PS, so as to allow for the absorption of photons with opposite spins 
which permit the transition of the PS from the ground state (lower energy molecular 
orbitals) to an excited singlet state (higher energy molecular orbitals) (Horne and 
Cronjé, 2017). However, the excited singlet state is short lived and extremely 
unstable, the excited PS molecule that now possesses extra energy from 
absorbing photons, must then return to the ground level state as it relaxes, and in 
the process, there is a loss of energy by either emittance of light, heat loss or 
intersystem crossing (Horne and Cronjé, 2017). The excited PS may emit a lower 
energy photon with a different wavelength from the photon that initiated excitation, 
which may result in the release of excess energy in the form of fluorescence 
emitted light, which can be utilized in PDD applications (Ishikawa-Ankerhold et al., 
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2012; Horne and Cronjé, 2017).  The PS in this singlet-excited state cannot partake 
in any cellular mechanisms, which induce cell signaling death pathways, since this 
activation is short-lived, with a lifespan that usually lasts anywhere between a few 
nanoseconds to a short picosecond and so can only be effective within diagnostic 
illumination (Josefsen et al., 2012; Naidoo et al., 2019). This fluorescence 
mechanism is depicted in a schematic Jablonski diagram illustrating the PDD 
mechanism of action (Figure 7).  
2.6.2.2  PDT Mechanism of Action 
The PDT mechanism of action involves two pathways that an activated PS and 
oxidation of biomolecules or oxygen undergo, cause cytotoxic cell death in cancer 
tissues (Mroz et al., 2011) (Figure 6).  
In a type I pathway, which is often referred to as electron transfer,  the PS may be 
reduced after direct interaction with organic substrates or biomolecules, such as 
reduced NADPH, guanine in nucleic acids, and tryptophan and tyrosine in proteins 
in surrounding tumour cells, to produce a hydrogenated form of the PS and oxidant-
hydroxyl radicals know as ROS, which are lethal to cancer cells (Kruger and 
Abrahamse, 2018).  
In a type II pathway, PSs have photons in their shells with opposite spins located 
in low energy molecular orbitals at ground level (Debele et al., 2015). When these 
ground level PSs become excited with red laser irradiation, the PS undergoes a 
conversion from its ground state to a short-lived excited singlet state, whereby its 
electron spins in a molecular electronic state (Figure 8) (Abrahamse and Hamblin, 
2016; Kwiatkowski et al., 2018). This excited-singlet-state PS then can crossover 
through a mechanism called intersystem crossing, and so can transfers this energy 
into a more stable excited triplet state, with a longer lifespan and the same spin 
orientation (Debele et al.,  2015). The PS can then transfer this excess energy to 
surrounding tumour oxygen molecules, resulting in the formation of 1O2 (Itri et al., 
2014). This 1O2 species is electrophilic and so enables the destruction of tumour 
cells by oxidizing its lipid plasma membranes, proteins, and genetic materials (Itri 
et al., 2014). The presence of these highly reactive 1O2 species in cancerous 
tissues can also induce an oxidative reaction that overpowers its biochemical 
defenses leading to its ultimate destruction (Nita and Grzybowski, 2016).  
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Overall, both PS tumour cell-mediated pathways lead to the generation of either 
cytotoxic ROS or 1O2 species, which react with biomolecules, such as unsaturated 
lipids, DNA, or cholesterol and oxygen to induce phototoxicity and oxidation within 
tumour cells (Kruger and Abrahamse, 2018). Therefore, PDT is proven to be a 
more effective cancer therapeutic option, owing to its specificity and minimal 
adverse side effects, when compared to conventional therapies (Calixto et al., 
2016).  
 
Figure 8 Jablonski diagram showing PDT type I and II photooxidation 
mechanism of action to directly trigger cancer cell death (Calixto et 
al., 2016).  
2.6.3 PDT Mechanism of Cell Death  
The efficacy of PDT in order to initiate cellular death is believed to be influenced 
by several factors that include; type, concentration and accumulation of the PS 
used, presence of surrounding molecular oxygen and concentration within the 
specific cancerous tissue, intensity, and fluency of wavelength, as well as the light 
penetration tissue depth to activate PSs (Benov, 2015; Van Straten et al., 2017). 
Most the PSs utilized in PDT clinical settings may sub cellularly localize within 
organelles such as the mitochondria, lysosomes, endoplasmic reticulum (ER), 
plasma membrane, and Golgi apparatus (Anzengruber et al., 2015). PDT usually 
eradicates tumours through direct tumour cell damage, with indirect vascular 
shutdown, as well as activates various immune response to trigger cell death 
(Anzengruber et al., 2015). The therapeutic efficacy of PDT takes place through 
three intracellular cell death mechanisms which initiate tumour destruction namely, 




Figure 9 PDT cancer treatment can provoke tumour cell death by three 
subroutines: apoptosis, autophagy, and necrosis. PDT can also harm 
the vasculature, induce hypoxia, and rapidly recruit immune cells, 
such as macrophages, dendritic cells, and granulocytes to assist in 
treatment outcomes (Panzarini et al., 2011). 
2.6.3.1  Apoptosis 
Apoptosis is a multi-pathway form of cell death that results in rapid nuclear and 
membrane degradation (Tynga et al., 2015). It is mainly consists of a caspases 
mediated cell death (extrinsic usually called Type I) or a mitochondrial signaled cell 
death (intrinsic pathway Type II) (Tynga et al., 2015). Apoptotic cells are naturally 
characterized by distinctive morphological properties, such as cell shrinkage, 
nuclear condensation, and fragmented apoptotic bodies (Panzarini et al., 2011). 
Within the apoptosis pathway type I, the apoptotic effector caspase, caspase-3, 
cleaves Inhibitor of Caspase Activated DNase (ICAD), which in turn forms 
Caspase-Activated DNase (CAD) and so subsequently leads to DNA disintegration 
(Mroz et al., 2011). The distribution of caspases that auto-activate other caspases, 
is important in promoting nuclear apoptosis, by mediating nuclei shrinkage, 
degrading cytoskeletal structures and nuclear proteins, as well as the formation of 
apoptotic bodies and expression of ligands for phagocytic cell receptors, which  
result in rapid cell death (Mroz et al., 2011). 
Generally apoptosis is the most observed cell death in PDT mediated treatments, 
which is triggered by oxidation of cellular components upon ROS production (Mroz 
et al., 2011; Domagala et al., 2018). This initiates a stress response through 
activation of cell death receptors or the translocation of the cytochrome c from 
mitochondria to the cytoplasm (in Type II reactions) (Tsubone et al., 2017). PDT 
generated ROS is associated with DNA damage in cancerous cells, which induces 
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apoptotic cell death (Tynga et al., 2015). Oleinick and colleagues (2002) have 
noted that when irradiated PS cancer tissue generates short-lived ROS, a PDT 
related response and phototoxic mechanism, usually results in apoptotic cell death 
(Oleinick et al., 2002). Several studies have noted that mitochondria are one of the 
targeted PS organelles which activate pro-apoptotic signals for the initiation of 
apoptotic cell death (Oleinick et al., 2002; Tynga et al., 2018). However, 
lysosomes, Golgi apparatus and ER PS targeted cellular organelles also play an 
important role in prompting pro-apoptotic signaling cascades (Oleinick et al., 2002). 
2.6.3.2  Autophagy 
Autophagy is an intracellular catabolic mechanism that enables cells to engulf 
themselves to sustain a balance between the synthesis, degradation, and recycling 
of cellular fragments after photochemical damage within the cell (Grasso et al., 
2012). In essence, autophagy facilitates the transportation of protein and cellular 
organelles via the lysosomal degradation pathway, which enables organelle 
homeostasis and quality control mechanisms, such as cell survival, differentiation, 
and development (Yang and Klionsky, 2009). In this process, several autophagy-
related genes (ATG) mediate the formation of the autophagosome, which engulfs 
parts of the cellular cytosol, such as dysfunctional organelles and misfolded 
proteins and combines them with lysosomes (Yang and Klionsky, 2009). Moreover, 
the activity of the PI3K-MTOR (phosphoinositide 3-kinase-mechanistic target of 
rapamycin) pathway controls autophagic flux (Yang and Klionsky, 2009). 
Subsequently, lysosomal enzymes breakdown the autophagosome engulfment’s 
as enables the recycling of the generated metabolites (Domagala et al., 2018). 
This cell death pathway is in fact, triggered to endorse cellular survival during 
metabolic stress, induced by nutrient deprivation, however excessive stress 
signals such as oxidative mediated PDT can sometimes result in cell death (Garg 
et al., 2015). It is still unclear how autophagy promotes cell survival or promotes 
cell death following PDT. However, studies have noted that autophagy plays a 
protective role in mitochondrial-targeted PDT and this protection role can only be 
inactivated if PS localize within lysosomes during PDT applications (Chilakamarthi 
and Giribabu, 2017). Thus, overall since there is a possibility tumorous cells can 
survive within PDT induce autophagy cell death, it is often considered an 
unfavorable cellular death pathway to prompt (Garg et al., 2015).  
2.6.3.3  Necrosis 
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Necrosis has traditionally been associated with a sudden, unprogrammed 
destruction in tumour cells, which results in a large fraction of cell death within a 
population when ATP depletion occurs (Chilakamarthi and Giribabu, 2017). 
Morphologically, necrotic cells are characterized by the swelling of cytoplasmic 
membranes and membranous organelles, which cause cellular chromatin to 
condense and so induce an irregular DNA degradation pattern (Escobar et al., 
2015). This in turn results in the release of cellular cytoplasm from the intracellular 
space to the extracellular space and pro-inflammatory molecules trigger an acute 
inflammatory response, leading to cellular damage (Escobar et al., 2015). PDT 
activated PSs when localization in tumour cells plasma membranes, tend to initiate 
vascular endothelial injury and the loss of plasma cell membrane integrity (Van 
Straten et al., 2017). Furthermore, hypoxia and thrombosis are induced during the 
rapid depletion of intracellular ATP, within tumours leading to necrosis. Within in 
vitro and in vivo studies performed by Van Straten et al. (2017), results noted that 
the activation of receptor-interacting protein 1 (RIP1 under caspase inhibition when 
triggered by tumor necrosis factor TNF) and Fas receptors prompted necrosis to 
occur within PDT treatments (Van Straten et al., 2017). In PDT, there is a possibility 
that an increased concentration of PS and high light fluency, or both, can trigger 
more membrane damage resulting in necrosis, while lower-dose PDT tends to 
promote more apoptotic related cell death forms (Mroz et al., 2011). 
Since most PDT-approved PSs are believed to accumulate preferentially in 
cancerous cells, and tend not to accumulate in nuclei, the cellular cytotoxicity 
induced by PDT, results in negligible DNA damage, which could limit its 
carcinogenic effectiveness by promoting genetic resistance (Agostinis et al., 2011).  
Thus, overall intracellular localization of a PS, type of PS, and cell type can 
influence the mode of cell death undertaken by the specifically targeted tumour 
cells in PDT applications (Agostinis et al., 2011). Therefore, due to the short 
lifespan of PDT produced cytotoxic species it is pertinent to ensure proficient 
delivery of PS to targeted cellular organelles, in order to promote the more 
favorable forms of either apoptotic or necrotic cell death, in order to enhance the 





2.7  PDD-PDT: Light Delivery and Dosimetry 
The dosimetry for PDD and PDT is influenced by several factors including 
heterogeneous tissue optics, variable light absorption in biological tissues and 
variable oxygen supply, which can be directly associated with the effectiveness of 
treatment outcomes (Van Straten et al., 2017). Generally, optical light propagation 
in biological tissues can be absorbed or scattered and with increased light intensity, 
both absorption and scattering spectra of different human organs vary since they 
possess different optical properties (Sandell and Zhu, 2011). Theses optical 
properties greatly influence the determination of the light fluency rate which can be 
applied in human tissues, as well as it distribution and depth of penetration (Sandell 
and Zhu, 2011). Regarding photodynamic light parameters, since light penetration 
is dependent on wavelength and optical properties of tissues, the appropriate 
wavelength of light, corresponding to the maximum absorption of the PSs, must be 
applied to activate it to either fluoresce for PDD applications or produce cytotoxic 
species for PDT applications (Rak et al., 2019; Yoon et al., 2013).  
Since most biomolecules in the tissue absorb light within the range of 400-600 nm, 
this often results in poor tissue penetration for effective PDT PS activation (Rak et 
al., 2019). Thus, the most effective PDT wavelength for PS activation is between 
650-780 nm, in the red visible region and the NIR region above 780 nm to ensure 
increased tissue penetration depth (Rak et al., 2019). Even though longer 
wavelengths (> 650 nm) are strongly preferred over shorter wavelengths for 
activation of the PSs for in vivo clinical studies, longer wavelengths do not provide 
enough activation energy to excite PSs for PDT applications (Yoon et al., 2013). 
Generally, the effective wavelength range, to mediate PDT for CRC treatment, is 
between 600 nm to 850 nm, which is within the therapeutic window for PDT (Yoon 
et al., 2013).  
Additionally, PSs with absorption in the blue region at 400 nm and red wavelength 
range between 600nm to 850 nm is attractive for PDD and PDT applications 
respectively, since they offer increased excitation intensity for fluorescence, with 
maximum depth tissue light penetration for enhanced treatment outcomes (Mallidi 
et al., 2016; Mesquita et al., 2018). 
Researchers have made great advances in developing light sources which can 
enhance deep tissue penetration for the possible diagnosis and treatment of 
cancer over the years. These include monochromatic light from lasers, light-
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emitting diodes (LEDs), or filtered light from broad-spectrum incandescent lamps 
(Hugo, 2015).  
Lasers consist of 3 components to generate laser radiation: an active medium such 
as atoms, molecules to emit radiation, and energy power to excite the media and 
a resonant cavity to reflect and bounce the light back into the system (Hugo, 2015; 
James et al., 2018). Lasers generally have monochromatic properties that are 
required to achieve the best PDD and PDT efficiency, optical fiber coupling, and 
emission of electromagnetic waves (James et al., 2018). 
However, some characteristics of a light source in relation to a PS must be taken 
into consideration for effective PDD and PDT treatment. These include the PS 
wavelength (nm) of activation, light generation power source, incident light energy, 
energy fluence rate (W/cm2), the quantum yield of the PS to fluoresce or generate 
sufficient cytotoxic species, radiant fluence or energy density (J/cm2), molar 
extinction coefficient (cm−1M−1), exposure time (s, min, h) and concentration (mol/L) 
(James et al, 2018). 
2.8  PDD-PDT: PS Delivery and Dosimetry 
The optimum interval time between the administration of a PS and the activation 
by the light source of a specific wavelength, to achieve a high PDT-ROS effect on 
the target cell, will determine if the PS will be effective for PDD (Zhang et al., 2014). 
The type of tumor, physicochemical properties of the PS, intracellular subcellular 
localization, and uptake of the PS are some of the important factors that should be 
taken into account for effective PDD-PDT therapy (Zhou et al., 2016). Since PSs 
begin as circulating molecules before they accumulate in the tumor tissues, they 
are and when exposed interactions with other molecules in circulation (Zhang et 
al., 2014). Such interactions with different molecules can change the PSs 
concentration and bioavailability within the target tumour tissue (Zhang et al., 
2014).  
Thus, the spectral properties of light must correspond to the wavelength range of 
the PS in order to ensure maximum activation of the limited amount PS, which 
actually manages to accumulate in target tumour tissues, as to ensure favorable 
PDD and PDT treatment outcomes (Zhang et al., 2014). For example, second-
generation PSs are advantageous in PDD and PDT applications, since most of 
these porphyrin-based structures (phthalocyanines, naphthalocyanines, and 
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benzoporphyrins PSs) have high absorption coefficients within the PDT therapeutic 
transparency window and so produce high levels of ROS, as well as show high 
fluorescent emission at shorter wavelengths for PDD applications (Zhou et al., 
2016). 
Furthermore within PDT treatments, oxygen supply, as well as the location of 
tumour cells are also significant issues. PDT reactions directly depend on the 
presence of tumor surrounding oxygen molecules to yield high enough levels of 
cytotoxic species to induce cellular destruction (Zhou et al., 2016). However, the 
lifespan of these cytotoxic species if often cut short, due to their rapid interaction 
tumour biomolecules, and so monitoring of high enough yields of cytotoxic species 
is crucial in PDT applications (Rak et al., 2019). Furthermore, a rapid depletion in 
oxygen concentration within the tumour cells often results in poor cytotoxic species 
generation and so this can affect PDT treatment outcomes (Yoon et al., 2013). 
Considering these limitations, over recent years, approaches to ensure increased 
effectiveness of PDT, often one facilitates oxygenation to cancer cells before PDT 
applications, to potentiate cytotoxic tumour effects (Sun et al., 2020) 
2.9  Limitations of Classical PDD and PDT Treatments 
PDD and PDT are attractive diagnostic and treatment options for cancer, since 
they are less invasive, when compared to surgical excision, which carries the risk 
of causing functional harm to adjacent tissues of the colon (Agostinis et al., 2011). 
Additionally, in comparison to typical conventional chemotherapy,  PDT has lower 
systemic toxicity and since it enables specific and localized tumor treatment, with 
minimal toxicity to surrounding tissues (Park et al., 2018).  
Nevertheless, PDD and PDT applications also have some limitations, which are 
mostly due to PS inherent properties. Most traditional PSs are activated within 
short wavelength ranges and so the tissue penetration depth of visible light is 
limited to 5-10 mm, which can be problematic for deep seated tumours (Hong et 
al., 2016). Furthermore, within PDD applications, short-wavelength excitation is 
required for PS fluorescence and poor tissue depth penetration of light can affect 
the accumulative fluorescence contrast (Celli et al., 2010). In order to circumvent 
the low penetration depth of visible light in tumour tissues, longer wavelengths, 
with optimal exposure time, is required to ensure effective PS illumination in PDD 
application, as well as assist in producing high yields of cytotoxic species in PDT 
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applications, to ensure effective tumour eradication (Zhou et al., 2016). Another 
drawback in PDT applications, is that sometimes tumours are dense or present 
themselves with necrotic tissues, limiting the surrounding molecular oxygen supply 
and so diminished the PDT effects can be observed (Zhou et al., 2016; Calixto et 
al., 2016). Another issue within PDT applications, is sometimes photosensitivity 
arises from the unwanted accumulation of PSs in healthy tissues and so unwanted 
side effects can be experienced (Kruger et al., 2018). Furthermore, PDD and PDT 
applications can also become rate limiting due to the low water solubility of some 
PSs, resulting in a poor tumour uptake (Kruger et al., 2018). Lastly, some PSs are 
hydrophobic and so tend to aggregate in physiological conditions when 
administered intravenously, which also hinders their successful concentrated 
uptake (Kruger and Abrahamse 2018).  
Thus, in order to eliminate some of these drawbacks, advanced research is 
currently oriented around investigation of more efficient and tumor-selective PSs 
delivery systems, which also accommodate longer wavelengths of light activation, 
for more effective tissue depth penetration, as to ensure improved PDD and PDT 
treatment outcomes (Naidoo et al., 2018). 
2.10  Types of PSs for Effective PDD and PDT Applications 
A PS is a light-absorbing photo- chemical compound or dye and is one of the most 
important components involved within PDD and PDT processes, since it requires 
light activation in order to mediate fluorescence, as well as induce cytotoxic 
damage in cancerous cells (Allison and Moghissi, 2013). However, not all PSs are 
an ideal candidate for PDD or PDT, since some PS are not readily taken up by 
tumour cells, some photo bleach and other can cause unwanted side effects such 
as skin photosensitivity (Dos Santos et al., 2019). Therefore, in order to harness 
the ideal photophysical properties of PSs for diagnostic and therapeutic purposes, 
an PS must possess the following indispensable properties: 
• A PS must possess chemical and physical stability properties (Dobson et al., 
2018). 
• Its light absorption coefficient should be ideally within the therapeutic index of red 
or far-infrared (wavelength 650–780 nm) to enable optimum tissue penetration 
and activation for PS to yield toxic ROS species for PDT (Deda and Araki, 2015). 
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However, in PDD PS diagnostic applications its wavelength should range 
between 330-400 nm for fluorescence (Dobson et al., 2018).  
• The PS should possess a somewhat selective passive affinity toward tumour 
cells and the triplet energy generated should be more than 94 KJ /mol (Allison et 
al., 2011). 
• A PSs should be quickly excreted from the body after treatment, to circumvent 
skin photosensitivity on healthy tissues (Deda and Araki, 2015). 
• A PSs should have an optimal life span and concentration in tumour cells 
between administration and light absorption in order to allow for effective PDD 
and PDT applications (Deda and Araki, 2015). 
• A PS should be a chemically pure biomolecule in order to allow for simple and 
efficient synthetic synthesis, as well as allow for ease of conjugation to 
macromolecular carriers (Deda and Araki, 2015). 
• A PS should be water-soluble at room temperature, should not tend to aggregate 
for effective results (Castano et al., 2004; Kwiatkowski et al., 2018). 
PSs are classified into three main generations; first-generation PS, second-
generation PS, and third-generation PS, based on their order of development, their 
overall complexity, and abilities to generate successful application outcomes 
(Abrahamse and Hamblin,2016). 
The first-generation PSs include hematoporphyrin derivatives (HpD) and photofrin, 
which were the first to be utilized in clinical studies (Kou et al., 2017; Naidoo et al., 
2019). Initially, they were described as diagnostic fluorophores, due to their 
fluorescence properties, however, they possess unfavorable traits of low 
intracellular localization, due to large quantities needing to be administered for 
effective phototherapeutic outcomes (Allison et al., 2013; Van Straten et al., 2017). 
Photofrin is a haematoporphyrin derivative (HpD) (after isolation from haemoglobin 
and purification of hematoporphyrin) that has been approved by the FDA (Kou et 
al., 2017). Photofrin was the first approved PS for the treatment of esophageal 
cancer (Baskaran et al., 2018).  Since then, photofrin has been widely used for the 
PDT eradication of various cancer such as melanoma, breast, bladder, lung, 
oesophageal, gastric, ovarian, and early cervical cancer (Naidoo et al., 2019). 
Furthermore, Photofrin was been extensively used in clinical PDD studies (Kou et 
al., 2017; Naidoo et al., 2019). However, clinical studies noted that these PSs are 
associated with some inherent drawbacks, such as profound photosensitivity in 
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patients’ skin and have relatively low absorption when activated at long 
wavelengths of light (Zhang et al., 2018). It has also been reported that their poor 
chemical purity, prolonged half-life after systemic administration, and intense 
accumulation in normal tissues, due to poor tissue penetration, tends to limit their 
clinical application as first-generation PSs (Kou et al., 2017; Kruger et al., 2019). 
Thus, second generation PSs, were developed with improved properties, in order 
to overcome the shortcomings of classical first-generation PSs (Yoon et al., 2013).  
Some of the well-known second-generation PSs comprise of porphyrin and 
chlorin structures that have individual distinctive properties, such as deep tissue 
penetration, improved optical absorption properties, and reduced photosensitivity 
(Kou et al., 2017). Within this grouping, most of the PSs presented improved PDT 
chemical and purity properties, when compared to first-generation PSs, especially 
in relation to minimized side reactions upon activation (Kou et al., 2017). 
Furthermore, second generation PSs are far more efficient within PDD and PDT 
applications, since they require activation at longer wavelengths, which allows for 
deeper tissue light penetration (Kou et al., 2017). Examples of second-generation 
PSs that have been extensively studied, include; chlorins, protoporphyrin IX 
(PpIX), benzoporphyrins, hypericin, phthalocyanines, and 5-aminolevulinic acid (5-
ALA), which is a biological precursor of PpIX (Yoon et al., 2013; Kou et al., 2017). 
Nevertheless, some of these second-generation PSs noted limitations, such as 
being hydrophobic in nature, as well as being prone to aggregation (Park et al., 
2018). Furthermore, various studies have noted that second generation PSs still 
possess inadequate tumour selectivity, which limits their passive absorption and 
sub-cellular localization in targeted tissues and so imperfect diagnostic and 
treatment outcomes in patients were reported (Baskaran et al., 2018). 
These outcomes led to many studies developing third-generation PSs for PDT and 
PDD applications, which showed enhanced tumour specificity, with active PS 
subcellular localization in target tumours, with longer-wavelengths of light 
activation (for deeper tissue penetration), as well as noted insignificant 
photosensitivity (Baskaran et al., 2018). Novel third-generation PSs are achieved 
by combining second-generation PSs with either nanoparticles (NPs) or active 
targeting biomolecules in order to enhance their uptake in target tumour cells 
(Naidoo et al., 2019).  
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Several strategies have been used to bridge second generation PS to third-
generation PS, such as conjugating  PSs to NP carriers or liposomes, to promote 
their passive absorption in target tumour cells, or improve their hydrophilic nature 
by coating these NPs with various layers, such as a poly-ethanol glycol (PEG) 
(Naidoo et al., 2019). Other formulations that have been considered to improve 
intracellular uptake of third-generation PSs involve conjugating either the PS itself 
or the NP carrier to various bio-targeting moieties such as; antibodies or ligands 
which can identify overexpressed markers in tumour cells and so enhance specific 
active uptake of PSs, when these targeted cancer cells are recognized (Kruger and 
Abrahamse, 2018).  
Table 1 displays some of first and second-generation PSs which have been 
approved or are under clinical trials for cancer treatment. 
Table 1 Photophysical and photochemical properties of clinically approved 
or under clinical trials PSs for cancer treatment, as well as their 
subcellular localization in target tumour sites.  
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As can be observed from Table 1 second-generation PSs, such as 
phthalocyanines, chlorins, and benzoporphyrins are potential candidates for PDD 
and PDT applications, due to their maximum wavelengths of emission and  so 
researchers should focused on their manipulation and modification into third-
generation PSs for enhanced cancer diagnostic and treatment outcomes (Senge 
et al., 2011). These PSs can be photoactivated within the low fluorescent 
wavelength ranges for PDD applications and most effectively activated within the 
high red PDT therapeutic wavelength ranges, for enhanced tissue penetration and 
high cytotoxic species yields, with uncompromising treatment outcomes (Senge et 
al., 2011; Baskaran et al., 2018). Furthermore, most of the PSs in this second 
generation category, have structures that can be modified, thus current research 
strategies related to the development of third-generation PS, should be focused on 
combining these particular PS with targeting moieties, such as antibodies and NPs 
in order to allow for better targeting, as well as improved delivery to cancerous 
tissues. 
2.11  Recommended PSs for PDD and PDT CRC Applications   
Ideally, the potential of PSs in PDD applications require a PSs to display the 
following properties: they need to offer preferential selective uptake for their 
respective target tumour cells, with high affinity, exhibiting a high fluorescence 
quantum yield within the 330-400 nm range to enable photodetection of the 
cancerous tissue, they must be rapidly eliminated from the body and exhibit a 
minimal degree of toxicity (Sekkat et al., 2012; Abrahamse and Hamblin, 2016). 
These characteristics, along with the ability to preferentially accumulate in cancer 
tissues, with minimal phototoxic adverse reaction, as well as the ability to possess 
strong absorptions of light in the red to NIR wavelengths (600-800 nm) (for 
maximum tissue light penetration, in order to generate high enough levels of 
cytotoxic species to induce tumour damage, makes PSs ideal candidates for 
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clinical PDT applications (Yoon et al., 2013; Debele et al., 2015; Zhang et al., 
2018). 
With reference to Table 2, Photofrin or hematoporphyrin derivative (HpD) is the 
most widely used first-generation PS, which presents characteristic bands at the 
Soret and Q bands wavelength region of 350nm-630 nm and it can effectively be 
utilized for CRC PDD and PDT applications. (Abrahamse and Hamblin, 2016; van 
Straten et al., 2017). However, PDD and PDT post-clinical studies by Allison and 
Moghissi et al. (2013) and Kawczyk-Krupka et al. (2016) on solid CRC tumors 
noted several disadvantages such as; insufficient tissue selectivity, prolonged 
photobleaching of the skin, with shorter peak of absorption, which reduced 
penetration of light for activation and phototoxicity, was reported in patients and so 
this hindered the use of HpD PS within these applications (Allison et al., 2013; 
Kawczyk-Krupka et al., 2016). Several other clinical trials supported that HpDs 
PDD and PDT for CRC applications may be effective, however, investigations also 
noted poor outcomes, due to unwanted side effects (Kohno et al., 2008; 
Zavadskaya et al., 2015).  As such, improved second-generation PSs which offer 
advantages over first-generation PSs have been developed. 
Thus, even though first generation PSs have dominated in PDT cancer research, 
several limitations, such as phototoxicity have spurred researchers on to 
investigate second-generation PSs that can alleviate the shortcoming of first-
generation PSs, as well as possess simpler composition and structures, with 
improved spectral and photochemical properties for PDD and PDT CRC 
applications (Singh et al., 2018; Kruger et al., 2019). Second-generation PSs have 
gained popularity and are extensively studied for PDD-PDT applications, owing to 
their good photochemical properties, such as excitation at a long wavelength, 
which results in deeper light penetration for improved outcomes (Baskaran et al., 
2018). 
Table 2 The outcomes and parameters of PSs’ used during PDD to diagnose, 
as well as PDT to treat CRC. 
Utilized PSs for PDD treatment of CRC 









Fluorescence accumulated consistently 
within the CRC cells, with no side adverse. 








Utilized PSs for PDD treatment of CRC 












Significant sensitivity of visual detection of 
fluorescence within the malignant lesions 
in the colon ranged at 94.9% and the 







1g of 5-ALA,  





Tumour visualization was observed. The  
overall sensitivity, specificity, and accuracy 
rate in detecting CRC cancer following  5-
Aminolevulinic acid (ALA) treatment  was 
between 57.7 to 66.7 %. 
Namikawa 
et al., 2015 
5-Aminolevulinic 
acid (5-ALA) 
250 mg/kg 5 –ALA, 
excitation of 405 nm 
HT-29 cells 
in mice 
The quantitative fluorescence ratio (red 
value assigned to 5-ALA) was increased in 
peritoneal metastases compared to 
healthy cells. 






In vitro 5 μM (O-chlorin) 
wavelength for excitation 
405 and 420 nm 
HT29 cells 
For PDD, O-chlorin showed higher tumor 
localization and higher fluorescence 
activity compared to the control PS 5-ALA.  
Nishie et al., 
2016 
Utilized PSs for PDT of CRC 





In vitro PDT; wavelength 
660 nm, energy of 16 J/cm HT29 cells 
O-chlorin accumulates in the lysosomes 
and induced apoptosis after irradiation in 
O-chlorin mediated PDT. 
Nishie et al., 
2016 







Significant reduction of tumour and relieve 
of symptoms, however, severe post-PDT 
skin photosensitivity. 




250 mg/kg 5-ALA , peak 
wavelength 635 nm, 
fluence rate 16 mW/cm2 
and fluence of 3.0 J/cm2 
HT-29 cells 
250 mg/kg 5-ALA effectively induced 
tumor death in vitro and in vivo. With tumor 
growth inhibition rate of 88 %. 
Hatakeyama 










(5-ALA) mediated PDT treatment resulted 
in a dose-dependent decrease of 80 to 93 









11.6µM) m-THPC, 24h, 
laser irradiation at 660 nm 





m-THPC-mediated PDT led to the 
inhibition of cell proliferation and reduced 
migration ability, which subsequently led to 
significant photo-killing of cultured cells. 
Abdulrehma
n et al., 
2018 
Chlorin e6 (Ce6)  SW620 CRC cell lines 
Administration of Ce6 PDT resulted in a 
tumour reduction, however, the possibility 
of CRC recovery was likely due to 
autophagy form of cell death from which 
CRC cells can recover, which was 
observed to be prominently present. 
Kaizhen et 
al., 2018 
Chlorin e6 (Ce6) 
0.5 μM(Ce6) irradiated 
with 16 J/cm2, wavelength 





Induced CRT translocation and HMGB1, 
which triggered immunogenic cell death. 
Tanaka et 
al., 2016 
Chlorin e6 (Ce6) 
8μg/ml Chlorin e6 
subjected to laser 
irradiation at 650 nm, 
light (6J /cm2) 
SW480 cells 
 
High dosage of Ce6 can effectively result 
in cell death, low dosage induced 
autophagy which can shield tumor, 
generally e6 mediated PDT, in a dose-




dependent manner, can enhance ROS 
generation and apoptosis, inhibit cell 
proliferation, reduced migration ability, and 
colony formation ability. 
Utilized PSs for PDT of CRC 




20µM ZnPcSmix, laser 





Loss of cellular viability with 40% cytotoxic 
induction of apoptotic cell death that is 
promoted by lysosomal photooxidation. 
Sekhejane 




100 ng/mL DVDMS, laser 
radiation at 630nm, 
fluency at 10 J/cm², 




Dose-dependent DVDMS-PDT effectively 
inhibited HCT116 cell proliferation and 
presented higher photocytotoxity and 
significant antitumor efficiency. 




1.25 mg/kg PPa,6h later, 
laser irradiation at 670 nm, 




7h post-treatment, tumor cell death in PDT 
was triggered by the release of singlet 
oxygen, efficacy dependent on PPa 
accumulation by photoexcitation of PS. 







TαPcZn stock solution 
diluted with final DMSO 
conc of 0.1% to get 54 
µmol/l. irradiation with red 





TαPcZn-PDT significantly induced 
cytotoxic apoptosis in LoVo treated cells. 





5μM(PaH), after 24h 
irradiated by visible light 
470 nm, the energy 
density of 10.8 J/cm2 
HT-29 cells 
PaH mediated PDT treatment destroyed a 
significant population of HT-29 cells. The 
rate of the most effective cell death was 
observed with an increase in a PaH 
concentration-dependent and light dose-
dependent manner. 
Wu et al., 
2016 
 
With reference to Table 2, researchers have extensively considered second-
generation PSs, such as porphyrin-like molecules (e.g. 5-aminolevulinic acid, 
chlorins), natural compounds like Hypercin, or structures that comprise of aromatic 
fused to pyrrole rings (e.g. phthalocyanines) for CRC PDD and PDT treatments. 
These second generation PSs have been considered for improved CRC PDD and 
PDT treatment outcomes, since they have longer absorption coefficients in the 
region of fluorescence and a high therapeutic transparency window, which permits 
for deeper tissue penetration, they also possess a shorter half-life, which offers 
negligible side effects, as well as selective passive tumor tissue accumulation 
(Singh et al., 2018).  
 
In CRC PDD, 5-aminolaevulinic acid (5-ALA) is commonly utilized PS for diagnosis 
(Ishizuka et al., 2011). 5-ALA is an endogenous biosynthetic precursor of the PS 
protoporphyrin IX (PpIX) and after accumulation in the cancerous tissue it has been 
utilized for various diagnosis and treatment of cancers, owing to its unique photo-
properties (Ishizuka et al., 2011; Ormond and Freeman, 2013). 
Hexaminolevulinate, is an n-hexyl ester of 5-ALA and it has been US FDA 
approved for the diagnosis of bladder cancer and several other PSs within this 
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family have been clinically approved for PDT applications (Ormond and Freeman, 
2013). 5-ALA can be used for  CRC PDD when activated at a short wavelength to 
produce fluorescence and it also can be activated at long wavelengths, allowing it 
to be used for both CRC diagnostic and PDT treatment applications (Ishizuka et 
al., 2011; Tewari et al., 2018). Several studies have shown the CRC PDD and PDT 
efficiency of PpIX, since it exhibits two particular emissions peaks; one at 375 to 
445 nm, which emits blue, or violet fluorescence for PDD applications and the other 
which emits at 705 nm for PDT treatment (Dobson et al., 2018; Inoue et al., 2012; 
Rollakanti et al., 2013). Nakamura et al. (2015) and colleagues reported on the 
selective accumulation, as well as visualizing CRC tumours with negligible side 
effects when using 5-ALA PDD (Nakamura et al., 2015). They showed that 
photoactivation of PpIX with a 400-410 nm laser light could mediate fluorescence 
visualization of CRC (Nakamura et al., 2015). Kitajima et al., (2019) also reported 
on a higher PpIX accumulation, within HT-29 CRC cells compared to healthy cells. 
The HT 29 CRC cells exhibited strong fluorescence, suggesting that the 5-ALA-
derived PpIX passively accumulated more within CRC cells (Kitajima et al., 2019). 
This study strongly recommended further research into the application of PpIX for 
enhanced PDD and PDT treatment of CRC tumours (Kitajima et al., 2019). Thus, 
the simultaneous PDD-PDT strategy appears to be a feasible application in CRC 
studies (Kitajima et al., 2019). However with reference to Table 2, several authors 
have reported on the diagnosis and treatment of CRC cancer, using 5-ALA and 
PpIX however, despite the successful outcomes, the overall sensitivity, specificity, 
and accuracy rate in detecting CRC was low and  effective PDT treatment was 
poor, due to the short absorption peaks of its activation (Hatakeyama et al., 2013; 
Ormond and Freeman, 2013). Thus, further studies are required to establish 
accuracy and optimization for PDD, as well as approaches to 5-ALA-PDT to 
mitigate its unwanted side effects. 
Chlorins belong to the second-generation PS group and they are a derivative form 
of porphyrins, with one reduced pyrrole rings within their structure, which offers a 
higher red-light absorption capacity (Glowacka-Sobotta et al., 2019). One 
formation of the Chlorins group, is the FDA-approved metatetra (hydroxyphenyl) 
chlorin (m-THPC), which has been approved for the treatment of several cancer 
types (Kawczyk-Krupka et al., 2016; Kaizhena et al., 2018). Chlorin PSs have been 
utilized for the PDT treatment of gastric, advanced head and neck, and metastatic 
breast cancer (Agostinis et al., 2011; Senge and Brandt, 2011). Chlorin PSs 
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generally have good solubility, with higher absorption bands within the red range 
(652 nm to 680 nm), that permit effective light penetration of the skin, hence there 
are several PS within the chlorin family that are under evaluation for PDT 
applications (Table 2) (Ormond and Freeman, 2013). Additionally, only small doses 
Chlorin PSs are needed to exert an effective treatment (Ormond and Freeman, 
2013). It has been reported that m-THPC PDT successfully activated apoptotic  
pathways in some CRC studies (Abdulrehman et al., 2018; Kaizhen et al., 2018). 
Furthermore, several studies reported that m-THPC mediated PDT triggered 
significant cellular morphology, viability, proliferation, and cytotoxicity responses in 
CRC tumour sites, however, induction of possible unwanted pro-survival 
autophagy cell death pathways and PDT resistance mechanisms was also 
observed (Kukcinaviciute et al., 2017; Ouyang et al., 2018; Lange et al., 2019; 
(Kaizhen et al., 2018). Even though Chlorin PSs have been extensively 
investigated for the PDT treatment of CRC, their PDD applications are limited 
owing to their inability to modulate sufficient fluorescence at short wavelengths 
(Kawczyk-Krupka et al., 2016). Studies by Shimizu et al. (2018) investigated 
Talaporfin sodium (TS: mono-l-aspartyl chlorine e6, or NPe6), which is chlorin 
derivative PS, that exhibited encouraging absorption peaks in the Soret band of 
398 nm and Q bands of 502, 530, 620, and 654 nm. Results from these studies 
reported that TS can emit fluorescence upon activation within its Soret band, as 
well as generate ROS and singlet oxygen when activated within its Q-band region 
(Shimizu et al., 2018). Several studies have reported on the diagnosis and 
antitumor of TS based PDD and PDT treatment of brain tumours, however, 
investigations into its photodynamic activity for CRC diagnostic and treatment 
applications remains unknown (Shimizu et al., 2018). 
Within second-generation PSs, Hypericin is a potent naturally occurring PS 
compound which has dual absorption within the short blue and high red 
wavelengths of light,  allowing for its application in dual PDD-PDT treatments 
(Jendželovská et al., 2016) (Table 2). Hypericin has been clinically evaluated for 
various cancers such as bladder, head and neck cancers, or gliomas treatment, 
however to date; hypericin has shown little success in CRC PDD and PDT 
applications (Jendželovská et al., 2016; van Straten et al., 2017). Several factors 
have been implicated in its underlying limited success. Studies by Jendželovská et 
al. (2016) and Kaleta-Richter et al. (2020) noted little success in CRC PDD and 
PDT applications, since Hypericin itself reported severe hydrophobicity and 
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aggregation issues in cells, which interfered with its tissue distribution, resulting in 
its inability to sensitively diagnose CRC, as well as produce enough cytotoxic 
species that could exacerbate cancerous tissues. Moreover, CRC resistance was 
associated with Hypercin PDT treatment, due to hypoxic effects being noted after 
irradiation, which could subsequently facilitate the survival of p53 deficient tumor 
resistant cells and so the risk of CRC recurrence became apparent (Kawczyk-
Krupka et al., 2016). Additionally, studies by Jendželovská et al. (2016), found 
multidrug-resistant Hypercin drug efflux transporters (i.e. ABC, MRP1, and BCRP) 
up-regulated in CRC cells, which could enable efflux of the intracellularly localized 
hypericin PS, resulting in decrease therapeutic effects for PDD or PDT applications 
(Jendželovská et al., 2016). 
According to literature, phthalocyanines (Pcs) are regarded as one of the most 
promising and commonly investigated second generation PSs, since they are 
extremely stable compounds (Sekkat et al., 2012). The absorption spectra for Pcs 
typically consist of two main bands, Soret-B band in the near UV in the region of 
300 – 400 nm, which is appealing for CRC PDD fluorescence, and a Q band with 
an intense, longer wavelength in the red to NIR region (670–750 nm) region for 
PDT applications (Sekkat et al., 2012). Since Pc PS possess a relatively strong 
absorption in the red visible spectrum, when compared to first-generation PS, they 
allow for activation within deeper-seated tumours to produce high yields of 
cytotoxic species and so are favorable in PDT treatments for various types of 
cancers (Sekkat et al., 2012; Chin et al., 2014). Furthermore, Pc PSs do not exert 
cytotoxic effects in a non-illuminated state and so their skin photosensitivity is 
minimal (Chin et al., 2014). However, in general the clinical utilization of Pc PSs in 
PDD and PDT applications, are limited, due to their water insolubility and strong 
tendency to form aggregates, which diminishes their effectivity (Chin et al., 2014). 
However, the presence of Pcs stable central core, give them the ability to 
accommodate various metallic and non-metallic ions, which can enhance their 
solubility, as well as longer wavelengths of activation, making them exceptional 
candidates in PDD- PDT application for CRC (de la Torre et al., 2013). Among 
these metallic ion Pcs PSs, zinc phthalocyanines (ZnPCs) have demonstrated 
significant potential for successful CRC PDD and PDT treatment (Calixto et al., 
2016). ZnPCs PSs are particularly attractive for CRC PDT applications, since they 
have intense absorption within the far-red visible spectra, which provides long 
triplet lifetimes and high levels of cytotoxic species (Gümrükçü et al., 2014). 
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Furthermore, ZnPCs PSs also exhibit Soret band peaks between 330 to 350 nm, 
which is feasible for PDD, however little to no research has been done with this 
particular PS in relation to CRC PDD applications (Brozek-Pluska 2015; 
Abramczyk et al., 2017).  
Overall, Table 2 displayed a summary of CRC investigations within in vitro and in 
vivo phases of clinical trials, with various classes of first- and second-generation 
PSs which noted improved outcomes for the diagnosis and eradication of CRC 
using PDD- PDT treatment. After evaluation of the results from Table 1 and 2, 
second-generation Pc PSs seemed to be the most favorable candidate for the 
treatment of CRC owing to their structural integrity, as well as the longer spectral 
and photochemical properties they possess, with PDD possible applications 
(Kruger et al., 2019). 
Therefore, development of third-generation PSs can be achieved through chemical 
modification, conjugation, or encapsulation of existing common second-generation 
PSs into various platforms such as NPs, in order to improve passive tumour PS 
absorption (Kruger and Abrahamse, 2019). Furthermore, they can be bound to 
targeting biomarkers, which include monoclonal antibodies, peptides, and small 
ligands, to allow PSs to specifically and actively localize in target tumor site only 
(Kruger and Abrahamse, 2019).  
Table 4 summarizes some research studies which have investigated third-
generation PSs for enhanced PS delivery in CRC. These current studies have 
suggested that third-generation PSs have the potential to improve PS tumor cell-
specific uptake and localization, allowing improved PDD PS photophysical and 
fluorescent properties, as well as concentrated tumor cytotoxic species generation 
for improved PDT treatment outcomes in CRC patients (Mehraban et al., 2015; Hu, 
2017).  
2.11.1   Zinc Phthalocyanine (ZnPc) PSs 
There have been significant efforts devoted to the development of PSs to improve 
the depth of drawbacks of PS activation, within deep seated tumours for photo 
medical applications (Zhang et al., 2018). ZnPcs are synthetic second generation 
PSs which comprise of a Pc central core that is metallated with Zinc substitutes, to 
allow for a further red-shifted absorption in the NIR region, which accommodates 
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long-lived excited states for potent PDT phototoxicity and allow for improved light 
tissue depth penetration (Sekkat et al., 2012) (Figure 10). 
 
Figure 10 Skeletal structure of metal phthalocyanine, zinc(II)phthalocyanine- 
tetrasulfonic anion (Abramczyk et al., 2017). 
According to studies by Chin et al. (2014), structurally modified diamagnetic Pcs, 
such as ZnPcs PSs are favorable candidates for PDT-PDD applications in cancer 
research, due to their improved chemical purity, efficient singlet oxygen production, 
high fluorescent quantum yields, with absorption Q bands and Soret bands which 
allow for simultaneous photo- diagnostic and treatment applications (Chin et al., 
2014). Additionally, since ZnPcs PSs strongly absorb in the red and NIR regions 
of the visible spectrum, with pronounced peaks greater than 630 nm, this facilitates 
maximum light penetration of 6-8 mm into the tumor region, allowing for high yields 
of cytotoxic species production in  PDT applications (Schmidt et al., 2018). 
Furthermore, since they possess a minimal absorbance between 400–600 nm, this 
contributes to reduced photosensitivity unwanted side effects (Sekkat et al., 2012). 
Studies by Schmidt et al. (2018) demonstrated that ZnPc-PDT showed improved 
cancer treatment efficacy, due to its PS intracellular localization within the nucleus 
and mitochondria cellular organelles, which enhanced apoptotic forms of cell 
death. Moreover, various studies have reported that ZnPcs PSs cause minimal skin 
photosensitivity and are rapidly cleared from the body post-PDT treatment, when 
compared to first-generation clinical PSs (Gümrükçü et al., 2014). One in vitro 
study revealed that excited ZnPc was taken up by tumoral cells and accumulated 
within intracellular organelles, such as the cytoplasm and mitochondria, and in a 
dose and time-dependent manner produced considerable long-lasting oxidative 
damage to cancer cells, with minimal toxicity to surrounding healthy tissues 
(Kuzyniak et al., 2016). Furthermore, reports by Mfouo-Tynga and Abrahamse, 
(2015) noted that ZnPc PSs exhibit promising phototherapeutic application 
properties, since its zinc central diamagnetic atom can generate high fluorescence 
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quantum yields, which effectively determine triplet state quantum yields of ROS 
and prolonged triplet lifetimes upon excitation. Additionally, in a study by  
Sekhejane et al. (2014), it was noted that PDT assays using a zinc phthalocyanine 
sulfonated mix (ZnPcSmix) PS apoptotic cell death was triggered within in vitro  
cultured CRC cell lines (DLD-1 and CaCo-2), since ZnPcSmix had a high affinity for 
neoplastic tissues and localized within mitochondria and lysosome organelles.  
However, since ZnPc PSs are derivatives of Pcs, their limitation in relation to 
effective PDT treatments or use as PDD fluorescence markers, is often due to their 
poor aqueous solubility and aggregation behavior (Chin et al., 2014). Therefore, in 
order to enhance their solubility and passive cellular uptake, ZnPCs are usually 
further functionalized with hydrophilic moieties or by modifying its sulphide groups 
into thioacetate groups (Chin et al., 2014). Moreover, accumulating evidence has 
noted that the simple structure of ZnPcs makes them ideal PSs for chemical 
modification and adaptation into third-generation PSs (Manoto et al., 2012; Naidoo 
et al., 2019). Zinc Phthalocyanine Tetrasulfonic Acid (ZnPcS4) is a solubilized 
tetrasulphide ZnPcs derivative PS, which has 4 SH / thioacetate groups, which 
enhance solubility, as well as enables easy chemical conjugation to various nano 
platform carriers (Siriwandana et al., 2014). ZnPcS4 has three major Q bands of 
emission: 583, 634, 674 nm, within the far-red spectral range for maximum tissue 
depth penetration and PS excitation for effective PDT outcomes applications 
(Abramczyk et al., 2017). Other studies have also noted that ZnPcS4 has an 
additional short-blue absorption B band, between 330 to 350 nm, which is ideal for 
PDD applications (Brozek-Pluska 2015). Furthermore, studies by Brozek-Pluska 
et al. (2020) utilized Raman imaging and spectroscopy to characterize and 
differentiate normal and cancerous colon tissues, based on ZnPcS4 PS vibrational 
features and found that ZnPcS4 PS noted a higher affinity subcellular localization 
uptake in CRC cells and reported excitation wavelengths at 340 nm and 689 nm, 
suggesting that this PS could possibly be successfully applied in PDT and PDD 
applications for the successful CRC photo- diagnosis and treatment, however 
further investigation was required (Brozek-Pluska et al., 2020). The above studies 
suggest that ZnPcS4 can preferentially accumulate within the CRC tissues and that 
upon absorption within the short blue light range, it can emit fluorescence for 
possible PDD applications, as well as has idealistic PDT generating cytotoxic 
abilities with the red light region and so this PS was selected as the choice for this 
study in order to investigate combinative PDD-PDT treatments in CRC cells. 
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2.12  Nanotechnology for the Passive and Actively Targeted Delivery of 
PSs 
In the last few decades, nanomaterials have become a popular approach to 
achieve precise and efficient delivery of drugs for diagnostic and therapeutic 
treatments in various cancer fields, since they can enter tissues at the molecular 
level (Patra et al., 2018; Kruger et al., 2018). NP structures have been developed 
as effective carriers and drug delivery systems, due to their specific 
physicochemical properties; large surface area to improve the passive payload of 
PS delivered to target cells for efficient absorption (Sivasubramanian et al., 2019). 
Furthermore, they have a simple, stable structure that can easily be functionalized 
to capacitate the combination of both diagnostic and therapeutic modalities into 
one combinative application (Patra et al., 2018). Further to this, the use of these 
engineered nanostructures specifically, offers several advantages and resolves 
some of the most critical limitations encountered within clinical diagnostic and 
treatment  applications (Patra et al., 2018). They improve the solubility and stability 
of drugs and so minimizing the off-target toxicity of anticancer drugs.  
Furthermore, they also offer the ability to distribute drugs, to the specific target 
sites when bound  with targeting agents such as monoclonal antibodies (ud Din et 
al., 2017). According to studies by Kruger and Abrahamse (2018) and 
Sivasubramanian et al. (2019), the small sizes of targeted NPs allow for the 
accurate intracellular uptake of drugs in the desired target cells, as well as allows 
for the accurate biodistribution of drugs in tumour cells and so yield prolonged 
lifespans of drugs in the blood circulatory system.  
Studies by ud Din et al. (2017) also noted that solid tumors, generally have a poor 
lymphatic drainage system, which can cause retention of circulatory molecules 
leading to the promoted passive accumulation of nanocarriers at a tumor site. 
Thus, nanodrug carrier formulations can be used as multistage vectors to enhance 
passive targeting  of drugs into tumour cells, through the enhanced permeation 
and retention (EPR) effect, whereby a NP drug passes through the gaps within the 
walls of tumours and they are sequentially not secreted, due a tumours suppressed 
lymphatic drainage (Golombek et al., 2018). This can improve passive drug uptake 
and transport in tumour cells and so assist in avoiding undesirable non-specific 
drug distributions (Sivasubramanian et al., 2019). However, some problems, 
including minimum delivery of the PSs at tumour site and NP to pore size ratio of 
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the tissue can affect nanocarriers drug uptake by the EPR effect within a tumours 
microenvironment (Zhang et al., 2017).  
Therefore, more recent studies tend to functionalize nanodrug carriers with active 
targeting agents, such as antibodies, proteins, and peptides, which can interact 
with receptors that are overexpressed at a tumour site and so specific and targeted 
uptake of drugs can be promoted (Singh et al., 2019). This approach can also 
increase the solubility of hydrophobic PSs, as well as improve selectivity and 
stability of PSs and most importantly reduce unwanted side and dark toxicity 
effects, due to a PSs selective uptake in target tumour cells only (Singh et al., 
2019). Studies by Sethi et al. (2014) have suggested that the particular properties 
of NPs, in relation to solubility, size, surface charge, shape, high drug loading 
capacity and drug efflux are of great advances in nanomedicine, in terms of the 
development to promote effective strategies which cab revolutionize cancer 
diagnosis and treatment. 
2.12.1  Nanocarrier Platforms for Enhanced PS Uptake in Tumours 
In order to achieve the high effectiveness of anticancer drugs, the administered 
drug should penetrate through tissue barriers and have the ability to selectively kill 
cancer cells (Crous and Abrahamse, 2020). Thus, functionalized NP platforms are 
widely used for targeting cancer cells to increase the intracellular concentration of 
drugs within the tumour and reduce dose-limiting toxicities towards healthy cells 
(ud Din et al., 2017; Crous and Abrahamse, 2020).  
 
Figure 11 Various organic NPs (micelles, liposomes, nanogels and dendrimers) 
and inorganic NPs (superparamagnetic iron oxide (SPIO), gold, 
quantum dots (QD) and lanthanide ions) carrier platforms used for 
enhanced PS uptake (Karimi et al., 2015). 
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Studies have reported the NP targeting strategy as an approach that can be used 
for efficient and actively targeted delivery of the PSs to the tumour tissues for 
enhanced PDD and PDT treatments (Kruger and Abrahamse, 2018). Various 
organic NPs, such as polymer/micelles, liposomes, and dendrimers and inorganic 
NPs, including carbon nanotubes, gold nanoparticles, and quantum dots) have 
unique physiochemical properties, with high capabilities to carry anticancer drugs 
to targeted cancer sites (Figure 11) (Kruger and Abrahamse, 2018). 
2.12.2  Passive Nanocarrier PS Uptake for PDD and PDT Applications 
in CRC  
One of the attractive sites that can contribute to the anticancer effect of 
conventional PDT is the tumour vasculature (Mesquita et al., 2018). The highly 
cytotoxic species generated by PDT light when the tumour site is irradiated, usually 
results in localized damage of cancer tumours, as well as their blood vessels 
(Mesquita et al., 2018). A passive uptake strategy in PDD and PDT applications 
facilitates the enhanced deposition of NP-PS formulations in tumour tissues via the 
EPR effect (Figure 12) (Bertrand et al., 2018).  
 
Figure 12 Schematic illustration of NP passive and active PS targeting 
strategies. In passive uptake, the PS-NPs cross through the leaky 
walls of a tumour and localize at the tumor site via the EPR effect. In 
active  targeting strategies specific ligands are conjugated to PS-NP 




The enhanced uptake of PSs in NP-PS formulations is improved upon, since NP 
carriers promote solubility, stability, and limit non-specific toxicity of PSs 
(Hodgkinson et al., 2017). Furthermore, NPs exploit tumour biology in relation to 
leaky tumor vasculature and impaired lymphatic drainage, in comparison to normal 
cells (which lack these features) and so NP-PS formulations enhance their passive 
absorption in tumour microenvironments more selectively using this morphological 
characteristic and so remain undistributed in normal tissues (Yu et al., 2016; 
Hodgkinson et al., 2017; Mesquita et al., 2018). The passive uptake of PS nano 
carriers is highly governed by a NPs distinctive physicochemical characteristics 
and distribution, as well as their longevity, size, shape, and surface composition, 
which all influence the overall the circulation time, penetration speed, and their 
overall intracellular internalization (Yu et al., 2016; Mesquita et al., 2018; Zhang et 
al., 2017). Some reports suggest that the utilization of shorter PS light intervals, to 
possibly necessitate PDT mediated vasculature effects only, by activating the PSs 
which are localization within tumour blood vessels, when compared to longer PS 
light intervals, which exert overall extensive damage, to entire tumour tissues 
(Chen et al., 2009; Agostinis et al., 2011 ). Gold NPs, silver NPs, quantum dots, 
polymer-based NPs, and silica-based materials are examples of PDT NP-PS 
delivery systems, which have been considered as idealistic delivery platforms for 
improved PS passive absorption in third-generation PS studies (Mehraban et al., 
2015). 
Overall, the application of PS-NPs to improve the efficiency of PDD and PDT has 
many advantages, such as fewer undesirable side effects, reduced dark toxicity, 
and improves the selective accumulation of the PS within the tumour (Hodgkinson 
et al., 2017). Generally, PS-NPs should be 50-200 nm in diameter, for favorable 
passive EPR mediated uptake, if it is larger than this in size, the tumour vascular 
permeability decreases, and consequently, tumor uptake rates decline (Bertrand 
et al., 2014).  
However, some studies have noted that elevated levels of tumour interstitial fluid 
exerted by the leaky blood vessels, can result in higher pressures within tumour 
sites, which reduces the blood supply to them and so impairs the passive 
absorption of PS-NP from reaching the inside cores of tumours (Zhang et al., 
2017). These downsides of passive PS-NP uptake can be overcome through 
utilizing specific cancer cell targeting PS-NP bioconjugates, to enhance PS directly 
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specific cancer cell uptake (ud Din et al., 2017). Thus, an optimal PS delivery and 
accumulation is greatly influenced by variables such as NP size, tumor location, 
and delivery mode (Patra et al., 2018). 
Table 3 lists several studies that have reported on effective use of PS-NP carrier 
platforms in order to promote passive PS delivery in CRC tumours. However, since 
gold NP platforms for enhanced passive PS absorption in CRC cells, were utilized 
within this particular research study they have been discussed in further detail 
below. 
Table 3 Summarizes various passive PS-NP platform delivery systems for 
enhanced PDD and PDT treatment of CRC. 
Passive PS-NP platforms for CRC PDT 






HT-29 cells irradiated with 6 J/cm2 of red light, 
wavelength 653 nm for 12 min, phototoxicity 
between 93-94% cell death, with 8 μg/mL pTHPP 
concentration. 
Pramual et al., 
2016 
Zinc phthalocyanine Liposomal 
Combination of PDT with SDT, irradiation at 
wavelength 670 nm, resulted in a 20% reduction in 
CT26 CRC cells . 
Bakhshizadeh 
et al., 2017 
5-Aminolevulinic acid (5-
ALA) 
Co polymer methoxy 
poly (ethylene glycol)-
chitosan 
PEG-Chito-5-ALA NPs exhibited higher 
accumulation and phototoxicity with significant 
apoptotic and necrotic forms of CRC tumor cell 
death than when compared to 5-ALA PDT alone 
within in vitro CT26 CRC cells. 
Chung et al., 
2013 
Chlórin e6 (Ce6) MPEG-Ce6 conjugates (Pe6) 
Enhanced delivery and ROS production, increased 
phototoxicy within the HCT116 human colon 
carcinoma cells. 
Chung et al., 
2016 
Chlorin e6 (Ce6) Methoxy poly (ethylene glycol) (MePEG) 
Enhanced singlet oxygen generation rate, with 
enhanced delivery and PDT cell death within the 
colon cells, improved cancer tissue penetration, and 
localization. 
Ryu et al., 
2018 





Pc9-T1107as a photocytotoxic agent, accumulated 
mainly in lysosomes and endoplasmic reticulum to 
trigger apoptotic cell death in 2D and 3D colon 








FosPeg®-PDT inhibited HT-29 CRC cells growth in 
a dose-dependent manner triggering apoptotic cell 
death. 








Effects of TPPOH-X SNPs-PDT on HT-29, HCT116, 
and SW620 CRC cell lines, reported enhanced 
antitumor efficacy, stronger cellular uptake, apoptotic 
cell death and improvement in tumor-targeting. 
Bretin et al., 
2019 
Passive PS-NP platforms for CRC PDD 
Conjugated PS Passive NP Platform Result Ref. 




5-ALA encapsulated in NPs was successfully 
released within Caco-2 CRC cells and subsequently 
was converted into PpX , which upon irradiation at 
635nm it emitted red fluorescence for tumor 
detection. 






2.12.3  Gold Nanoparticles (AuNPs) PS Delivery Platforms for PDD-
PDT Applications in CRC 
In recent years, the application of gold NPs (AuNPs) has expanded in different 
medical fields, and their therapeutic applications have been extensively studied in 
cancer treatment, as they are easy to synthesize through gold – thiol chemistry 
(Mesquita et al., 2018). Their high affinity of functional groups such as amino and 
cyano groups can be exploited to facilitate conjugation of target ligands, such as 
antibodies and PS molecules onto the high surface areas they possess (Mesquita 
et al., 2018).  Thus, owing to their biocompatibility and the high surface area they 
possess, AuNP surface functionalization may offer great capabilities for the 
development of a method that can provide maximum uptake and selective delivery 
of PS to the desired target sites, with reduce toxicity effects to healthy tissue, as 
well as promote the efficiency of simultaneous cancer diagnosis and PDT 
treatment (Deda and Araki, 2015). Moreover, they have exceptional tunable optical 
properties, due to their surface plasmon resonance, which is beneficial in PS light 
activation within the visible to NIR range (Abrahamse et al., 2017; Singh et al., 
2018). In addition, the surface plasmon resonance of AuNPs that are attached to 
PSs, has been associated with increased oxygen molecules upon laser light 
exposure, which is a beneficial aspect for effective ROS generation and 1O2 
production in PDT (Mesquita et al., 2018; Montaseri et al., 2020). Furthermore, 
studies by Abrahamse et al. (2017) have noted that AuNPs conjugated to PSs tend 
to promote PDT treatment outcomes in cancer cells, since their metallic center Au 
core, release photothermal heat upon laser irradiation activation and so assists in 
tumour cell destruction.  
Examples of the potential of targeting AuNPs by surface conjugation to target 
ligands, include a study by Obaid et al. (2015) which showed the targeted C11Pc 
PS PDT efficiency of jacalin and an anti-HER-2 antibody conjugated to C11Pc-
PEG AuNPs. C11Pc-PEG AuNPs were functionalized with jacalin, which is a lectin 
specific for the cancer-associated Thomsen-Friedenreich (T) carbohydrate antigen 
and they were functionalized with monoclonal antibodies specific for the human 
epidermal growth factor receptor-2 (HER-2) (Obaid et al., 2015). The PS actively 
targeted AuNPs demonstrated a cytotoxic effect against HT-29 CRC cells with a 
significant 80-90% decrease in cell viability. Within another study by Azhdarzadeh 
et al. (2016), applied thiol modified MUC-1 aptamers and photothermal gold-coated 
superparamagnetic iron oxide NPs, which not only displayed increased cell death 
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rates in CRC PDT, but also exhibited promising properties for theranostic 
modalities, which could allow for cancer cell imaging (Azhdarzadeh et al., 2016). 
Thus, AuNPs which have been conjugated to PSs, with surface-modified targets, 
could be utilized for the enhanced passive and active uptake of PSs in CRC 
tumours in order to promote PDD and PDT treatments is a feasible option, and so 
were chosen as the ideal PS platform for this study.  
2.12.4   Active Nano Drug Targeting PDD and PDT in CRC 
A defining aspect of active targeting is the surface modification of NPs using 
specific ligand conjugation (Hong et al., 2016). Active targeting NPs, use suitable 
cell-specific targeting ligands on the surface of NPs, which can bind to specific 
receptors on the surfaces of target cells to improve PS uptake and so improve PDD 
and PDT therapeutic efficacies (Jahan et al., 2017) (Figure 11). Inorganic 
nanomaterials such as quantum dots, solid lipids, self-illuminating nanocrystals, 
metal-oxide based NPs, and up conversion NPs are mostly utilized as PS carriers 
for efficient active targeting in PDD-PDT applications (Naidoo et al., 2018). 
Common examples of surface target ligands are biomolecules such as peptides, 
nucleic acids, and antibodies that have been used to overcome the limitations of 
passive targeting (Bertrand et al., 2014). The active targeting of NPs can permit 
modified PS to efficiently accumulate in cancer tissue, while minimizing the 
phototoxic side effects in healthy cells (Naidoo et al., 2018).  
Ideally, the targeted receptors that often bind to the specific biological ligands on 
surface-modified nanocarriers should be over-expressed in cancer cells, in 
comparison to healthy cells, in order to achieve active absorption of PSs for 
improved photo- diagnostic and therapeutic outcomes (Hong et al., 2016). 
Furthermore, the active targeting approach should have the capacity to improve 
the bioavailability of the PS without unnecessary shedding into the bloodstream 
before delivery to its target site, as well as exert minimal cytotoxic effects of PS 
drug to adjacent normal tissues (Hong et al., 2016). Within PDD-PDT applications 
for CRC, a targeting nano vehicles are usually conjugated to a PS, in order to 
promote its actively selective uptake in diseased polyps, whereby they can then be 
irradiated with a specific wavelength of light from a colonoscope (Kruger and 
Abrahamse, 2019).  
Studies by Abdelghany et al. (2013) investigated the therapeutic effectiveness of 
a chitosan/alginate nanoplatform comprising of a meso-Tetra(N-methyl-4-pyridyl) 
58 
 
porphine tetra tosylate (TMP) PS, which was bound antibodies, that directly 
targeted the overexpressed death receptor-5 (DR5) in CRC cells. The study 
revealed improved PS internalization and uptake enhancement through active 
targeting within an in vitro cultured HCT116 cell line, as well as improved tumour 
inhibition (Abdelghany et al., 2013). Studies by Sehgal et al. (2013) investigated 
the conjugation of ZnPcS PS to a monoclonal antibody directed against 
carcinoembryonic antigen (CEA) to improve targeted PS uptake within CRC cells. 
Their results showed that the CRC cell uptake of the bioconjugate was 37 times 
higher than compared to free ZnPcS administration. Furthermore, there was 
intense fluorescence, as well as high selectivity within CRC cells with negligible 
phototoxicity, when light excitation at 550 nm was applied to the co-culture (Sehgal 
et al., 2013). Thus, this study evaluated selective targeting of ZnPc-anti-CEA 
conjugate in CEA overexpressed CRC, suggesting that it could be particularly 
useful for PDT treatment, as well as be utilized as a PDD agent for the fluorescent 
surveillance of CRC cells (Sehgal et al., 2013). 
Other examples of the potential to improve PDD-PDT efficacy using active PS nano 
targeting platforms for CRC, have been included in Table 4.  
Table 4 Summarizes various active PS-NP platform delivery systems for 





Active PS-NP platform delivery systems for CRC PDD 
PS Active NP Platform Result Ref. 
Chlorin e6 (Ce6) Polyvinyl alcohol (PVA) nanoparticles 
The encapsulation of Ce6 in PVA resulted in a higher 
tumor-to-normal ratio and greater photobleaching in vivo 
fluorescence imaging with advanced necrosis after Ce6-




Phthalocyanine Silica NP 
Particle size was 28nm, absorption at 674nm, reduced and 
delayed photobleaching, and high efficiency in the 




chlorin e6 (Ce6) 
Hyperbranched Ce6 
was conjugated with 
hyaluronic acid (HA). 
HA used as a specific 
ligand to target CD44 
receptor 
Ce6tetraHA was recognized by CD44 receptor-over-
expressed in HCT116 cells. Enhanced accumulation, 
higher ROS productivity, and increased PDT efficacy. In  
vivo study observed that fluorescence intensity within the 
tumour was stronger than in healthy cells, however, 
blocked CD44 receptor by HA decreased the fluorescence 
intensity in tumor tissues. CD44 receptor- and GSH- dual 
sensitivity was observed when Ce6tetraHA nano 






Active PS-NP platform delivery systems for CRC PDT 
PS Active NP Platform Result Ref. 
Chlorin e6 (Ce6) 
Hyaluronic acid with 
single-walled carbon 
nanotubes (SWCNTs) 
In vitro cultured Caco-2 CRC cells displayed enhanced 
apoptotic cell death after PDT irradiation at 660nm, 









UCNP-Ce6-R837 nanoparticles with NIR enabled an  
enhanced PDT destruction of CRC tumors via the CTLA-
4 checkpoint blockade and R837 promoted strong 
antitumor immune responses, to eliminate the growth of 
distant tumors left behind after treatment. 
Xu et al., 
2017 
Chlorin e6 (Ce6) 
TBC-Hf an 
immunotherapy agent 
that inhibits indoleamine 
2,3-dioxygenase (IDO)  




The study observed a significantly effective PDT with 
suppressed  local and distant tumor growth in CRC 






Hypericin Histone deacetylase inhibitors (HDACis)  
The study observed  an enhanced CRC Hypercin 
mediated PDT within in vitro cultured HT-29 cells using 
Histone deacetylase inhibitors (HDACis) to evoke 
sensitization of CRC cells external stimuli to overcome 
their resistance to Hypercin by epigenetically reactivating 
the expression of CDKN1A. 
Halaburko
vá et al., 
2017 
Hypericin Pluronic P123 (P123) 
Hypericin was effectively delivered and studies reported 
potency of the P123 nanocarrier, which displayed 
improved permeation of Hyp into CRC cell membrane 








The study observed that HTfNPs enhanced  
bioavailability within CRC cells and high uptake of PS as 
well as aided in PDT epigenetic-based CRC therapy 
Sardoiwal













Pc9-T1107 conjugate demonstrated enhanced uptake in 
CRC lysosomal vesicles and the endoplasmic reticulum 
cellular regions with significant apoptotic cell death, 
as well as efficiently reduced cellular viability  
 
Chiarante 




Antibody or lectin 
conjugated 
C11Pc-PEG AuNP 
specific for human 
epidermal growth factor 
receptor-2 (HER-2) 
Irradiated at 633nm, singlet oxygen produced that 
mediated selective PDT, phototoxicity within the HT-29 












an IgG specific for CEA, 
a PS 
 
Radiant exposure of 94.5 J/cm2. Wavelength 690nm, 
LoVo, LS174T, DLD-1, and HT-29 cell line treated had 
different levels of susceptibility for PDT, the effect of 
antibody conjugate dose and light dose-dependent on 
the availability of CEA, within the CEA-expressing 
human colon adenocarcinoma. Increased specific 
binding and higher doses of (DTPA-hMN-14-700DX) 
conjugate resulted in effective treatment. 
 
Elekonaw
o et al., 
2019 
Chlorin e6 (Ce6) Ce6 conjugated to a monoclonal antibody 
Photo immunoconjugates (PICs) - constructed from Ce6 
conjugated and mAbs targeted and destroyed HT29 
cells CRC antigens with about 90% reduction in cell 






H+-coupled amino acid 
transporter PAT1 
(SLC36A1) 
PAT1 is an effective ALA transporter and may 










HANP/Ce6 facilitated accumulation within human colon 
cancer and destroyed tumour growth after irradiation at 
630 nm 




Even with these extensive ongoing studies aimed at designing novel NP-PS 
bioconjugates, further research to exploit opportunities on the NP-PS formulations, 
and the overexpressed specific antigen on CRC cell surfaces as targets for NP-PS 
delivery in PDD and PDT applications is still required (Naidoo et al., 2018).  
2.13 Receptor Based PS Drug Delivery Systems for the Specific PDD -PDT 
Active Targeting of CRC  
CRC is among the most difficult cancers to eradicate, due to the deep-seated 
nature of the neoplasm, which makes it hard to diagnose with conventional 
methods (Tiernan et al., 2013). Currently, the widely studied tumor-specific 
markers that have great potential to allow active targeting in CRC are 
carcinoembryonic antigen (CEA), folate receptor alpha (FRα), and the epidermal 
growth factor receptor (EGFR and HER2), since they are overexpressed within 
CRC cells (Tiernan et al., 2013; Xiang et al., 2013). Several other overexpressed 
proteins by CRC cells, that could be possible targets, are fibroblast growth factor 
receptor (FGFR), cluster of differentiation 44 (CD44), epithelial cell-adhesion 
molecule (EpCAM), carbonic anhydrase IX (CA IX), peroxisome proliferator-
activated receptor γ (PPARγ) and cyclooxygenase-2(COX-2) (Xiang et al., 2013).  
Various target ligands such as antibodies, aptamers, peptides, folic acid, and 
hyaluronic acids among others may also be used to actively target CRC tumors to 
enhance PS-NP drug delivery and improve internalization into these targeted cells 
(Tiwari et al., 2019). Studies by Tanaka et al. (2016) investigated immunogenicity 
of PDT with G-chlorin treatment in CT26 mouse CRC cells and found that PDT with 
G-chlorin generated ROS, which eradicated tumours by inducing necrosis and 
apoptosis. Furthermore, this cellular death subsequently resulted in the surface 
exposure of calreticulin (CRT) and the release of box 1 protein (HMGB1) in dying 
cells, which was relatively crucial for the indirect activation of immune effectors 
which enhanced PDT efficacy (Tanaka et al., 2016).  Studies by Xiang et al. (2013) 
reported that in all stages of colorectal tumorigenesis, there is an overexpression 
of Guanylyl cyclase C (GUCY2C, GC-C) on the apical surfaces of intestinal 
epithelial cell membranes.  
2.13.1 Anti-Guanylate cyclase C: Specific Monoclonal Antibody for 
Active Targeting of the Guanylyl cyclase C Receptor in CRC 
Cells 
Transmembrane intestinal receptor guanylyl cyclase C (GC-C) is a tissue-specific 
receptor that is expressed predominantly in the apical membrane surface of 
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intestinal epithelial cells and serves to regulate and increase intracellular cyclic 
guanosine monophosphate (cGMP) production and concentration in CRC cells 
(Rappaport and Waldman, 2018). When GC-C encoded by the GUCY2C gene 
binds to the endogenous gastrointestinal hormones guanylin and uroguanylin, it 
regulates proliferation and plays an essential role in metabolism, inflammation, and 
mucosal barrier function in the intestine (Danaee et al., 2017). Guanylyl cyclase C 
(GUCY2C) is a tumour mucosa receptor that has been found to abundantly 
expressed by CRC cells (Danaee et al., 2017). The overexpression of GUCY2C 
by CRC tumor tissue can be exploited as a potential biomarker for this type of 
cancer (Aka et al., 2017). Other studies accomplished the active delivery of 
cytotoxic drugs to CRC cells by using antibody-drug conjugates (ADCs), whereby 
a model of GUCY2C-targeted ADC was developed, comprising of a GUCY2C 
antibody, ricin toxin payload and cleavable disulfide linker (4-
succinimidyloxycarbonyl-α-methyl-α-2-pyridyldithio]- toluene; SMPT (Aka et al., 
2017). It was also observed that the GC-C receptor is overexpressed within more 
than 95% of primary and metastatic CRC cells and so specifically targeted drug 
delivery systems could be conjugated Anti-Guanylate Cyclase monoclonal 
antibodies (Anti-GC-C mAb) in order to enhance active drug uptake (Danaee et al., 
2017). The clinical advantages of CRC PDD and PDT lie in the capability of a PSs 
to be selectively absorbed within targeted cancer cells and so using Anti-GC-C 
mAbs to targeting CRC overexpressed GUCY2C receptors, could potentially aid in 
precise and efficient PS active delivery in CRC tissues (Hong et al., 2016; Aka et 
al., 2017). Thus, the Anti-GC-C mAb was the chosen biomarker target in this study 
for incorporation in the NP-PS formulation, to possibly enhance actively targeted 
PS delivery for possible enhanced PDD-PDT applications in CRC cells.  
2.14  Summation 
During the past decade, the incidence and mortality rate of CRC has risen sharply 
with nearly 1 million new CRC cases and annual 700,000 deaths recorded globally 
(Hodgkinson et al., 2017). As the global burden of CRC continues, a significantly 
large number of cases and deaths could be optimally reduced by early diagnosis 
and treatment of colorectal polyps (Simon, 2016). From this review it can be 
concluded that even though several traditional CRC diagnostic and treatment 
modalities are currently used, they have not shown optimal results, due to 
numerous limitations, such as invasiveness, damage to healthy tissue, and non-
specific targeting (Marmol et al., 2017). To overcome some of the challenges, it is, 
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therefore, necessary to develop a more effective and less invasive CRC early 
diagnosis and effective treatment modality, with limited side effects. PDD and PDT 
are indispensable diagnostic and treatment modalities, that have shown promising 
combinative outcomes for the effective diagnosis and treatment of cancer (Naidoo 
et al., 2019). 
Studies by Portilho et al. (2013) and Calavia et al. (2018), suggested that the 
ZnPcS PSs and AuNPs conjugates exhibited substantial potential in PDT and PDD 
applications. They showed a significant increased passive PS uptake within cancer 
cells, with high triplet and singlet oxygen quantum yields in PDT treatments and 
reported improved PPD illumination in comparison to ZnPcS PSs administration 
alone. This was due to the PSs nanocarrier enhanced solubilization of the PS and 
its promoted NP mediated passive localization within tumour cells (Portilho et al., 
2013; Calavia et al., 2018). However, these studies noted that further 
functionalization of the ZnPcS-AuNPs conjugates into active targeting moieties 
could potentially promote PDD and PDT outcomes in cancer.  
Thus within this study, in order to further enhance host PS active accumulation and 
specific cellular targeting of CRC PDD-PDT treatment, mAbs antibodies (such as 
Anti-GC-C) were conjugated onto the surface of a AuNPs-ZnPcS4 PS nanocarrier, 
which was Pegylated to enhance the biocompatibility and stability of the 
nanoconjugate, in order to study if it could effectively enhance CRCPDD-PDT 
treatment outcomes, when the PS was administered, within its actively targeted 
















3.1 Study Design 
Appendix A outlines the methodical workflow of this study in a form of a flow 
diagram. This research study was approved by the Higher Degrees Committee 
(HDC-10-2019) and the Research Ethics Committee (Ethical Clearance Reference 
Number REC-01-13-2019) of the Faculty of Health Sciences, University of 
Johannesburg as indicated in Appendix B. Appendix C is a compilation of all 
consumables used in this study including the catalogue numbers and the 
manufacturer they were purchased from. In addition, Appendix D lists all 
chemicals, reagents and media utilized in this study. Appendix E shows all the 
formulas and calculations implemented within this study. 
To ensure the integrity, validity and reliability of the results, as well as safeguard 
the health and safety of the laboratory personnel, it was of paramount importance 
to adhere to the Good Laboratory Practices (GLP) guidelines throughout this study. 
Therefore, to minimize contamination, all necessary equipment and lab 
consumables were sterilized before use and constant aseptic disinfection 
techniques were upheld by spraying 70 % ethanol (D1). Furthermore, appropriate 
personal protective equipment (PPE) (such as lab coats, surgical mask safety 
goggles, gloves, disposable sleeve protectors) were always worn and all 
experiments were conducted under sterile conditions using a biosafety level 2 
cabinet. Lastly, all solid and liquid waste was disposed of in the appropriate 
biological waste containers, which was removed and disposed of by the University 
in the appropriate manner. 
3.2 Aim of Study  
The aim of this study was to combine an efficient cytotoxic oxygen generating 
hydrophilic tetra sulphonated metal based PS known as Zinc Phthalocyanine 
Tetrasulfonic Acid (ZnPcS4), with CRC specific targeting antibodies – Anti-
Guanylate Cyclase Ab (Anti-GCC) on the surface of heterobifunctional PEG amine 
stabilized AuNPs, in order to enhance the active PS uptake specifically in CRC 
cells, so the PDD and PDT treatment of CRC tumours could be improved. 
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3.3 Chemical Composition of Actively Targeted PS Nanoconjugate  
3.3.1  Zn (II) Phthalocyanine tetrasulfonic acid (ZnPcS4) PS 
Zinc (II) Phthalocyanine tetra-sulphonic acid (ZnPcS4) was the PS used in this 
study and it was purchased from Santa Cruz® Biotechnology (sc-264509A, 
molecular weight 898.15 g/mol). ZnPcS4 is a typical phthalocyanine PS which has 
two typical major absorption bands, one at 340 nm (B or Soret band) and one 
between 600-700 nm (674nm - Q band), which is typical for phthalocyanines 
(Brozek-Pluska et al., 2015). ZnPcS4 powder can be solubilized in distilled water 
or 0.001M Phosphate buffered saline (PBS) and three major Q bands of emission 
can be noted at 583, 634, 674 nm within the far-red spectral range (Brozek-Pluska 
et al., 2015). Moreover, ZnPcS4 is tetra-sulphide derivative and so has 4 
thioacetate groups, seen as sulphur-hydrogen (SH) bonds in its chemical 
composition. These sulphide derivatives allow for ta ligand exchange process to 
be used to link the ZnPcS4 PS to AuNP-PEG5000-SH-NH2 and so form a strong 
gold-sulphur bond (Au-S) (Siriwandana et al., 2014) (Figure 13). Additionally, a 
ligand absorption process can also occur, whereby the PS ZnPcS4 sulphonated 
groups can link to the polyethylene glycol (PEG5000-SH) surface coating of the 
AuNP-PEG5000-SH-NH2, forming weak di-sulphide bonds (Nombona et al., 2011; 
Siriwandana et al., 2014). 
 




3.3.2  Gold Nanoparticles PEG5000-SH-NH2 Functionalized (AuNP-
PEG5000-SH-NH2) 
Gold nanoparticles (AuNP) of approximately 10 nm in diameter which were amine 
(NH2) functionalized and Polyethylene glycol (PEG 5000 SH) coated were 
purchased from (Sigma-Aldrich 765309). They have an absorption spectrum 
reading of 520nm, molecular weight of 18.02 g/mol and concentration optical 
density of 50, which equates to 2.85 X 1015 particles per ml dispersed in water.  
The commercially purchased AuNPs employed in this study were amine (NH2) 
functionalized in order to facilitate the linkage of an antibody for enhanced targeted 
delivery of the ZnPcS4 PS to CRC tumour sites (Figure 14). The attachment of the 
target antibody to the AuNP was achieved via EDC (1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride) and NHS (Dhydroxysulfo-
succinimide sodium salt) chemistry. This chemical bonding approach was used to 
establish amide bond formation by activating the carboxyl group of the c’ terminus 
of the target antibody to interact and so bind with the amine functionalized AuNPs. 
Moreover, the AuNPs were PEG 5000 coated to enhance stability and ligand 
exchange, within the final actively targeted PS nanoconjugate (Siriwandana et al., 
2014). 
Figure 14 Chemical structure of PEG5000-SH-NH2 functionalized AuNP. 
Since, Hong et al. (2015) noted that AuNPs can be further functionalized with 
targeting biomolecules (such antibodies) that are overexpressed in tumour cells, 
causing a nano drug carrying system to only actively and specifically bind to 
targeted receptor tumour sites and studies by Conde et al. (2012) noted that in 
PDT applications AuNPs have laser light induced theranostic properties, which 
assist in tumour annihilation, this NP seemed to be an excellent choice as a 
nanocarrier platform. 
3.3.3  Anti-Guanylate Cyclase Antibody (Anti-GCC Ab)  
Guanylyl cyclase C (GCC) is a cancer mucosa antigen universally overexpressed 
by primary and metastatic human CRCs, suggesting its unique utility as an 
antigenic determinate active target site for NP-PS active drug delivery (Danaee et 
al. 2017). Anti-Guanylyl cyclase C antibody (Anti-GCC Ab) was purchased from 
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Abcam (ab122404) and was conjugated to the bound AuNPs and ZnPcS4 
nanoplatform for active PS delivery and enhanced PDT, since it has tissue 
specificity for all  types of CRC cells (Almhanna et al., 2016). 
3.3.3.1 Anti-GCC Ab Purification  
Commercially available antibodies often contain impurities (e.g. BSA, glycine, tris, 
and azide) that interfere in molecular bonding reactions. The AbSelect™ 
Purification System (Expedon: 860-0010) was used to remove the azide 
contaminates from the commercially purchased Anti-GCC Ab, following the 
recommended manufacturers protocol. Briefly, the method involves capturing the 
antibody on the AbSelect Protein A resin. Protein A resin has a high affinity for the 
Fc regions of antibodies. Once the antibody has bound to the Protein A resin, 
unwanted substances can be removed by simply washing the resin. The antibody 
is then eluted and neutralized.  
The eluted, neutralized and purified Anti-GCC Ab’s from the AbSelect protein 
collection tubes were pooled into a final volume of 300 ul.  The Jenway Genova 
Nano Plus Life Science Spectrophotometer protein direct UV option was utilized to 
determine the antibodies concentration before and after purification. The 
antibodies concentration after purification was found to be 457.7 ug/ml. Then the 
purified Anti-GCC Antibody was diluted to 200 µg/ml (D2) with 0.69 ml of 0.001 M 
PBS (D3). This working concentration of the diluted Anti-GCC Ab was then stored 
at -20°C, in frozen aliquots and only thawed upon use.  
3.4  Chemical Synthesis of Actively Targeted PS Nanoconjugate 
3.4.1 Zinc(II) Phthalocyanine tetra-sulphonic acid (ZnPcS4) Solubilization 
In order to solubilize ZnPcS4 and make a stock concentration of 0.0005M, 0.0006 
g of ZnPcS4 powder was added to 1.25 ml of 0.001M Phosphate Buffer Solution 
(PBS) (D4). The ZnPcS4 stock solution was then mixed well, wrapped in aluminum 
foil (as it is a light sensitive and exposure to light before required laser light 
irradiation activation can result in pre-mature oxidation and so render it in effective) 
and stored in the dark at room temperature. To make a working stock concentration 
of 0.000125 M or 125 µM (D5), 1 ml of ZnPcS4 stock solution (0.0005M) was diluted 
with 4 ml of 0.001M PBS and mixed to make a diluted 0.000125 M or 125 µM 
concentration which was used throughout the experimentation, this concentration 
was determined in ZnPcS4 PDT dose response assays (Section 3.10). 
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3.4.2  Conjugation of ZNPcS4 to AuNP-PEG5000-SH-NH2: Ligand Adsorption 
and Exchange on Pegylated Gold Nanoparticle Surfaces  
1 ml of AuNP-PEG5000-SH-NH2 which contained 2.85 X 1015 AuNPs per ml were 
added to 1 ml of 0.000125 M working stock ZnPcS4 (D5) in a micro tube, which 
was covered with tin foil to prevent premature light exposure. The micro tube 
contents were mixed at room temperature overnight using a multifunction vortex 
mixer set (DAIHAN-brand® MVM-10 with a Microtube Platform Head purchased 
from Celsius), at 1500 rpm, in order to enhance gentle mixing of both compounds 
with a constant circular, oscillating movement to promote spontaneous ligand 
exchange and adsorption within both chemicals through gentle agitation. Studies 
by Woehrle and colleagues (2005), noted that a ligand exchange and absorption 
reaction time is highly dependent on the thiol ligand and chain length of molecular 
conjugate and so the time required for this process to occur can range from 30 
minutes up to 24 hours. During the ligand exchange process the intention was that 
the gold (Au) of the AuNP and the sulphur groups on the ZnPcS4 would create a 
strong Au-S bond (Siriwandana et al., 2014). Additionally, the hope was that the 
ligand absorption process would occur between the sulphonated ZnPcS4 and the 
SH group on the AuNP-PEG5000-SH to create weak di-sulphide bonds 
(Stuchinskaya et al., 2011).  
The next day the mixture was purified by micro-centrifugation using a B115-18R - 
NovaFuge High Speed refrigerated centrifuge with a 0112022/18 - Fixed Angle 
Rotor - 12 x 2,2ml from Celsius Scientific at 4°C, 18000rpm / 20860xg for 1 hour. 
Note: such a high centrifugation speed was required in order to ensure that the 10 
nm AuNPs could successfully be pelleted out of solution (24000g for 45min for 
10nm size particles). The supernatant was then removed in order to discard any 
unbound ZnPcS4 that remained free in solution. The pellet which contained the 
conjugated ZnPcS4 and AuNP-PEG5000-SH-NH2 was re-suspended in 1 ml of 
0.001 M PBS (D3). 
The re-suspended conjugated ZnPcS4 – AuNP-PEG5000-SH-NH2 was then further 
utilized in experiments below, as well as subjected to molecular characterization 
assays (Section 3.5). When not in use it was stored in the dark at 4°C. 
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3.4.3 Conjugation of Anti-GCC Ab to AuNPPEG5000-SH-NH2 - ZnPcS4: 
Amide Bond Formation  
In order to successfully bind the previously purified Anti-GCC Ab (Section 3.3.3.1) 
to the above conjugated ZnPcS4 – AuNP-PEG5000-SH-NH2 (Section 3.4.2) amide 
bonding formation was needed.  
This amide bond was achieved by covalent mode carbodiimide crosslinker two-
step coupling chemistry utilizing EDC and NHS coupling chemistry methods, which 
were adapted from Decker and Oldenberg (2017), Stuchinskaya et al. (2011) and 
Vashist et al. (2012). This two-step coupling chemistry allowed for the activation of 
the carboxylic group on the c’ terminus of Anti-GCC Ab (Jazayeri et al., 2016). This 
activation converted the carboxylic moiety of Anti- GCC Ab to a succinimidyl ester, 
which then reacted with the amine group (NH2) on the functionalized AuNPs in the 
ZnPcS4 – AuNP-PEG5000-SH-NH2 conjugate, forming a stable amide bond 
between the ZnPcS4 – AuNP-PEG5000-SH-NH2 and the Anti-GCC Ab (Jazayeri et 
al., 2016). The working concentration of 200 µg/ml of the previously purified and 
diluted Anti-GCC Antibody (D2) that was stored at -20°C, in frozen aliquots was 
thawed upon use.  
0.4 mg of EDC N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride and 
1.1 mg of N-Hydroxysulfosuccinimide sodium salt ≥ 98 %, were added to 500 µl of 
the thawed 200 µg/ml Anti-GCC Ab (D2). The mixture was the gently vortex until 
all reagents became solubilized. The mixture was then incubated at room 
temperature for 30 minutes with gentle agitation at 1500 rpm (using the 
multifunction vortex mixer set) to allow for activation of the carboxyl groups on the 
Anti- GCC Ab c’ terminus. Then 10 µl of quencher (50 % w/v hydroxylamine) (D6) 
was added to deactivate any active NHS-esters and the mixture was then vortex 
and incubated at room temperature for 10 minutes with gentle agitation again. The 
mixture was then subjected to 13 500 rpm micro-centrifugation at 4°C for 5 minutes 
in order to concentrate and collect the activated Anti-GCC Ab. The pelleted Anti-
GCC Ab was then re-suspended in 0.001 M PBS (D3) to bring its final 
concentration to 200 µg/ml, which was confirmed using the Jenway Genova Nano 
Plus Life Science Spectrophotometer protein direct UV option.  This activated Anti-
GCC Ab (200 µg/ml) was then added to the ZnPcS4 – AuNP-PEG5000-SH-NH2 in 
1 ml 0.001 M PBS, which was synthesized above and vortexed. The mixture was 
then gently agitated overnight at 1 500 rpm to encourage and promote Anti-GCC 
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Ab attachment to the amine functionalized groups of the PEG coating on the 
AuNPs. The next day the mixture was purified to discard any antibody that 
remained free in solution by micro-centrifugation at 15 200 rpm, 4°C for 1 hour. 
The supernatant was removed, and the pellet was re-suspended in 1 ml 0.001 M 
PBS (D3). The final actively targeted PS nanoconjugate (ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab) was then subjected to molecular 
characterization assays (Section 3.5).  When not in use it was stored in the dark at 
4°C.  
Note: as to ensure the efficient conjugation of the Anti-GCC Ab to primary amines 
on AuNPs all experiments were performed at physiologic pH. Moreover, it must be 
mentioned that only the Ab (and not the AuNP-PEG5000-SH-NH2) was treated with 
EDC/NHS carbodiimide crosslinker coupling chemistry. This was done as to 
ensure that only the carboxyl c’ terminus of the Anti-GCC Ab was activated and so 
could bind to the amide functionalized group on the AuNPs PEG coating, allowing 
the n’ terminus of the Ab to remain unbound and unaffected during the conjugation 
process, in order to preserve the Abs n’ terminus active targeting for effective and 
specific PS uptake targeting. The EDC/NHS chemistry could have been applied to 
the Ab and AuNPs, however this would have also activated the carboxylic group 
on the PEG coated AuNP, causing the n’ terminus of the Abs to bind to the 
activated carboxyl’s on PEG, blocking their active sites. This would have impaired 
the function of the Anti-GCC Ab antigenic binding sites, sterically blocking them 
upon conjugation to the AuNP-PEG5000-SH-NH2 and so effective PS targeting of 
CRC cells would have been unachievable. Thus for this reason, only the Anti-GCC  
Ab was activated with EDC/NHS chemistry, as to ensure the correct orientation of 
the Ab attachment (i.e. c’ terminus bound to AuNP-PEG5000-SH-NH2 and n’ 
terminus free for active site targeting), to the PS carrying molecule (ZnPcS4 – 
AuNP-PEG5000-SH-NH2) in order to produce a bio-active Ab targeting NP for 
effective PS delivery. 
3.5  Molecular Characterization of the Final Actively Targeted PS 
Nanoconjugate 
In order to validate the effective binding of Ab and PS to functionalized AuNP 
surfaces as well as the stability of the  multicomponent active nano-PS molecular 
drug conjugate the following molecular characterization tests were performed; 
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3.5.1 UV-Visible Spectroscopy 
In order to substantiate the successful binding of the antibody and PS to the 
surface of the AuNPs, as well as PS photostability and ROS generation, the final 
actively targeted PS nanoconjugate underwent UV−Vis spectra analysis.  
The UV-Visible absorption and fluorescent spectra of the final actively targeted PS 
nanoconjugate (AuNP-PEG5000-SH-NH2 + ZnPcS4 + Anti-GCC Ab) and various 
controls (AuNP-PEG5000-SH-NH2, ZnPcS4, Anti-GCC Ab, AUNP-PEG5000-SH-
NH2 - ZnPcS4) were captured using a Jenway Genova Nano Plus Life Science 
Spectrophotometer. Upon blanking the instrument with 0.001M PBS (D3), 2 ul of 
well-mixed samples devoid of bubbles were loaded onto the sample pedestal. The 
absorption and fluorescent spectra were analysed by spectrum/purity scan mode 
within the 198 to 800nm spectral region and 220nm protein direct UV option.  
The protein and ZnPcS4 PS concentration, as well as number of bound AuNP of 
the final actively targeted PS nanoconjugate was confirmed by comparing original 
spectra of unbound chemical components (ZnPcS4, AuNP-PEG5000-SH-NH2, 
Anti-GCC Ab) at known concentrations with final spectra obtained from the bound 
final actively targeted PS nanoconjugate (ZnPcS4 – AuNP-PEG5000-SH-NH2 – 
Anti-GCC Ab) (Tan et al., 2015).  
3.5.2 Fourier Transform Infrared (FTIR) Spectroscopy  
Fourier Transform Infrared (FTIR) spectroscopy in an analytical technique used to 
identify the occurrence of different types of chemical bonds present in a sample by 
yielding an infrared absorption spectrum as a molecular “fingerprint” (Athar, 2015). 
FTIR is a method used to detect the chemical bonding occurring in organic and in 
organic complexes (Athar, 2015). It is used for the quantification of components in 
an unknown mixture (Athar, 2015). The wavelength of light absorbed signifies a 
particular chemical bond in a molecule (Athar, 2015). Molecular bonds vibrate at 
different frequencies dependent on types of bonds and elements involved (Athar, 
2015).  
FTIR analysis was therefore performed on the AuNPPEG5000-SH-NH2 - ZnPcS4 
conjugate for confirmatory ligand exchange and absorption bond analysis, by 
noting and identifying the existence of strong Au-S and weak disulphide bonds in 
FTIR spectra when compared to AuNPPEG5000-SH-NH2 alone. Furthermore, the 
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final actively targeted PS nanoconjugate (AuNPPEG5000-SH-NH2 + ZnPcS4 + 
Anti-GCC Ab) was also subjected to FTIR analysis for confirmatory amide bond 
analysis, by noting and identifying the formation of amide bonds when compared 
to the FTIR spectra of AuNPPEG5000-SH-NH2 alone. 
In order to ensure the accuracy of PerkinElmer FT-IR spectrometer, the liquid 
samples were solidified into a powder form so that the instrument could not only 
detect the peaks of the 0.001M PBS solvent. Thus, 50 µl was removed from each 
sample to be analyzed and kept in a -80 freezer overnight. The following day the 
frozen samples were kept in a freezer dryer for 2 days to solidify. Thereafter, the 
solidified samples were grinded into a fine powder ready to be analyzed. 
Prior to running the samples, the PerkinElmer FT-IR spectrometer was cleaned 
with acetone and blanked with potassium bromide (KBr). Each sample was mixed 
with KBr and the mixture was compressed using a hydraulic press to form a pellet. 
The pellet was then placed on sodium chloride plate of the FT-IR spectrometer for 
analysis. The infrared spectra results were recorded using far infra-red solution 
software at frequencies ranging from 400 to 4000 cm-1 with 25 scans.  
3.5.3 Dynamic light scattering (DLS) and Zeta potential (ZP) 
Size distribution and surface charge of therapeutic drug delivery systems are 
paramount parameters which require investigation, as they influence in vivo 
kinetics and interactions with cellular and biological membranes and so allows one 
to determine the overall efficiency of the delivery systems (Rahdar et al., 2019). 
Dynamic light scattering (DLS) and Zeta potential (ZP) are convenient and 
reproducible techniques used to establish particle size distribution, shape, surface 
charge, purity and functionalization (for active targeting), as well as assist in 
identifying successful biomolecular conjugation (Bhattacharjee ,2016). 
DLS and ZP measurements were performed in triplicate with 15 runs each, using 
the Malvern Zetasizer Nano ZS (Malvern Instruments, Malvern UK), which has a 4 
mW He-Ne laser of 633 nm wavelength. Twelve microliters of each sample were 
loaded into a clean, scratch free plastic Zeta 3 x 3 mm dip cell cuvette, which had 
in-built electrodes capable of DLS and Zeta measurements. All analyzed samples 
were heterogeneous or homogenous 10 to 50 µg/ml diluted suspensions in water, 
which were free of any form of precipitation. All experiments were performed at 
25°C, at a 13° and 173° angle. Samples to be analyzed and compared consisted 
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of AuNP-PEG5000-SH-NH2, ZnPcS4, ZnPcS4 – AuNP-PEG5000-SH-NH2, Anti-
GCC Ab and ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab. 
However, studies by Brozek-Pluska et al. (2016) stated that chromatic or 
fluorescent samples, such as the ZnPcS4 PS drug investigated within this final 
actively targeted PS nanoconjugate study possess fluorophores, which absorb at 
350nm and emit at 583,634 and 674nm range. The one emission wavelength of 
ZnPcS4 lies within the range used by DLS for data acquisition, slightly above the 
633nm laser wavelength, and therefore possible interference with the results could 
be reported (Geißler et al., 2015). Hence, additional UV-Vis and FTIR spectra 
techniques (as discussed above) were used to further validate the successful 
conjugation of all components within the final actively targeted PS nanoconjugate. 
3.5.4 Presumptive ROS Generation  
Considering that the final actively targeted PS nanoconjugate contained ZnPcS4 
which absorbs at 350nm (Soret Band) and emits at 583, 634 and 674nm range (Q 
band) in PBS (Brozek-Pluska et al., 2016), it should have the capacity to generate 
ROS. However, it is argued that the conjugation of PSs to NPs may result in a 
quenched fluorescence and so reduced ROS production (Wu et al., 2017). 
Thus, in order to presumptively substantiate if the final actively targeted PS 
nanoconjugate was capable of yielding ROS prior to conducting PDT experiments, 
its UV-Visible absorption and fluorescent spectra were captured, before and after 
laser irradiation exposure.  
Laser irradiation experiments consisted of transferring 1ml of the final actively 
targeted PS nanoconjugate solution in a small cell culture dish and subjecting it to 
laser light from a Roithner 1000mA 673nm high power diode laser (Arryo 4210) at 
a fluence 10 J/cm2, for approximately 10 minutes in the dark, while vigorously 
stirring it and then measuring its UV-Vis absorption post-irradiation. UV-Vis 
absorption and fluorescent spectra readings were recorded using a Jenway 
Genova Nano Plus Life Science Spectrophotometer, using the spectrum/purity 
scan mode within the 198 to 800nm spectral region. Small increments of 2 µl of 
well-mixed samples, which were free of bubbles, were loaded onto the sample 
pedestal, after being blanked with 0.001M PBS (D3).  
The presumptive production of ROS of the final actively targeted PS 
nanoconjugate was determined by comparing the decay in absorbance intensity of 
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the UV-Vis Q band in the known 634 and 674 nm range of ZnPcS4, pre and post 
laser irradiation with that of a previously run control sample of ZnPcS4 alone.  
3.5.5 Photostability Analysis 
Photostability testing of drugs is a crucial parameter in the pharmaceutical industry, 
as several drugs are sensitive to light and may degrade during production, storage 
and administration (Ahmad et al., 2016). Therefore, this may hamper the potency 
and therapeutic efficacy of the drug, as well as cause unwanted biological effects 
(Ahmad et al., 2016).  
In PDT, an ideal therapeutic PS should be stable and remain in the triplet state for 
a relatively long time (Rojkiewicz et al., 2013). Only upon irradiation, it should 
transform into an excited state, transfer its energy to adjacent molecules and then 
decay back to the ground state (Rojkiewicz et al., 2013). Sometimes PS can 
degrade overtime and so lose their absorption and excitation properties. This 
degradation many be due to many external properties, such as the solvent they 
have been suspended, storage conditions, additional substituents being present or 
aggregation (Rojkiewicz et al., 2013). 
In order to determine the photostability of the final actively targeted PS 
nanoconjugate the Soret and Q bands values were measured prior to laser light 
irradiation experiments over the duration of experimental assays with a UV-Vis 
spectrophotometer (Genova Nano Plus Life Science Spectrophotometer - 
Jenway), using the spectrum/purity scan mode within the 198 to 800 nm spectral 
region. Three microliters of well mixed samples, that were free of bubbles were 
loaded into the machines mechanism head, after being blanked with 0.001 M PBS 
(D3). The results were captured and reported over an 8-week period, to note any 
changes within its UV spectra. Any obvious changes in the UV spectra would 
suggest that the compound had become unstable, and any shift changes within 
the high absorption (340 nm - Soret Band) and emission (583, 634 and 674 nm - 
Q band) peaks would indicate that the ZnPcS4 within the final actively targeted PS 
nanoconjugate had quenched.  
3.6 Cell Culture 
3.6.1 Human CRC (CaCo-2) Cell Culture 
Commercially purchase Human CRC cells (CaCo-2 Cellonex Cat SS1402 CCAC-
FL; CCAC-C) were purchase for this study at a passage number of 13. A vial of 
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frozen CaCo-2 cells was retrieved from the liquid nitrogen storage. The vial was 
thawed under strict aseptic conditions by gentle agitation in a 37ºC water bath for 
approximately 3 minutes. To reduce any potential contamination, 70% ethanol (D1) 
was used to disinfect the vial before taking it to the BSL-2 laminar-flow hood. 
Thereafter, the cells were cultivated in a 75 cm2 (E1) culture flask containing 
complete pre-warmed DMEM Media, enriched with 10% Foetal Bovine Serum 
(FBS), 4mM sodium pyruvate, 4mM L-glutamine, 2.5 g/ml amphotericin B, and 100 
U Penicillin 100 g/ml streptomycin solution (D7). The re-constituted cell culture was 
incubated at 37ºC in 5% CO2 and 85% humidity. 
The cells were observed daily macroscopically and microscopically using inverted 
light microscope (Wirsam Olympus CKX41) to monitor morphology (Figure 15), 
confluence, growth rate, media pH (yellowing) and to ensure the cell culture was 
free from contamination. 
 Figure 15 Ovoid shaped morphology of Human CRC (CaCo-2) cells (40x). 
After every 48 hrs, old medium was removed and replaced with fresh pre-warmed 
complete growth medium, after rising twice with 10 ml of Hanks Bank Salt solution 
(HBSS). Upon reaching 90% confluence, the monolayers of cells were detached 
from the flask by adding 5 ml of Tryple Express (TE) and incubated at 37 ̊C for 5 
minutes with gentle agitation to detach the cells from the cell culture flask. 
Microscopic observation of cells was performed to confirm this detachment and the 
cellular suspension was then aspirated into a 50 ml centrifuge tube and centrifuged 
at 2200 rpm for 4 minutes at 20ºC, after which the supernatant was then discarded. 
The pellet was then re-suspended in 1 ml of complete cell growth medium and 
transferred to a T175 flask to yield enough cells for experimentation. 
At 90% confluency, the cells were washed twice with HBSS and 10 ml of TE was 
added to the flask in order to dissociate monolayer cells and so yield a cellular 
suspension. The cellular suspension was aspirated into a 50 ml falcon tube and 
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centrifuged at 2200 rpm for 4 min at 20 ̊C, after which the supernatant was 
discarded. The pellet was then re-suspended in 1 ml of complete cell growth 
medium and 20 µl of this cellular suspension was removed to perform the Trypan 
Blue Exclusion Test in order to quantify the number of viable cells per ml (Section 
3.12.2.1). After quantification, the cells were seeded at a density of 6 X 105 cells/ml 
(E2) into 3.4 cm diameter cell culture plates, which contained 3ml of completed cell 
culture media (D7) and used for various biochemical assays discussed below.  
The remaining cells were cultured into a T175 flask at a high subculture ratio (1:3 
or 1:4) or cryopreserved in 2 ml cryovials at a density of 5 X 106 cells/ml (E3) in bio 
freezing medium and first placed in the -80°C freezer for 24 hours, before being 
stored in liquid nitrogen for later re-constitution. 
3.6.2 Normal Human Fibroblasts (WS1) Cell Culture 
Commercially purchased WS1 Human Skin Fibroblasts were obtained from the 
American Type Culture Collection (ATTC CRL-1502). A vial of frozen WS1 cells 
was retrieved from the liquid nitrogen storage. The vial was thawed under strict 
aseptic conditions by gentle agitation in a 37ºC water bath for approximately 3 
minutes. To mitigate contamination, 70% ethanol (D1) was used to sanitize the vial 
before taking it to the BSL-2 laminar-flow hood. Thereafter, the cells were cultivated 
in a 75cm2 (E1) containing complete pre-warmed MEM Media, enriched with 2 mM 
L-glutamine, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 10% FBS, 
2.5 g/ml amphotericin B and 100 U Penicillin 100 g/ml streptomycin solution (D8). 
The re-constituted cell culture was incubated at 37ºC in 5% CO2 and 85% humidity. 
The cells were observed daily macroscopically and microscopically using inverted 
light microscope (Wirsam Olympus CKX41) to monitor morphology (Figure 16), 
confluence, growth rate, media pH (yellowing) and to ensure the cell culture was 
free from contamination. 
After every 48 hrs, old medium was removed and replaced with fresh pre-warmed 
complete growth medium, after rising twice with 10 ml of Hanks Bank Salt solution 
(HBSS). Upon reaching 90% confluence, the monolayers of cells were detached 
from the flask by adding 5 ml of Tryple Express (TE) and incubated at 37 ̊C for 5 
minutes with gentle agitation to detach the cells from the cell culture flask. 
Microscopic observation of cells was performed to confirm this detachment and the 
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cellular suspension was then aspirated into a 50 ml centrifuge tube and centrifuged 
at 2200 rpm for 4 minutes at 20ºC, after which the supernatant was then discarded. 
The pellet was then re-suspended in 1 ml of complete cell growth medium and 
transferred to a T175 flask to yield enough cells for experimentation. 
 
Figure 16 Spindle shaped morphology of WS1 Human Skin Fibroblasts cells 
(40x). 
At 90% confluency, the cells were washed twice with HBSS and 10 ml of Tryple 
Express (TE) was added to the flask in order to dissociate monolayer cells and so 
yield a cellular suspension. The cellular suspension was aspirated into a 50 ml 
falcon tube and centrifuged at 2200 rpm for 4 min at 20 ̊C, after which the 
supernatant was discarded. The pellet was then re-suspended in 1 ml of complete 
cell growth medium and 20 µl of this cellular suspension was removed to perform 
the Trypan Blue Exclusion Test in order to quantify the number of viable cells per 
ml (Section 3.12.2.1). After quantification, the cells were seeded at a density of 3 
X 105 cells/ml (E2) into 3.4 cm diameter cell culture plates, which contained 3 ml 
of complete cell culture media (D8) and used for various biochemical assays as 
discussed below.  
The remaining cells were cultured into a T175 flask at a high subculture ratio (1:3 
or 1:4) or cryopreserved in 2 ml cryovials at a density of 5 X 106 cells/ml (E3) in bio 
freezing medium and first placed in the -80°C freezer for 24 hours, before being 
stored in liquid nitrogen for later re-constitution. 
3.7 Sub Cellular Localization Confirmation of Final Actively Targeted PS 
Nanoconjugate 
Subcellular localization studies were performed in order to confirm if the final 
targeted PS nanoconjugate (ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC  Ab) 
was able to actively and specifically localize in CRC cells only and not in normal 
human cells (such as WS1 fibroblasts).  
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Colon cancer (CaCo-2) cells or normal human fibroblasts (WS1) cells were 
detached from cell culture flasks and seeded in culture plates (which already had 
sterile cover slips inserted into their base) at a density of 6 x105 cells/ml for CaCo-
2 and 3x105 cells/ml for WS1. The culture plates were incubated at 37ºC for 4hrs 
to allow for cellular attachment to the coverslips. After 4 hrs of incubation, the 
complete growth medium from the culture plates was removed and discarded. 
The culture plates produced were then divided into various experimental and 
control groups, as per the Table 5 and received varying volumes of completed cell 
culture media with either ZnPcS4 PS alone, ZnPcS4 – AuNP-PEG5000-SH-NH2 or 
ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC  Ab.  
Table 5 Description of sub-cellular localization experimental and control cell 
culture plate groups.  
Plate  
No. 
Contents of Culture 
Plates 







1 WS1 or CaCo-2 cells only 0 µl  3000 µl Control 
2 WS1 or CaCo-2 cells with 
0.125 µM ZnPcS4  
3 µl of 125 µM ZnPcS4 
PS working stock (D5) 
2 997 µl Control 
3 WS1 or CaCo-2 cells with 
0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 
*6.7 µl of bound 
0.0000555 M / 56 uM 
ZnPcS4 + AuNP stock 
2 993.3 µl  Control 
4 WS1 or CaCo-2 cells with 
0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-
GCC  Ab 
*10.71 µl of final bound 
0.000035 M final PS 
nanoconjugate stock 
2 989.29 µl  Experimental  
 
*Note: the concentration of 0.125 µM ZnPcS4 was pre-determined in Section 3.10, 
since results in Section 4.5.5 showed that the minimum inhibitory concentration of 
ZnPcS4 to induce 50 % cellular destruction was found to be 0.125 µM. Thus, the 
volumes of ZnPcS4 – AuNP-PEG5000-SH-NH2 and ZnPcS4 – AuNP-PEG5000-
SH-NH2 – Anti-GCC  Ab that were added to each plate were corrected as to ensure 
that the control and final PS nanoconjugate contained 125 µM ZnPcS4 after UV 
molecular characterization experiments, as to ensure result comparability, the 
calculations showing these concentration corrections have been described in 
Section 4.5.5.  
The complete cell culture media with allocated plate number contents were mixed 
thoroughly and were all covered with tin foil (due to light sensitivity of the ZnPcS4 
PS) and incubated again at 37ºC for an additional 20 hrs. Note: all experimentation 
that followed was conducted in the dark in order to ensure that the integrity of the 
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ZnPcS4 PS and subcellular localization fluorochromes did not become 
photobleached.   
After incubation the complete culture media from each culture plates were 
discarded. The culture plates were then placed on ice and rinsed once with 1 ml 
ice-cold 0.01 M PBS (D9), which was then discarded. The cultured cells were then 
fixed to their coverslips by the addition of 1 ml of 3.7% (v/v) Formaldehyde solution 
(D10) to each of the coverslips. All the culture plates were incubated on ice at room 
temperature in the dark for 10 minutes, to induce cellular fixation. After this 10-
minute incubation the formalin solution was removed from each culture plate and 
discarded, then the coverslips in each culture dish was rinsed briefly with 1 ml 0.01 
M PBS (D9) and then shortly afterwards with 1 ml tap water. Both rinsing solutions 
were immediately discarded.    
Then 1 ml ice-cold 0.01 M PBS in 1% (w/v) BSA and 0.01% (w/v) sodium azide 
buffer solution (D11) was briefly added to the culture plates and then discarded. 
Then 200µl of a diluted primary Ab [2 µg/ml ICAM-1 Mouse Monoclonal IgG1 Ab 
diluted in 0.01 M PBS in 1% (w/v) BSA and 0.01% (w/v) sodium azide buffer 
solution in a ratio 1:500 (D12)] was added onto each coverslip of the cultured cells 
and incubated for 30 minutes at room temperature on ice. After 30 minutes the 
primary Ab was discarded, and each culture plate was rinsed two times with 1 ml 
ice-cold 0.01 PBS in 1% (w/v) BSA and 0.01% (w/v) sodium azide buffer solution 
(D11). Then 200µl of a diluted secondary Ab [5 µg/ml Goat Anti-Mouse IgG-FITC 
human absorbed, fluorescein conjugated antibody, diluted in 0.01 M PBS in 1% 
(w/v) BSA and 0.01% (w/v) Sodium Azide Buffer Solution in a ratio 1:400 (D13)] 
was added onto each coverslip of the cultured cells and incubated for 30 minutes 
at room temperature on ice. After 30 minutes the primary Ab was discarded, and 
each culture plate was rinsed two times with 1 ml ice-cold 0.01 PBS in 1% (w/v) 
BSA and 0.01% (w/v) sodium azide buffer solution (D11). Then 50µl of 1µg/ml 40-
6-Diamidino-2-phenylindole (DAPI) (D14 -15) was added to each coverslip and the 
culture plates were incubated for 5 min at room temperature, after which they were 
rinsed with 1ml HBSS. The coverslips were then carefully removed from the culture 
plates and inverted onto glass microscope slides to which 50 µl of Fluoromount™ 
Aqueous Mounting Medium (D16) had previously been added to them. The 
coverslip boarders were then sealed with nail varnish and the slides were 
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examined using the filter settings of a Carl Zeiss Axio Z1 Observer immuno 
fluorescent microscope.  
The 358Ex / 461Em filter was used to detect blue DAPI counter stained nuclei in 
cultured cells, while the 495Ex / 519Em filter was used to detect any green FITC 
stained ICAM-1 membrane proteins in cultured cells. According to studies by 
Kotteas et al. (2014), Intracellular Adhesion Molecule 1 (ICAM-1) proteins are 
found to be expressed on the surface layers of various endothelial cells. Thus, 
ICAM-1 proteins may be used to indirectly (when conjugated to a fluorochrome, 
such as FITC) to counter stain endothelial cells membranes and so easily locate 
and view them when conducting immuno fluorescent microscopy experiments. 
Lastly, the 589Ex / 610Em filter was used to detect any Cy5 red auto fluorescent 
signal that was produced from the ZnPcS4 PS alone or within the control and 
experimental molecular conjugates, which were added to cultured cells in order to 
determine if the final targeted PS nanoconjugate was capable of active PS delivery 
in CRC cells only and had no effective uptake in fibroblast cells.  
3.8 Photodiagnosis of CRC using the Final Actively Targeted PS 
Nanoconjugate 
PDD is similar to PDT, since it forms a part of photomedicine based diagnostics, 
which also incorporates a PS and light, however it induces no cellular damage - 
due to a shorter purple to blue wavelength of light being applied (Dobson et al.,  
2018). The development of new rapid diagnostic techniques is the basis for modern 
and effective treatments of cancer, as an early diagnosis allows physicians to 
rapidly initiate treatment and so substantially increases the chances of patient 
survival (Dobson et al., 2018). In comparison to PDT, PDD is based on 
fluorescence elicited by shorter purple to blue wavelength light (330 – 400 nm) 
(Oniszczuk et al.,  2016). Available literature indicates that most PDD methods are 
based on precursors of protoporphyrin IX (PpIX) or phthalocyanines (Pc) having a 
Soret band within the 300 – 400nm range (Oniszczuk et al., 2016).  
In order to determine if the final actively targeted PS nanoconjugate could be 
successfully absorbed by CRC cells only (and not normal fibroblast cells), as well 
as be utilized for fluorescent PDD of CRC, intercellular cell adhesion molecule-1 
(ICAM-1) immunofluorescent morphological staining and fluorescent microscopy 
imaging assays were performed. ICAM-1 is a cellular surface marker membrane 
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protein, which is expressed within almost all in vitro adherent cells, however 
different type of cell lines exhibit different morphological shapes and so this allows 
one to distinguish identify different cell membrane shapes (i.e. fibroblasts – spindle 
shaped versus CRC cells – ovoid shaped) (Jeong et al., 2016). 
Colon cancer (CaCo-2) cells or normal human fibroblasts (WS1) cells were 
detached from cell culture flasks and seeded in culture plates (which already had 
sterile cover slips inserted into their base) at a density of 6 x105 cells/ml for CaCo-
2 and 3x105 cells/ml for WS1. The culture plates were incubated at 37ºC for 4hrs 
to allow for cellular attachment to the coverslips. After 4 hrs of incubation, the 
complete growth medium from the culture plates was removed and discarded. 
The culture plates produced were then divided into various experimental and 
control groups, as per the Table 6 and received varying volumes of completed cell 
culture media with either ZnPcS4 PS alone, ZnPcS4 – AuNP-PEG5000-SH-NH2 or 
ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC  Ab.  




Contents of Culture 
Plates 







1 WS1 or CaCo-2 cells only 0 µl  3000 µl Control 
2 WS1 or CaCo-2 cells with 
0.125 µM ZnPcS4  
3 µl of 125 µM ZnPcS4 
PS working stock (D5) 
2 997 µl Control 
3 WS1 or CaCo-2 cells with 
0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 
*6.7 µl of bound 
0.0000555 M / 56 uM 
ZnPcS4 + AuNP stock 
2 993.3 µl  Control 
4 WS1 or CaCo-2 cells with 
0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-
GCC  Ab 
*10.71 µl of final bound 
0.000035 M final PS 
nanoconjugate stock 
2 989.29 µl  Experimental  
 
*Note: the concentration of 0.125 µM ZnPcS4 was pre-determined in Section 3.10., 
since results in Section 4.5.5 showed that the minimum inhibitory concentration of 
ZnPcS4 to induce 50 % cellular destruction was found to be 0.125 µM. Thus, the 
volumes of ZnPcS4 – AuNP-PEG5000-SH-NH2 and ZnPcS4 – AuNP-PEG5000-
SH-NH2 – Anti-GCC  Ab that were added to each plate were corrected as to ensure 
that the control and final PS nanoconjugate contained 125 µM ZnPcS4 after UV 
molecular characterization experiments, as to ensure result comparability, the 
calculations showing these concentration corrections have been described in 
Section 4.5.5.  
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The complete cell culture media with allocated plate number contents were mixed 
thoroughly and were all covered with tin foil (due to light sensitivity of the ZnPcS4 
PS) and incubated again at 37ºC for an additional 20 hrs. Note: all experimentation 
that followed was conducted in the dark in order to ensure that the integrity of the 
ZnPcS4 PS and subcellular localization fluorochromes did not become 
photobleached.   
After incubation the complete culture media from each culture plates were 
discarded. The culture plates were then placed on ice and rinsed once with 1 ml 
ice-cold 0.01 M PBS (D9), which was then discarded. The cultured cells were then 
fixed to their coverslips by the addition of 1 ml of 3.7% (v/v) Formaldehyde solution 
(D10) to each of the coverslips. All the culture plates were incubated on ice at room 
temperature in the dark for 10 minutes, to induce cellular fixation. After this 10-
minute incubation the formalin solution was removed from each culture plate and 
discarded, then the coverslips in each culture dish was rinsed briefly with 1 ml 0.01 
M PBS (D9) and then shortly afterwards with 1 ml tap water. Both rinsing solutions 
were immediately discarded.    
Then 1 ml ice-cold 0.01 M PBS in 1% (w/v) BSA and 0.01% (w/v) sodium azide 
buffer solution (D11) was briefly added to the culture plates and then discarded. 
Then 200µl of a diluted primary Ab [2 µg/ml ICAM-1 Mouse Monoclonal IgG1 Ab 
diluted in 0.01 M PBS in 1% (w/v) BSA and 0.01% (w/v) sodium azide buffer 
solution in a ratio 1:500 (D12)] was added onto each coverslip of the cultured cells 
and incubated for 30 minutes at room temperature on ice. After 30 minutes the 
primary Ab was discarded, and each culture plate was rinsed two times with 1 ml 
ice-cold 0.01 PBS in 1% (w/v) BSA and 0.01% (w/v) sodium azide buffer solution 
(D11). Then 200µl of a diluted secondary Ab [5 µg/ml Goat Anti-Mouse IgG-FITC 
human absorbed, fluorescein conjugated antibody, diluted in 0.01 M PBS in 1% 
(w/v) BSA and 0.01% (w/v) Sodium Azide Buffer Solution in a ratio 1:400 (D13)] 
was added onto each coverslip of the cultured cells and incubated for 30 minutes 
at room temperature on ice. After 30 minutes the primary Ab was discarded, and 
each culture plate was rinsed two times with 1 ml ice-cold 0.01 PBS in 1% (w/v) 
BSA and 0.01% (w/v) sodium azide buffer solution (D11). The coverslips were then 
carefully removed from the culture plates and inverted onto glass microscope 
slides to which 50 µl of Fluoromount™ Aqueous Mounting Medium (D16) had 
previously been added to them. The coverslip boarders were then sealed with nail 
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varnish and the slides were examined using the filter settings of a Carl Zeiss Axio 
Z1 Observer immuno fluorescent microscope.  
The 495Ex / 519Em filter was used to detect any green FITC stained ICAM-1 
membrane proteins in cultured cells. According to studies by Kotteas et al. (2014), 
Intracellular Adhesion Molecule 1 (ICAM-1) proteins are found to be expressed on 
the surface layers of various endothelial cells. Thus, ICAM-1 proteins may be used 
to indirectly (when conjugated to a fluorochrome, such as FITC) to counter stain 
endothelial cells membranes and so easily locate and view them when conducting 
immuno fluorescent microscopy experiments. Whereas, the 358Ex / 461Em DAPI 
filter was used to induce a blue fluorescence signal from the ZnPcS4 PS final 
actively targeted PS nanoconjugate, which contains specific Anti-GCC Abs, that 
should only bind to CRC cells (not WS1 cells) and so if successfully targeted and 
absorbed by CRC only, the phthalocyanine PS of the final actively targeted PS 
nanoconjugate,  when subjected to this wavelength of light should fluoresce blue 
for PDD (Magee et al.  2016), however induce no damage, due to non-activation 
of ROS at this particular wavelength of light. 
3.9 PDT Laser Parameters, Final Actively Targeted PS Nanoconjugate, 
and Controls Addition to Culture Plates and Laser Irradiation  
3.9.1 PDT Laser Parameters 
After 24 hours of incubation, the cells were irradiated using the Roithner 1000mA 
673nm high power diode laser (Arryo 4210) obtained from National Laser Centre 
of South Africa (Figure 17). Laser parameters are shown below in Table 7.  
  
 
Figure 17 Roithner 1000mA diode laser (Arryo 4210) emitting at a wavelength 




Table 7  Laser Parameters of the 673 nm diode laser 
Variable  Parameter 
Laser Type Semiconductor (diode) 
Wavelength  673.2 nm 
Spectrum  Red (Visible) 
Pulsed or Continuous  Continuous Wave 
Spot area 9.1 cm2 
Power density (Average) 9.40 mW/cm2 
Power output (Average)  74,95 mW 
Spot size 9.1 cm2 
Energy density (Fluences) 10 J/cm2 
Number of exposure 1 exposure on day 2 
Duration of exposure 16 mins 8 secs 
 
Cell culture plates were irradiated in the dark uncapped at a fluency of 10 J/cm2 
and untreated irradiated cells served as laser control. Prior to cell culture plate 
irradiation, the laser was switched on and allowed to stand for 10 minutes to 
stabilize and reach maximum power output. The photons which were released from 
the laser were directed through an optical fibre in order to reach the culture plates 
which required laser irradiation. The power output of the laser was measured using 
a power meter (Coherent Fieldmate Model 1098297). In order to obtain a fluence 
of 10 J/cm2 an irradiation time was calculated for the 673 nm laser. On average the 
power output for the 673 nm laser was 75 mW and therefore the time calculated to 
deliver a fluence of 10 J/cm2 to the cell culture plate requiring laser irradiation was 
16 minutes and 8 seconds (E4). 
3.9.2 Final Actively Targeted PS Nanoconjugate and Controls Addition to 
Cell Culture Plates 
Referring to Section 3.6  various groups of experimental and control culture plates 
seeded with human CRC CaCo-2 and normal human fibroblasts WS1 cells were 
prepared for ZnPcS4 PDT PS dose response assays (Section 3.10) or for final 
actively targeted PS nanoconjugate PDT response assays (Section 3.11).  
The cell culture plates were incubated for 4 hours to allow for cellular attachment, 
and thereafter their growth media was discarded. The control and experimental 
group cell culture plates which were not treated with ZnPcS4 or the final actively 
targeted PS nanoconjugate (within individual control chemical components) just 
had their growth media replaced with 3ml of fresh pre-warmed complete cell culture 
media. Whereas, the groups of cell culture plates which were treated with ZnPcS4 
or the final actively targeted PS nanoconjugate (within individual control chemical 
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components) had their 3 ml of complete fresh growth media replacement volumes 
adjusted to accommodate for the administered concentrations they required. 
Freshly added cell culture media in both control and experimental cell culture 
plates, particularly those containing administered concentrations of ZnPcS4 or the 
final actively targeted PS nanoconjugate (within individual control chemical 
compnents), were thoroughly mixed to disperse the PS throughout the cell culture 
plate and covered with tin foil (due to light sensitivity of the ZnPcS4). After this the 
cell culture plates were incubated at 37ºC in 5% CO2 and 85% humidity for an 
additional 20 hrs. 
3.9.3 Photo-Irradiation  
All experiments were conducted in the dark to avoid premature activation and 
photobleaching of the ZnPcS4 PS prior to laser irradiation.  
After 24hrs of incubation, groups of experimental and control cell culture plates of 
CaCo-2 cells for ZnPcS4 (Section 3.10) dose response assays or for final actively 
targeted PS nanoconjugate PDT response assays (which included WS1 cells) 
(Section 3.11), had their complete growth medium discarded. Thereafter, the cells 
were rinsed twice with 1ml of Hanks' Balanced Salt Solution (HBSS) to remove all 
traces of cell culture media, as well as any unabsorbed (PS / final conjugate or 
control components). 3 ml of fresh pre-warmed complete cell culture media (D7 or 
D8, depending on cell line) was used to replace the culture media in the control 
and experimental group cell culture plates, which did not require laser irradiation. 
Control and experimental cell culture plates which required laser irradiation 
received 1 ml of 0.01 M PBS (D9), to prevent cells from drying out, as well as 
prevent any light scattering, to ensure that the laser beam directly reached the 
monolayer of cultured cells. The cell culture plates to be irradiated were uncapped 
and all irradiation experiments were conducted in the dark. After irradiation, the 1 
ml of 0.01 M PBS was discarded from the culture plate and replaced with 3 ml of 
fresh complete cell culture media (D7 or D8, depending on cell line). All control and 
experimental culture plates were then covered with tin foil and incubated for an 
additional 24 hours. Following laser irradiation and an additional 24 hours of 
incubation, the cell culture plates underwent various biochemical cellular test 
assays (Section 3.12).  
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3.10 CaCo-2 ZnPcS4 PS PDT Dose Response Assays  
These experiments were conducted in order to establish the lowest inhibitory 
concentration (ICD50) that was required to be administered to cells in order to 
induce 50% cytotoxicity post-PDT, as some cells were still required to be viable in 
order to determine various biological cellular responses post-PDT treatment. 
0.0006 g ZnPcS4 powder was solubilized in 0.001M Phosphate Buffer Solution 
(PBS) (D4) to make a stock concentration of 0.0005M. To make a working stock 
concentration of 0.000125 M or 125 µM (D5), 1 ml of ZnPcS4 stock solution 
(0.0005M) was diluted with 4 ml of 0.001M PBS (D4). This working stock 
concentration of ZnPcS4 was further diluted in order to acquire the four varying 
dose concentrations (0.0312; 0.0625; 0.125; 0.25 µM) (E5).   
In vitro CaCo-2 cultured cells in cell culture plates received four varying dose 
concentrations (0.0312; 0.0625; 0.125; 0.25 µM) of ZnPcS4 PS, after 4 hrs of 
attachment (Table 8) within their adjusted complete cell culture media of 3ml 
(Section 3.6). The various experimental and control groups were then incubated 
for an additional 20 hrs, where after those that required laser irradiation, received 
irradiation (Section 3.9.3), and all cell culture plates were then incubated for an 
additional 24hrs, before being subjected to various biochemical assays (Section 
3.12). 
Table 8 Description of various volumes and concentrations which 
experimental and control groups of CaCo-2 cell culture plates 
received for ZnPcS4 PS PDT Dose Response Assays 
Plate 
No. 
CaCo-2 Culture Plate Contents *Volume 
of ZnPcS4 
Volume of Cell 
Culture Media 
Group Type 
1 Cells only - 3000 µl Control 
2 Cells plus irradiation  - 3000 µl Control 
3 Cells plus 0.0312 µM ZnPcS4 0.75 µl 2999.25 µl Control 
4 Cells plus 0.0625µM ZnPcS4 1.5 µl 2998.5 µl Control 
5 Cells plus 0.125µM ZnPcS4 3 µl 2997 µl Control 
6 Cells plus 0.25 µM ZnPcS4 6 µl 2994 µl Control 
7 Cells plus 0.0312 µM ZnPcS4 and 
irradiation (PDT) 
0.75 µl 2999.25 µl Experimental 
8 Cells plus 0.0625µM ZnPcS4 and 
irradiation (PDT) 
1.5 µl 2998.5 µl Experimental 
9 Cells plus 0.125µM ZnPcS4 irradiation 
(PDT) 
3 µl 2 997 µl Experimental 
10 Cells plus 0.25 µM ZnPcS4 and 
irradiation (PDT) 
6 µl 2994 µl Experimental 
*Note: the calculations for the various volumes and concentrations of ZnPcS4 PS which was added 




Note: The ICD50 dose response of ZnPcS4 PS after PDT treatment that induced 
50% cytotoxicity was found to be 0.125 µM (Section 4.5.5). Once this had been 
established then further PDT final actively targeted PS nanoconjugate induced 
experimental studies could be conducted utilizing the final synthesized conjugate 
at the recommended (ICD50) adjusted dose of 0.125 µM ZnPcS4 PS concentration 
(Section 3.11). This was done in order to compare ZnPcS4 PS PDT cytotoxicity 
alone versus final actively targeted PS nanoconjugate (AuNPPEG5000-SH-NH2 - 
ZnPcS4 - Anti-GCC Ab) PDT induced cytotoxicity and so determine if the 
multicomponent active nano PS  carrier actually enhanced CRC PDT treatment 
outcomes. 
3.11  Final Actively Targeted PS Nanoconjugate PDT Response Assays  
These assays were to determine if the final actively targeted PS nanoconjugate 
(ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab) was capable of enhanced 
PDT induced cell death, due to its functionalized active Ab targeting abilities and 
AuNP passive promoting nanocarrier, when compared to ZnPcS4 PS drug 
administration alone.  
Table 9 Description of various volumes and concentrations which 
experimental and control groups of CaCo-2 and WS1 cell culture 




CaCo-2 and WS1 Culture Plate 
Contents  
*Volume  






1 Cells only / 3 ml  Control 
2 Cells plus irradiation / 3 ml Control 
3 Cells plus 0.125 µM ZnPcS4 3 µl 2 997 µl Control  
4 Cells plus 0.125 µM ZnPcS4– AuNP-
PEG5000-SH-NH2 
6.7 µl 2 993.3 µl Control  
5 Cells plus 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab 
10.71 µl 2 989.29 µl Control 
6 Cells plus 0.125 µM ZnPcS4 and 
irradiation 
3 µl 2 997 µl Control  
7 Cells plus 0.125 µM ZnPcS4– AuNP-
PEG5000-SH-NH2 and irradiation 
6.7 µl 2 993.3 µl Control  
8 Cells plus 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab and 
irradiation  
10.71 µl  2 989.29 µl  Experimental  
*Note: the concentration of 0.125 µM ZnPcS4 was pre-determined in Section 3.10, since results in Section 4.5.5 
showed that the minimum inhibitory concentration of ZnPcS4 to induce 50 % cellular destruction was found to be 
0.125 µM. Thus, the volumes of ZnPcS4 – AuNP-PEG5000-SH-NH2 and ZnPcS4 – AuNP-PEG5000-SH-NH2 – 
Anti-GCC  Ab that were added to each plate were corrected as to ensure that the control and final PS 
nanoconjugate contained 125 µM ZnPcS4 after UV molecular characterization experiments, as to ensure result 
comparability, the calculations showing these concentration corrections have been shown in E6. 
 
Therefore, CaCo-2 and WS1 cells were harvested from a T-175 cell culture flask 
and seeded into cell culture plates and incubated for 4hrs for attachment (Section 
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3.6), after which they were divided into various control and experimental groups.  
The control or experimental groups of cell culture plates consisted of irradiated and 
non-irradiated cells, treated with ZnPcS4, ZnPcS4 – AuNP-PEG5000-SH-NH2 or 
ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab (Table 9).  
After cell culture plates had the various experimental and control drugs 
administered to them, they were incubated for an additional 20 hrs. After incubation 
cell culture plate groups which required irradiation were irradiated and incubated 
for an additional 24 hrs (Section 3.9.3). Post incubation, cell culture plates were 
then subjected to various biochemical assays (Section 3.12).  
3.12  Post-Irradiation Biochemical and Cellular Response Assays 
Inverted light microscopy was used to analyze morphological changes in all cell 
culture control and experimental groups prior to and post-laser irradiation; digital 
images were recorded and analyzed (Section 3.12.1). 50 µl of complete culture 
growth medium was aspirated from all control and experimental cell culture plates 
and added to 96 well plates used for cellular cytotoxicity assessment in triplicate 
(Section 3.12.2.3). The remaining cell culture media was discarded all cell culture 
plates, and the cells were rinsed twice with 1 ml of pre-warmed HBSS. Thereafter, 
500 µl of Tryple Express (TE) was added to each culture plate and incubated at 
37ºC for 5 minutes with gentle agitation to detach the cells. The culture plates were 
then visualized under the inverted light microscope to confirm the detachment of 
the cells, and the cellular suspensions were aspirated into the Eppendorf tubes. 
Furthermore, each plate was rinsed with 500 µl of HBSS, which was also added to 
the cellular suspensions in the Eppendorf tubes (this was done to clear any 
remaining cells from the cell culture plates, as well as counteract any further effects 
from the TE). The contents were then centrifuged at 2,200 rpm (Tomy Micro Vac 
MV-100) for 4 minutes at 20ºC. 1 ml of HBSS was used to resuspend the cellular 
pellets once the supernatants were discarded. From the various control and 
experimental cellular suspension groups (from Section 3.10 and 3.11), cellular 
quantification assays such as cellular viability, proliferation and cytotoxicity were 
investigated (Section 3.12.2).  
Additionally, the different control and experimental cellular suspensions only from 
Section 3.11 - Final Actively Targeted PS Nanoconjugate PDT Response Assays, 
were subjected to cell death pathway (Section 3.12.3) and DNA damage (Section 
88 
 
3.12.4) analysis. Each experiment was repeated six times in duplicate, graphically 
presented and statistically analysed (Section 3.13).  
3.12.1  Morphological Assessment by Light Microscopy 
Morphological changes in CaCo-2 and WS1 cells prior to and post-laser irradiation 
were observed at a 100x magnification using the inverted microscope (Olympus 
CKX41) that had a built-in digital camera (Olympus C5060-ADUS). The images 
were captured in a dark room. Captured images of cell structure were evaluated 
based on the cells distinct shape and changes such as size, shape and presence 
of apoptotic bodies. Viability and non-viability were contrasted by assessing the 
amount of lysis and debris as indicators of cell death. 
3.12.2  Cellular Quantification, Viability and Cytotoxicity Assays 
3.12.2.1  The Trypan Blue Exclusion Test 
The Trypan Blue Exclusion test is a vitally important stain used to quantify the 
number of viable cells present in the cell suspension. This assay is based on the 
principle that viable cells do not take up the trypan blue dye, due to their intact cell 
membranes, whereas nonviable cells do so, due to their damaged membranes 
(Avelar-Freitas et al., 2014). Therefore, a viable cell will have a clear cytoplasm, 
while a nonviable cell will have blue cytoplasm (Strober, 2015). Following the 
detachment of the cells from either a culture flask or cell culture plate, the quantity 
of viable cells was assessed using an automated cell counter, Countess® II FL 
(Invitrogen). 20µl of cell suspension was well mixed an equal volume of 0.4% 
trypan blue solution (Sigma Aldrich: T8154) in a 1ml test tube and left for 5 minutes 
to allow for effective staining of cells. After staining, 10 µl of the sample was loaded 
into both chambers of the Countess® cell counting slide. After inserting the slide 
to the slide reader, the instrument automatically focuses sample slides and so 
captures and displays the cell quantification results as total number, percentage 
viability and concentration of viable and non-viable cells. The Trypan Blue 
Exclusion Test was performed for various cell-seeding ratios, such as culturing 
flasks (E1), when making cell culture plates (E2) or cryopreserving cells (E3). The 
cellular viability of CaCo-2 and WS1 cells post-PDT irradiation for the various 
control and experimental groups of ZnPcS4 dose responses, as well as the final 




3.12.2.2  Adenosine Triphosphate (ATP) Cell Proliferation Assay 
Metabolically active cells generate adenosine triphosphate (ATP), which signifies 
their viability. The CellTiter-Glo® luminescent assay (AnaTech: Promega, 
PRG7571) is a homogeneous method for determining cellular proliferation and the 
quantification of ATP present in metabolically active cells. This assay is based on 
the properties of a proprietary thermostable luciferase, which generates a stable 
luminescent and at the same time inhibits endogenous enzymes released during 
cell lysis (i.e. ATPases) which interferes with the accurate detection of ATP.  
In compliance with the instructions of the manufacturer, 100 µl of the cellular 
suspension was added to an equal volume of the CellTiter-Glo® Reagent 
(Promega) (D17) in an opaque-walled 96 multi-well plate.  
 
A reference control plate well consisting of a 100 µl of complete growth media was 
also included so that background luminescence could be subtracted from results 
the obtained, in order to ensure the correct luminescent reading for only 
metabolically active cells was taken. The contents were mixed on a cell shaker for 
2 min to induce lysis. The contents were then incubated at room temperature, in 
the dark, for 10min to stabilize the luminescence signal. The luminescent signal 
was determined in Relative Light Units (RLU) using the Perkin-Elmer, VICTOR3 ™ 
Multilabel Counter (model 1420).  
The cellular proliferation of CaCo-2 cells post-irradiation for the various control and 
experimental groups of ZnPcS4 dose responses and the final actively targeted PS 
nanoconjugate was determined and the differences were graphically presented. 
3.12.2.3  The Lactate Dehydrogenase (LDH) Cellular Cytotoxicity and 
Membrane Integrity Assay 
CytoTox 96® Non-Radioactive Cytotoxicity Assay was used to quantitatively 
measure lactate dehydrogenase (LDH), a cytosolic enzyme that is released upon 
cell lysis. The presence of LDH in the cell culture media indicates cell membrane 
damage and cellular toxicity. Healthy cells possess intact membranes that are 
impermeable to LDH, unlike damaged cells whose membranes allow LDH to leak 
into the extracellular fluid.  
Therefore, post-irradiation and 24 hours incubation, 50 µl of culture media was 
removed from each culture dish and added to the wells in triplicate in flat clear 
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bottom 96 well plate. A culture medium background control was included to 
subtract background absorbance. 50 µl of LDH Reconstituted Substrate Mix (D18) 
was added to each well containing complete media. In order to determine the 
maximum release of LDH, a positive control was set-up by taking a 100 µl of 10x 
Lysis Solution and adding it to a cells only control culture plate, which contained 1 
ml culture medium. This control culture plate of cells only was incubated at 37ºC 
for an additional 45 minutes in order to induce cell lysis, so that a positive control 
reading could be obtained for a comparable 100 % cell death result. After 
incubation the solution was aspirated from the positive control cell culture plate into 
a microcentrifuge tube and centrifuged at 2200 rpm for 4 minutes at 20ºC, to 
remove cellular debris. The pellet was then re-suspended in 50 µl of complete cell 
culture media this supernatant was also added to the 96 well plate, with an 
additional 50 µl of LDH Reconstituted Substrate Mix (D18).  
The contents were incubated in the dark, covered in tin foil, at room temperature 
for 30 min. Then 50 µl of Stop Solution was added to each well to terminate further 
reactions and the resulting colour intensity was proportional to the number of lysed 
cells. The colour change was due to the conversion of tetrazolium salt (INT) into a 
red formazan product. Absorbance was read at 490 nm using a spectrophotometer 
(Perkin Elmer, Victor3, 1420 Multilabel Counter) and cell death and membrane 
damage was determined by calculating the percentage cytotoxicity. The 
percentage cytotoxicity was calculated initially by subtracting the background cell 
value from the LDH readings to obtain corrected LDH values. The corrected LDH 
values were divided by the maximum LDH release value to obtain the percentage 
cytotoxicity.  
The cellular cytotoxicity of CaCo-2 cells post-irradiation for the various control and 
experimental groups of ZnPcS4 dose responses and the final actively PDT targeted 
PS nanoconjugate was determined and the differences were graphically 
presented. 
3.12.3  Flow Cytometry Annexin V-FITC/PI Cell Death Pathway 
Detection Assay 
Annexin V-FITC/PI cell death detection kit (BD Scientific: BD/556570), was used 
for detection and quantitation of cells undergoing early or late apoptosis, cells dying 
from necrosis cells, or cells remaining viable within experimental samples 24 hours 
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post laser irradiation, using flow cytometry. This assay was performed in order to 
determine if the final actively targeted PS nanoconjugate (ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab), was able to enhance PDT treatment more than 
ZnPcS4 PS administration alone, by preparing various control and experimental 
cell culture plates.  
 
Figure 18 Representation of flow cytometry scatter plot; Cells negative for both 
Annexin V-FITC and PI are viable (lower left quadrant), whereas cells 
positive for PI only indicate that cells are in necrosis (upper left 
quadrant). Cells positive for both Annexin V-FITC and PI represent 
late apoptosis (upper right quadrant). Cells positive for Annexin V-
FITC and negative for PI are considered to be in early apoptosis 
(lower right quadrant). 
The membrane phospholipid known as phosphatidylserine is typically located in 
the inner surface of the cell membrane. During apoptosis, phosphatidylserine 
becomes translocated to the outer surface of the plasma membrane, exposing it to 
the external environment. Annexin V is a protein that has high affinity for exposed 
phosphatidylserine in the presence of calcium. To analyse the binding of the 
Annexin V to the phosphatidylserine, Annexin V conjugated to fluorescein 
isothiocyanate (FITC) was used to detect the apoptotic fluorescence of cells. 
Staining with Annexin V-FITC precedes the loss of membrane integrity, which 
accompanies the latest stages of cell death resulting from apoptotic processes. 
Therefore, staining with Annexin V was used in conjunction with a propidium iodide 
(PI), a pivotal and specific dye use to identify necrotic cells. This is because healthy 
cells with integral membranes exclude PI, while dead and damaged cells take up 
PI, due their disrupted membranes. Therefore, viable cells with intact cell 
membranes are both Annexin V and PI negative, whereas cells undergoing early 
apoptosis are Annexin V positive and PI negative, and cells that in late apoptosis 
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are both Annexin V and PI positive and necrotic cells are only PI positive (Figure 
18). 
The maximum absorption of Annexin V-FITC is 492 nm and the maximum emission 
is 520 nm, whereas the maximum absorption for PI is 370 nm with an emission 
range of 560 to 680 nm. Thus, staining with both Annexin V-FITC and PI enables 
detection and differentiation of viable cells, cells in the early apoptotic or late 
apoptotic phases, as well as necrotic cells. 
In conformity with the manufacturer’s protocol, cellular suspensions in 
microcentrifuge tubes were centrifuged at 2,200 rpm for 4 minutes at 20ºC. The 
supernatants were pipetted out and cellular pellets were washed twice with cold 
0.01 M PBS (D9). Thereafter supernatants once again were pipetted out and 
cellular pellets were re-suspended in ice-cold 1x (v/v) Binding Buffer (D19) to 
approximately 5 X 105 cells/ml and the microcentrifuge tubes were kept on ice 
before analysing the samples.  
The various control and experimental group set ups for this assay have been 
described below and listed in Table 10. Then a 100 µl of each cellular suspension 
was removed and pipetted into a flow cytometry tube. To each cellular suspension 
5 µl of Annexin V-FITC solution and 5 µl of Reconstituted Propidium Iodide Staining 
Solution (D20) was added. The flow cytometry tubes, and their contents were 
gently vortexed and incubated at room temperature for 15 minutes in the dark. 
Then 400 µl of ice-cold 1x (v/v) Binding Buffer (D19) was added to all the flow 
cytometry tubes and cell preparations were analysed and interpreted using the 
Becton Dickinson (BD) AccuriTM C6 flow cytometer with appropriate filters. Prior to 
sample analyses all quality control procedures and calibrations were performed on 
the BD AcuriTM C6 flow cytometer C6 using a BD AccuriTM Flow Maintenance Kit 
(BD/653149) and BD Flow Cytometer Starter Kit (BD/653160). 
3.12.3.1  Flow Cytometry Annexin V-FITC/PI Controls and Experimental 
Groups 
Various negative and positive control cells groups consisting of human CRC cells 
(CaCo-2) or human fibroblasts (WS1) in cellular suspension were used to set up 
for flow cytometry compensation and various quadrant gating restrictions for the 
study (Table 10, plates no. 1 to 6).  
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Table 10 Description of various volumes and concentrations which 
experimental and control groups of CaCo-2 cell culture plates 
received for final actively targeted PS nanoconjugate PDT response 
assays for flow cytometry assays. 
Plate 
No. 
CaCo-2 or WS1 Culture 
Plate Contents  
*Volume  
of PS  
Conjugates 





Flow Cytometry Controls 
1 Cells only / 3ml No staining applied Negative 
Control 
2 Cells only / 3ml 5 µl of Annexin V-FITC 








4 Cells only / 3ml 5 µl of Annexin V-FITC 




5 Cells only / 1 ml media + of 3 % 
(v/v) Formaldehyde 
Solution 
5 µl of Annexin V-FITC 





6 Cells only / 1 ml media + 500 µl 
of concentrated 
Hydrogen Peroxide 
5 µl of Annexin V-FITC 





(ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab) PDT response assays 
7 Cells only / 3 ml  5 µl of Annexin V-FITC 
and 5 µl of PI staining 
solution 
Control 
8 Cells plus irradiation / 3 ml Control 
9 Cells plus 0.125 µM ZnPcS4 3 µl 2 997 µl Control  
10 Cells plus 0.125 µM ZnPcS4– 
AuNP-PEG5000-SH-NH2 
6.7 µl 2 993.3 µl Control  
11 Cells plus 0.125 µM ZnPcS4 – 
AuNP-PEG5000-SH-NH2 – 
Anti-GCC Ab 
10.71 µl 2 989.29 µl Control 
12 Cells plus 0.125 µM ZnPcS4 
and irradiation 
3 µl 2 997 µl Control  
13 Cells plus 0.125 µM ZnPcS4– 
AuNP-PEG5000-SH-NH2 and 
irradiation 
6.7 µl 2 993.3 µl Control  
14 Cells plus 0.125 µM ZnPcS4 – 
AuNP-PEG5000-SH-NH2 – 
Anti-GCC Ab and irradiation  
10.71 µl  2 989.29 µl  Experimental  
*Note: the concentration of 0.125 µM ZnPcS4 was pre-determined in Section 3.10, since results in Section 4.5.5 showed that 
the minimum inhibitory concentration of ZnPcS4 to induce 50 % cellular destruction was found to be 0.125 µM. Thus, the 
volumes of ZnPcS4 – AuNP-PEG5000-SH-NH2 and ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC  Ab that were added to 
each plate were corrected as to ensure that the control and final PS nanoconjugate contained 125 µM ZnPcS4 after UV 
molecular characterization experiments, as to ensure result comparability, the calculations showing these concentration 
corrections have been shown in E6. 
Apoptosis positive control cells (Table 10, plate no. 5), untreated cells were 
stimulated to undergo apoptosis by adding 1 ml of 3% (v/v) Formalin Solution in 
0.01 M PBS (D10) to a cell culture plate containing 1 ml of complete cell culture 
medium and 5 x 105 cells/ml. The culture plates were then incubated at 37ºC for 
30 minutes to induce cellular apoptosis. Thereafter the apoptotic cellular 
suspension was dispensed into a microcentrifuge tube and centrifuged at 2,200 
rpm for 4 minutes at 20ºC, in order to obtain a pellet and the cells were stained.  
Necrosis positive control cells (Table 10, plate no. 5), induction of necrosis was 
established by adding 500 µl of concentrated Hydrogen Peroxide to a culture plate 
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containing 1 ml of complete cell culture medium and 5 x 105 cells/ml. The culture 
plates were then incubated at 37ºC for 20 minutes in order for necrosis to be 
induced. After this the necrotic cellular suspension was dispensed into a 
microcentrifuge tube and centrifuged at 2,200 rpm for 4 minutes at 20ºC, in order 
for the cells to be pelleted out and the cells were stained.  
With reference to (Table 10) and (Figure 18) for the overall percentage of apoptotic 
(early stage and late stage), necrotic and viable cells to be calculated within 
experimental and control groups plate nos. 7 to 23, positive control groups (plate 
no. 4, 5 and 6) were used to define the basal level of viable, total apoptotic and 
necrotic cells within experimental set-up. The total percentage of viable cells within 
the experimental set up was calculated from the lower left quadrants of statistically 
analysed scatter grams (Figure 18), by subtracting the percentage values of viable 
cells in experimental and control groups plate nos. 7 to 23, from the percentage 
value of viable cells obtained for experimental control group (plate no. 4). The total 
percentage of early stage apoptotic cells within the experimental set up was 
calculated from the lower right quadrants of statistically analysed scatter grams 
(Figure 18), by subtracting the percentage values of early stage apoptotic cells in 
experimental and control groups plate nos. 7 to 23, from the percentage value of 
apoptotic cells obtained for positive control group (plate no. 5). The total 
percentage of late stage apoptotic cells within the experimental set up was 
calculated from the upper right quadrants of statistically analysed scatter grams 
(Figure 18), by subtracting the percentage values of early stage apoptotic cells 
experimental and control groups plate nos. 7 to 23, from the percentage value of 
apoptotic cells obtained for positive control group (plate no. 5). The total 
percentage of necrotic cells within the experimental set up was calculated from the 
upper left quadrants of statistically analysed scatter grams (Figure 18), by 
subtracting the percentage values of necrotic cells in experimental and control 
groups plate nos. 7 to 23, from the percentage value of necrotic cells obtained for 
positive control group (plate no. 6). 
The type of cell death of CaCo-2 and WS1 cells post-irradiation for the various 
control and experimental groups of within the final actively targeted PDT PS 




3.12.4 Nuclear DNA Damage Examination by Hoechst 33258 
Hoechst 33258 bisbenzimide derivate fluorescent stain is a nuclear DNA staining 
method which is used for the detection and assessment of cellular nuclear DNA 
damage. It can seek out and place itself within the minor grooves of the double-
stranded DNA with binding affinity within the A-T rich regions of the DNA, allowing 
for the detection of nuclei cell damage (Chen et al., 2016). Hoechst 33258 is a blue 
fluorescent dye that is excited by ultraviolet light at a wavelength of 352 nm and 
has maximum fluorescence at 461 nm in the violet-blue region. Hoechst 33258 is 
a cell permeable nucleic acid stain and according to Chen et al. (2016) it can 
differentiate between live, necrotic and apoptotic cell stages, due to the degree of 
nuclear damage that is caused by DNA conformation and chromatin state of the 
cell and the stains sensitivity.  
Thus, in order to confirm if the final actively targeted PS nanoconjugate was able 
to induce more notable PDT induced cellular DNA nuclear damage in CRC CaCo-
2 cells, than when compared to the administration of ZnPcS4 PS alone or ZnPcS4 
– AuNP-PEG5000-SH-NH2 alone, Hoechst 33258 bisbenzimide derivate 
fluorescent stain was performed.  
Therefore, human CRC cells (CaCo-2) were harvested from a T-175 cell culture 
flask and seeded into cell culture plates and incubated for 4hrs for attachment 
(Section 3.6.1), after which they were divided into various control and experimental 
groups.  The control or experimental groups of cell culture plates consisted of 
irradiated and non-irradiated cells, treated with ZnPcS4, ZnPcS4 – AuNP-
PEG5000-SH-NH2 or ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab (Table 
11). All experiments were performed in the dark in order to minimize any 
photobleaching of PS drugs or immune fluorescent stains.  
Post laser irradiation and after 24 hours incubation the complete culture media 
from the culture plates was discarded. The culture plates were then placed on ice 
and rinsed once with 1 ml ice-cold 0.01 M PBS (D9), which was then discarded. 
The cultured cells were then fixed to their coverslips by the addition of 1 ml of 3.7% 
(v/v) Formaldehyde solution (D10) to each of the coverslips. All the culture plates 
were incubated on ice at room temperature in the dark for 10 minutes, to induce 
cellular fixation. After this 10-minute incubation the formalin solution was removed 
from each culture plate and discarded, then the coverslips in each culture dish was 
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rinsed briefly with 1 ml 0.01 M PBS (D9) and then shortly afterwards with 1 ml tap 
water. Both rinsing solutions were immediately discarded.  
Table 11 Description of various volumes and concentrations which 
experimental and control groups of CaCo-2 cell culture plates 
received for final actively targeted PS nanoconjugate PDT response 
assays for Hoechst Staining. 
Plate 
No. 
CaCo-2 Culture Plate Contents  *Volume  
of PS  
Conjugates 
Volume of Cell 
Culture Media 
Group Type 
1 Cells only / 3 ml  Control 
2 Cells plus irradiation / 3 ml Control 
3 Cells plus 0.125 µM ZnPcS4 and 
irradiation 
3 µl 2 997 µl Control  
4 Cells plus 0.125 µM ZnPcS4– 
AuNP-PEG5000-SH-NH2 and 
irradiation 
6.7 µl 2 993.3 µl Control  
5 Cells plus 0.125 µM ZnPcS4 – 
AuNP-PEG5000-SH-NH2 – Anti-
GCC Ab and irradiation  
10.71 µl  2 989.29 µl  Experimental  
*Note: the concentration of 0.125 µM ZnPcS4 was pre-determined in Section 3.10, since results in 
Section 4.5.5 showed that the minimum inhibitory concentration of ZnPcS4 to induce 50 % cellular 
destruction was found to be 0.125 µM. Thus, the volumes of ZnPcS4 – AuNP-PEG5000-SH-NH2 
and ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC  Ab that were added to each plate were 
corrected as to ensure that the control and final PS nanoconjugate contained 125 µM ZnPcS4 after 
UV molecular characterization experiments, as to ensure result comparability, the calculations 
showing these concentration corrections have been in E6 
Then 1 ml of complete growth culture medium was added to each of the culture 
plates, ensuring that the entire surface area of each coverslip of cells was covered. 
Then each coverslip of cells was stained with 20 µg/ml of Hoechst Working Stock 
Solution Stain by adding a pre-determined amount of 20 µl of 1.0 mg/ml Hoechst 
33258 Fluorescent Dye Stock Solution Stain (D21). The culture plates were all 
wrapped in tin foil in order to minimize light exposure and were incubated at 37ºC 
for 30 minutes. 
After this incubation period the culture medium containing the Hoechst staining 
solution was removed from each culture plate and discarded. Then each coverslip 
was rinsed four times with 1 ml pre-warmed 0.01 M PBS (D9) for 5 minutes at room 
temperature. The rinsing solution was then discarded and each coverslip was 
carefully removed with a sterilized forceps and placed cell side down onto a 
labelled glass microscope slide, which had 50 µl of Fluoromount™ Aqueous 
Mounting Medium (Sigma Aldrich, F4680) (D16) pipetted onto it prior to the 
coverslip being inverted onto it. All the coverslip borders were sealed with clear 
nail polish on the microscope slide and each slide was examined using the 
358Ex/461Em DAPI filter to detect the blue Hoechst 33258 stain fluorescence’s on 
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a fluorescent microscope (Axio Observer Z1, Carl Zeiss). The Hoechst 33258 stain 
was viewed under the fluorescent microscope at 400x magnification using the 
broad band DAPI filter set, with an excitation wavelength of 352 nm and an 
emission wavelength of 455 nm. The blue Hoechst 33258 stained nuclei within the 
cells allowed for cellular orientation to be identified and the DNA damaged to be 
assessed in accordance with the size of the nuclei, as well as nuclear 
fragmentation.  
3.13  Statistical Data Analysis 
Data points shown on the graphs represent the mean and the standard deviation 
(+SD) of the biochemical assays done in duplicate for six independent experiments 
on different cell populations (n=6). Statistical analysis was performed using Sigma 
Plot software to determine the mean, standard deviation, standard error and 
significant changes of data. The distribution of the groups was confirmed using the 
Levene’s test for homogeneity of variances. The Students t-test and one-way 
analysis of variances (ANOVA), for comparing two or more means, was used for 
normal distributed data whereas the Mann-Whitney test was used for non-normal 
distributed data. These tests were used to determine the significance difference 
between the control and the experimental groups where values in the 95% 
confidence interval (P < 0.05*, P < 0.01** or P < 0.001***) were accepted as 
statistically different. 
3.14  Ethical Considerations 
This research project made use of commercially purchased, CACO-2 and WS1 
cells in order not to violate Human Tissue Act 65 of 1983. Special reference to 
section 18 of the Act which states that no tissue, blood or gamete shall be removed 











RESULTS AND DISCUSSION 
4.1  Bond Chemical Synthesis of Final Actively Targeted PS 
Nanoconjugate 
4.1.1  Conjugation of ZnPcS4 to AuNP-PEG5000-SH-NH2: Ligand Adsorption 
and Exchange on Pegylated Gold Nanoparticles 
Studies by van Lith et al. (2018) reported that current PS have poor water solubility 
and dark toxicity. Surface functionalization of NPs plays a crucial role in particle 
solubility and reactivity (Siriwandana et al., 2014). This raises the question of 
functionalization efficiency and can new methods probe the degree of surface 
coverage. Ligand exchange is an equilibrium reaction associated with Nernst 
distribution, which often leads to incomplete surface functionalization following 
“standard” literature protocols (Kluenker et al., 2018). However, methods by 
Kluenker et al. (2018) show that the surface coverage with a ligand depends on 
the (i) repeated exchange reactions with large ligand excess, (ii) size of NPs 
(curvature and reactivity) (iii) molecular size of the ligand and (iv) surface 
functionalization, during ligand exchange and can be improved upon when a thiol 
chemisorption driven ligand exchange method it utilized AuNPs to improve surface 
functionalization via tight binding. 
Studies by Siriwandana et al. (2014) noted PEG5000-SH molecules with a 
molecular weight equal to or larger than 2000 g/mol adopt a mushroom-like 
configuration on AuNP surfaces in water and that a large fraction of the AuNP 
surface under the PEG5000-SH mushroom caps is available for ligand adsorption 
in order to form weak disulphide bonds. Moreover, this same study noted that this 
PEG5000-SH mushroom-like configuration on AuNP surfaces in water, also 
exposes the actual AuNPs core to undergo ligand exchange and so form strong 
Au-S bonds. Therefore, since the amine functionalized AuNPs, which were 
purchased for this study were pegylated with a molecular weight of 5000 g/mol, the 
possibility of the ligand adsorption and exchange process occurring between the 
sulphides and PEG5000-SH existed. 
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Thus, theoretically, sulphides can be adsorbed onto pegylated AuNPs through one 
or more of the following three pathways: firstly, by occupying the AuNP surfaces 
that are under the PEG5000-SH “mushroom cap” and so form strong Au-S bonds; 
secondly, by displacing PEG5000-SH molecules previously attached to AuNPs 
and so form weak di-sulphide bonds; or lastly, by binding to the PEG5000-SH 
overlayer on the AuNPs through possible intermolecular interactions between 
PEG5000-SHs and the ligand molecules (Siriwandana et al., 2014). These 
interactions can namely be hydrogen bonding, van der Waals forces, electrostatic 
interactions and possibly even physical entanglement (Siriwandana et al., 2014). 
Since the ZnPcS4 PS which was used in this study is a tetrasulphide derivative 
which has 4 SH / thioacetate groups, the possibility of a ligand exchange process 
occurring between it and the AuNP-PEG5000-SH-NH2 to form strong Au-S bond, 
as well as a ligand absorption process occurring between it and the AuNP-
PEG5000-SH-NH2 to form weak di-sulphide bonds was a strong possibility 
(Nombona et al., 2011; Siriwandana et al., 2014; Sakamoto and Ohno-Okumura 
2009). 
4.1.2 Conjugation of Anti-GCC Ab to ZnPcS4 - AuNP-PEG5000-SH-NH2: 
Amide Bond 
According to studies by Stuchinskaya et al. (2011), AuNPs Ab targeted delivery 
conjugates have been effectively used in various PDT PS delivery applications, in 
order to enhance PS uptake and adsorption into target cancer cells. 
With referral to studies by Jazayeri et al. (2016), there are various physical and 
chemical interactions that can be used for attaching Abs to AuNP surface. Physical 
interactions between Abs and AuNPs depends on three phenomena: (1) ionic 
attraction between the negatively charged gold and the positively charged Ab; (2) 
hydrophobic attraction between the Ab and the gold surface; and (3) dative binding 
between the gold conducting electrons and amino acid sulphur atoms of the Ab. 
Additionally, chemical interactions between Abs and NP surface are achieved in 
the number of ways like chemisorption via thiol derivatives; through the use of 
bifunctional linkers; or through the use of adapter molecules like Streptavidin and 
biotin. Thus, when conjugating Abs to AuNPs, both covalent and non-covalent 
immobilization modes can be used by integrating these physical and chemical 
interactions (Jazayeri et al., 2016).  
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Non-covalent immobilization is whereby Abs are non-specifically or spontaneously 
adsorbed onto the AuNPs surface through a combination of ionic and hydrophobic 
interactions between the Ab and AuNP surface (Figure 19) (Jazayeri et al., 2016). 
Ionic interactions are formed between Ab’s positively charged groups, such as the 
amino acids and the N-terminal, and the negatively charged surface of AuNPs 
(Jazayeri et al., 2016) (Figure 19). Hydrophobic interactions involve the attraction 
between the hydrophobic parts of an Ab and the metal surface of the AuNP 
(Jazayeri et al., 2016) (Figure 19). According to Jazayeri et al. (2016) non-covalent 
modes have several major weaknesses, these include the necessity of a high 
concentration of Ab’s for the preparation of Ab - AuNPs conjugates, random 
orientation of Abs on the AuNP surface and within biological environments they 
can become uncoupled, due to external electrostatic forces, as well as changes in 
environmental pH (Figure 19). Therefore, fixed covalent modes are the most often 
used to bind Abs directly onto the AuNPs surface, through the use of bi-functional 
linkers in order to form a stable and strong bond (Jazayeri et al., 2016).  
Figure 19 Interactions between an Ab and AuNP surface. A- hydrophobic 
interaction, B- ionic interaction, C- covalent bonding due to dative 
binding. 
Within this study, the purchased AuNPs surface were functionalized with an amine 
PEG bi-functional linker in order to facilitate fixed covalent bonding of the Ab to its 
surface. However, in order to facilitate the bonding of the Abs c’ terminus to the 
AuNPs amine group and so form a stable amide bond, the Abs n’ terminus had to 
be correctly orientated outward from the AuNPs surface, in order to be freely 
available for the target Ab to bind to the antigen or over-expressed receptor sites 
on the CRC cells and so allow for active PS delivery. Only the c’ terminus carboxyl 
group was activated for binding through the use of EDC/NHS carbodiimide 
crosslinker coupling chemistry. When an Ab is exposed EDC/NHS its c’ terminus 
carboxyl group becomes activated by forming amine reactive-sulfo-NHS esters, 
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and when exposed to primary functionalized amine groups, a stable amide 
covalent bonds will be formed (Jazayeri et al., 2016) (Figure 20). 
Figure 20 EDC/NHS carbodiimide crosslinker coupling chemistry, in order to 
activate carboxylic protein acids or Ab carboxyl groups for effective 
linking with primary amines in order to create strong amide bonds 
(Kokkinis et al., 2013). 
Studies by Stuchinskaya et al. (2011) reported effective and targeted PDT of breast 
cancer cells using Ab-phthalocyanine-gold nanoparticle conjugates, whereby an 
active targeting Ab was successfully conjugated onto a functionalized AuNPs 
surface using EDC/NHS chemistry. Moreover, studies by Jazayeri et al. (2016) 
noted that an Abs c’ terminus carboxyl group can react with primary amines on 
functionalized AuNPs by means of a condensation reaction to yield amide bonds, 
when applying EDC/NHS chemistry. Thus, it was decided to use EDC/NHS 
chemistry within this study in order to activate and facilitate covalent bonding 
between the Anti-GCC Ab and the already conjugated ZnPcS4 - AuNP-PEG5000-
SH-NH2, in order to actively enhance the ZnPcS4 PSs drug absorption in targeted 
CRC cells for more efficient PDT. However, only the Anti-GCC  Ab was activated 
EDC/NHS chemistry, as to ensure the correct orientation of the Ab attachment (i.e. 
c’ terminus bound to AuNP and n’ terminus free for active site targeting), to the PS 
nanoconjugate (ZnPcS4 - AuNP-PEG5000-SH-NH2) in order to produce a bio-
active Ab targeting NPs for active PS delivery. 
4.2 Molecular Characterization Results Analysis of the Final Actively 
Targeted PS Nanoconjugate 
To ensure efficient binding of the Ab and PS to the surface of the functionalized 
AuNPs, as well as stability, the following molecular characterization assays were 




4.2.1 UV-Visible Spectroscopy 
In order to ensure efficient binding of the Anti-GCC Ab and ZnPcS4 PS to the 
surface of the AuNP-PEG5000-SH-NH2, as well as PS photostability and ROS 
generation, the final actively targeted PS nanoconjugate was subjected to UV−Vis 
spectra analysis.  
The UV-Visible absorption and fluorescent spectra of the final actively targeted PS 
nanoconjugate and various controls (ZnPcS4, AuNP-PEG5000-SH-NH2, Anti-GCC 
Ab, ZnPcS4 - AuNP-PEG5000-SH-NH2) were recorded using a Jenway Genova 
Nano Plus Life Science Spectrophotometer. The absorption and fluorescent 
spectra were read using the spectrum/purity scan mode within the 198 to 800 nm 
spectral region and 220 nm protein direct UV option. Moreover, the protein and 
ZnPcS4 PS concentration, as well as number of bound AuNP of the final actively 
targeted PS nanoconjugate was confirmed by comparing original spectra of 
unbound chemical components (ZnPcS4, AuNP-PEG5000-SH-NH2, Anti- GCC Ab) 
at known concentrations with final spectra obtained from the final actively targeted 
PS nanoconjugate (Tan et al., 2015).  
4.2.1.1 Ultraviolet-Visible Spectroscopy (UV-Vis) Analysis within the 400 
to 800 nm Spectral Region 
With reference to Figure 21, 000125 M or 125 µM of ZnPcS4 in 0.001 M PBS (w/v) 
predictably elicited two major Q bands of emission at 634 and 674 nm within the 
far-red spectral range (Brozek-Pluska et al., 2016). In addition, AuNPEG5000-SH-
NH2 as anticipated demonstrated an absorption spectrum of 520 nm, with an OD 
of 50 which equated to 2.85 X 1015 particles/ml.  
When comparing various controls (ZnPcS4, AuNP-PEG5000-SH-NH2, Anti-GCC 
Ab, ZnPcS4 - AuNP-PEG5000-SH-NH2) to the final actively targeted PS 
nanoconjugate (ZnPcS4 - AuNP-PEG5000-SH-NH2 – Anti-GCC Ab), it retained its 
respective absorption peaks, however with some reduction in absorption, signifying 
that both ZnPcS4 and AuNPEG5000-SH-NH2 had successfully bound together, 
however lowered in concentration.  
Therefore, by comparing the absorbance fold falls of 125 µM ZnPcS4 in 0.001 M 
PBS (w/v) at 673 nm and AuNPEG5000-SH-NH2 (2.85 X 1015 particles/ml) at 520 
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nm, to the absorbance peak values exhibited by the final actively targeted PS 
nanoconjugate within these ranges, the amount of ZnPcS4 loaded onto 
AuNPEG5000-SH-NH could be quantified, as well as the final number of AuNP 
present (Table 12). In relation to Table 12, the final actively targeted PS 
nanoconjugate (AuNPEG5000-SH-NH2 + ZnPcS4 + Anti-GCC  Ab) consisted of 
0.95 X 1015 particles/ml AuNPEG5000-SH-NH bound to 0.0000353 M or 35 µM of 
ZnPcS4 in 0.001 M PBS (w/v). 
 
Figure 21 UV-Visible absorption spectra of the final actively targeted PS 
nanoconjugate (ZnPcS4 - AuNP-PEG5000-SH-NH2 – Anti-GCC Ab) and 
various controls (ZnPcS4, AuNP-PEG5000-SH-NH2, ZnPcS4 - AuNP-
PEG5000-SH-NH2) within the 400 to 800 nm spectral region.  
Table 12 Absorbance fold fall comparison to determine concentration of 
bound ZnPcS4 and AuNP-PEG5000-SH-NH2 within the final actively 
targeted PS nanoconjugate (ZnPcS4 - AuNP-PEG5000-SH-NH2 - Anti-
GCC Ab). 
Sample UV Absorbance 
at 673 nm 
Fold Fall Concentration 
ZnPcS4 0.2321  0.000125 M / 125 µM 
ZnPcS4 - AuNP 0.1033 2.25 0.0000555 M or 56 µM 
ZnPcS4 - AuNP - Anti-GCC Ab 0.0655 3.54 0.0000353 M or 35 µM 
Sample UV Absorbance 
at 520 nm 
Fold Fall Concentration 
AuNP 1.0531  2.85 X 1015 particles/ml 
ZnPcS4 - AuNP 0.4337 2.43 1.17 X 1015 particles/ml 
ZnPcS4 - AuNP - Anti-GCC Ab 0.3522 2.99 0.95 X 1015 particles/ml 
As observed in Figure 21, the final actively targeted PS nanoconjugate presented 
a distinct absorption spectrum at 340 nm and 674 nm, which is closely related to 
the know absorption peak of ZnPcS4. The 674 nm absorption peak indicates that 
the photochemical properties of ZnPcS4 remained intact even after conjugation and 
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so was undoubtedly still capable of generating ROS and singlet oxygen in PDT 
experiments (Brozek-Pluska et al., 2016). The 340nm absorption peak indicated 
that the photodiagnostic potential photochemical properties of ZnPcS4 remained 
intact even after conjugation. Furthermore, the final actively targeted PS 
nanoconjugate also demonstrated a noticeable absorption spectrum of 520 nm, 
suggesting that AuNPEG5000-SH-NH2 still retained its desirable theranostic and 
photodynamic properties (Yao et al., 2016). 
Furthermore, looking at Figure 21, the absorption peaks obtained at 520 and 673 
nm by the final actively targeted PS nanoconjugate in comparison with ZnPcS4 and 
AuNPEG5000-SH-NH2 control peaks, did not broadened much and remained 
sharp and smooth, indicating that an ideal size distribution with negligible 
aggregation was achieved (Naidoo et al., 2019). However, with the absorption 
peaks of the final actively targeted PS nanoconjugate a slightly broadening could 
be noticed, this is indicative of a definitive bonding between all the chemical 
components, due to the increase in the molecular size (Crous and Abrahamse, 
2020). Lastly, the final actively targeted PS nanoconjugate noted a slight shift in 
the resonance peak position of AuNP at 520 nm, suggesting that ZnPcS4 and Anti-
GCC Ab had been successfully conjugated to its surface (Decker and Oldenberg, 
2017). 
4.2.1.2 UV-Visible Protein Direct Absorption Spectra Analysis within the 
200 to 310 nm Spectral Region 
Most proteins such as Abs typically exhibit a UV absorption peak around 280 nm. 
This absorption is attributed to constituent aromatic amino acids such as tyrosine, 
tryptophan, and phenylalanine (Prasad et al., 2017). Thus, their presence can be 
demonstrated by a definitive UV-Vis absorption spectra peak seen within the 280 
nm spectral region (Prasad et al., 2017). 
As shown in Figure 22, it is evident that the 200 µg/ml Anti-GCC Ab control 
obtained a significant UV-Vis absorption spectra peak within the 280 nm spectral 
range. However, there was a notable decline in the spectral features of the final 
actively targeted PS nanoconjugate versus the absorption spectra peak of the 
original 200 µg/ml Anti-GCC Ab control within this same range. These results 
clearly suggested that only a certain amount of the original 200 µg/ml Anti-GCC 





Figure 22 UV-Visible protein direct absorption spectra of the final actively 
targeted PS nanoconjugate and various controls (Anti-GCC Ab, 
AuNPEG5000-SH-NH2, ZnPcS4-AuNP- AuNPEG5000-SH-NH2) within 
the 200 to 310 nm spectral region for protein presence observation, 
as well as amide and di-sulphide bond confirmation.  
Therefore, by comparing the absorbance fold falls of the final actively targeted PS 
nanoconjugate to the original 200 µg/ml Anti-GCC Ab at 280 nm and removing any 
possible protein impurities from AuNPEG5000-SH-NH2 and ZnPcS4, within the 280 
nm absorbance peak range, the total concentration of Anti-GCC Ab conjugated to 
the surface of the final actively targeted PS nanoconjugate could be calculated 
(Table 13). In relation to Table 13, 30.91 µg/ml of Anti-GCC  Ab was successfully 
bound to the final actively targeted PS nanoconjugate, which as previously 
confirmed consisted of 1.17 X 1015 AuNPEG5000-SH-NH2 particles/ml and 
0.0000353 M or 35 µM of ZnPcS4 of ZnPcS4 in 0.001 M PBS (w/v). 
Table 13 Absorbance fold fall comparison to determine the final bound Anti-
GCC Ab protein concentration within the final actively targeted PS 
nanoconjugate (ZnPcS4 - AuNP-PEG5000-SH-NH2 - Anti-GCC Ab).   





Anti-GCC Ab 1.8255  200 µg/ml 
AuNP 0.0666   
ZnPcS4 0.2219   
ZnPcS4 - AuNP - Anti-GCC Ab 0.5705   
ZnPcS4 - AuNP - Anti-GCC Ab, 
calculation eliminating any protein 
presence from ZnPcS4 and AuNP 
0.5705 - 0.2219 - 0.0666 
= 0.282 
6.47 30.91 µg/ml 
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Standard literature highlights that amine functional groups (NH2) strongly absorb 
at 195 nm wavelength spectra, whereas a significant absorption peak at a 
wavelength spectra of 220 nm is indicative of amide peptide bond (CO-NH) 
formation following the condensation of an amine with a carboxylic acid (Naidoo et 
al., 2019). In relation to Figure 22, AuNPEG5000-SH-NH2 control revealed a 
significant amine functional group (NH2) absorption peak at a wavelength spectrum 
of 195 nm, which is anticipated since it was amine functionalized. Moreover, Anti-
GCC Ab control also revealed a strong prominent amine functional group (NH2) 
absorption peak at a wavelength spectrum of 195 nm, which is attributed to the 
amine groups on its n’ terminal. However, the final actively targeted PS 
nanoconjugate demonstrated a decayed amine functional group (NH2) absorption 
peak at a wavelength spectra of 195 nm, when compared to that of the 
AuNPEG5000-SH-NH2 control, indicating that amine functional group on the AuNP 
had condensed with the activated carboxylic group on the c’ terminus of the Abs to 
produce amide peptide bond (CO-NH). The final amide peptide bond (CO-NH) was 
also additionally confirmed within Figure 22, by assessing the 220 nm high 
absorption peak within the final actively targeted PS nanoconjugate wavelengths 
spectra. This result can corroborate that several carboxylic groups on the activated 
c’ terminus of the Anti-GCC Abs had certainly bound with functionalized amine 
groups (NH2) on the AuNPs to establish a rigid peptide bond. 
Furthermore, when comparing amine functional group (NH2) absorption peak at 
195 nm of the Anti-GCC Ab control to that of the final actively targeted PS 
nanoconjugate (Figure 22), it can be observe that there is an absorbance fold fall, 
however amine functional groups can still be detected in the final actively targeted 
PS nanoconjugate. This absorbance fold fall implies that not all of the initial 200 
µg/ml Anti-GCC Ab bound to final actively targeted PS nanoconjugate. 
Nonetheless, since the final actively targeted PS nanoconjugate still elicited an 
amine functional groups at the 195 nm absorption peak, this was conclusive that 
the n’ terminus active targeting sites of the Anti-GCC Ab within the final actively 
targeted PS nanoconjugate was well-preserved, perfectly orientated (i.e. bound to 
the AuNPEG5000-SH-NH at c’ terminus) and so was actively functional for PS 
delivery. 
Lastly, standard literature also mentions that the occurrence of di-sulphide bonds 
yields distinctive UV-Vis spectral absorption properties, typically within the 250 to 
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280 nm range (Li et al., 2002). With reference to Figure 22, it can be noted that the 
final actively targeted PS nanoconjugate exhibited a stronger and more prominent 
UV-Vis spectral absorption within the 250 to 280 nm range when compared to both 
AuNPEG5000-SH-NH2 and ZnPCS4 controls. This result indicates that the 
sulphonated ZnPCS4 PS and AuNPEG5000-SH could have possibly underwent 
ligand absorption in order to form di-sulphide bond between them within the final 
actively targeted PS nanoconjugate (Stuchinskaya et al., 2011). 
4.2.2 Fourier Transform Infrared (FTIR) Spectroscopic Analysis  
Fourier Transform Infrared (FTIR) spectroscopy has various applications in 
structural identification, and can be used for quantitative, as well as qualitative 
analysis of molecular bond formations (Ekka and Roy, 2014).  
Thus, the final actively targeted PS nanoconjugate was subjected to FTIR analysis 
for confirmatory ligand exchange and absorption bond analysis, by noting and 
identifying the formation of strong Au-S and weak disulphide bonds, when 
compared to the FTIR spectra of AuNP-PEG5000-SH-NH2 alone (Figure 23). 
Moreover, the final actively targeted PS nanoconjugate was also subjected to FTIR 
analysis for confirmatory amide bond analysis, by noting and identifying the 
formation of amide bonds when compared to the FTIR spectra of AuNP-PEG5000-
SH-NH2 alone (Figure 23). 
 
 
Figure 23 FTIR spectra analysis for confirmatory ligand exchange (Au-S) and 
absorption (S-S) bond confirmation between AuNP-PEG5000-SH-NH2 




With referral to studies conducted by Nguyen et al. (2012) and Mecozzi and 
Sturchio, (2017), FTIR spectrum in Figure 23 reported characteristic peaks closely 
related to the occurrence of Au-S ligand exchange bonding, since the FTIR spectra 
of AuNPEG5000-SH-NH2 + ZnPcS4, revealed a C-S (1050-1200 cm-1) stretch shift, 
indicating that AuNPEG5000-SH-NH2 had lost their C-S groups to bond with 
ZnPcS4. Additionally, the existence of Au-S ligand exchange bonding was 
confirmed since the FTIR spectra (Figure 22) of AuNPEG5000-SH-NH2 + ZnPcS4 
noted a loss of a C-S (1200 cm-1) sharp band when compared to ZnPcS4 alone, 
suggesting ZnPcS4 lost its C-S groups to bond with AuNPEG5000-SH-NH2. Finally, 
the FTIR spectra of AuNPEG5000-SH-NH2 + ZnPcS4 exhibited a sharp S-S (500-
540 cm-1) band indicating that ligand absorption between the sulphonated ZnPcS4 
PS and AuNPEG5000-SH-NH2 occurred to create a weak di-sulphide bond (Figure 
22).  
Figure 24 FTIR spectra analysis for confirmatory amide (CO-NH) bond 
confirmation between AuNP-PEG5000-SH-NH2 and the activated 
carboxylic group on the c’ terminus of the Anti-GCC Ab within the 
final actively targeted PS nanoconjugate. 
Furthermore, the final actively targeted PS nanoconjugate underwent FTIR 
analysis for confirmatory amide bond analysis, by examining and identifying the 
formation of amide bonds when compared to the FTIR spectra of AuNPEG5000-
SH-NH alone (Figure 24). With referral to studies conducted by Mecozzi and 
Sturchio (2017), FTIR characterization in Figure 24 revealed that final actively 
targeted PS nanoconjugate demonstrated a C=O (1680-1630 cm-1) stretch and 
sharp N=H band (1640-1650 cm-1), when compared to the AuNPEG5000-SH-NH2 
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alone, signifying that strong primary and secondary amide peptide bonds (CO-NH) 
had formed between the amine (NH) functionalized group on the AuNPs and the 
activated c’terminus of the Anti-GCC Ab. 
4.2.3 Dynamic Light Scattering (DLS) and Zeta potential (ZP) Analysis 
For the adequate characterization of NPs and drug delivery systems within initial 
stages of drug development studies in relation to particle size, shape, surface 
charge, dispersity, purity and functionalization for active targeting, as well as to 
ensure biomolecular conjugation dynamic light scattering (DLS) and Zeta potential 
(ZP) assays are often performed (Bhattscharjee et al., 2016). Furthermore, DLS 
technique is often applied to investigate and measure the hydrodynamic size of a 
NP drug delivery system in order to determine if the final nanomaterial is small 
enough for cellular uptake (Bhattscharjee et al., 2016).  
According to Yu et al. (2016) in relation to the design of NP-based carriers for 
targeted drug delivery, the average particle size distribution should not be any 
larger than 100 - 150 nm, in order to ensure successful cellular uptake and 
absorption. The final actively targeted PS nanoconjugate was noted to have a 
mean Z-average diameter of 57.18 ± 3.04 nm (Table 14), suggesting that it was 
indeed small enough to be considered as an active nanodrug carrying system, with 
the definitive possibility of cellular uptake and absorption. 
Table 14 DLS and ZP results for characterization of final NP PS drug delivery 
system. 
Sample Mean Z-Average 
Diameter Measured 






AuNP 11.78 ± 0.966 0.351 
(Monodisperse) 
 
ZnPcS4 18.15 ± 1.44 0.107(Monodisperse)  
Expected average ZnPcS4 - 
AuNP  
48.08 ± 1.20   
Result average ZnPcS4 - 
AuNP  
44.57 ± 0.564 0.250 
(Monodisperse) 
 
Anti-GCC  Ab 5.21 ± 0.51 0.400 
(Monodisperse) 
 
    
Expected average ZnPcS4 - 
AuNP - Anti-GCC Ab 
54.99 ± 0.537   
    
Result average ZnPcS4 - 
AuNP - Anti-GCC Ab (final 
actively targeted PS 
nanoconjugate) 
57.18 ± 3.04 0.353 
(Monodisperse) 





DLS also allows for the homogeneity or purity of a sample to be determined in NP 
drug delivery studies, whereby the hydrodynamic radius distribution graph should 
produce one single peak that is identical from multiple measurements (Stetefeld et 
al., 2016; Lim et al., 2013). If a sample produces multiple peaks, it suggests that 
the sample is a heterogeneous mixture of various particle sizes and so is not pure 
(Stetefeld et al., 2016; Lim et al., 2013). If a sample produces one major definitive 
peak, with smaller minor follow on peaks, this suggests that the sample could be 
homogenous, however have unwanted aggregates, which is sometimes 
problematic in active drug targeting delivery studies, as it could be an indicator of 
particulate clumping and so hinder the active targeting abilities of Abs (Stetefeld et 
al., 2016; Jans et al., 2009). Additionally, reports by Bhattscharjee et al. (2016) and 
Jans et al. (2009), noted that in terms of DLS data interpretation for NP purity 
characterization the hydrodynamic radius distribution graph should produce one 
single major compact peak, that is very narrow in width, for a particle to considered 
spherical in shape, with no aggregation. With reference to Figure 25 below, it can 
be observed that the DLS hydrodynamic radius distribution graph of the final 
actively targeted PS nanoconjugate produced one single major peak (repeated in 
triplicate) with a narrow width and no additional smaller side peaks, suggesting that 









Figure 25 DLS hydrodynamic radius distribution graph of final actively targeted 
PS nanoconjugate consisting of ZnPcS4 - AuNP-PEG5000-SH-NH2 - 
Anti-GCC Ab, repeated in triplicate. 
Furthermore, DLS measurements can be used to monitor successful biomolecule 
conjugation in nanoconjugate carriers (Jans et al., 2009). This is due to the fact 
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that when a complete layer of bound biomolecules is successfully absorbed onto 
a NPs outer core, a soft external surface coat is formed around the NPs hard core, 
which also scatters light (James and Driskell, 2013). This biomolecule outer 
coating causes the diameter a NPs surface to increase by at least two times the 
diameter of the originally measured protein / Ab or drug molecule that was bound 
to it (Jans et al., 2009; James and Driskell, 2013). The increase in the final size of 
the nanocarrier platform can be  compared to the original size of the NP alone, 
protein / Ab or drug molecule alone controls and so allow one to determine if 
biomolecule conjugation and surface functionalized of the nanocarrier platform was 
successful (Figure 26) (Jans et al., 2009; James and Driskell, 2013). If a NP alone 
has a diameter of a least 3 nm, the absorption and formation of a stable monolayer 
of a protein for example on an NPs surface is readily detectable using DLS and so 
will cause the molecule to approximately increase by 6 nm in size (Jazayeri et al., 
2016). 
Figure 26 Two times increase in diameter of a NPs surface by addition of 
biomolecule external coat.  
With reference to Table 14, the mean z-average DLS diameters of Anti-GCC Ab is 
5.21 ± 0.51nm and ZnPcS4 is 18.15 ± 1.44 nm. The original size of the AuNP was 
(11.78 ± 0.966 nm) (Table 14).  If both the Anti-GCC Ab and ZnPcS4 bound to the 
AuNP, this would have doubled the size diameter of the original AuNP pre-
determined diameter, equating to a final actively targeted PS nanoconjugate 
expectancy average size of 54.99 ± 0.537 nm (Table 14). The mean z-average 
DLS diameter of the final actively targeted PS nanoconjugate was found to be 
57.18 ± 3.04 nm, which is very similar to the expected average calculated result of 
54.99 ± 0.537nm, taking the standard deviation into account and so this result pre-
confirmed the biomolecule effective conjugation of the Anti-GCC Ab and ZnPcS4  
to the AuNPs (Table 14). However, since it was questionable if the DLS laser light 
scattering at 633 nm could have slightly interfered with the molecular integrity of 
ZnPcS4, as it’s a fluorochrome which is excitable at 634 nm, the successful 
conjugation of ZnPcS4 and Anti-GCC Ab to AuNPs, was additionally and further 
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confirmed using the above discussed UV-Vis and FTIR spectra techniques 
(Geißler et al., 2015; Bhattscharjee et al., 2016). 
Moreover, DLS can calculate the Polydispersity Index (PDI) of a sample by 
measuring the intensity of light scatter and so determine the purity of a sample 
(Bhattscharjee et al., 2016). Monodisperse samples are considered to be pure, 
singular samples of the same size and generally have a PDI value range between 
0.1 to 0.4, due to a compact light scatter, whereas polydisperse samples have a 
PDI ≥ 0.4 and so are considered to be a mixture of various particle sizes 
(Bhattscharjee et al., 2016). With reference to Table 14, it can be observed that 
the final actively targeted PS nanoconjugate noted a PDI value of 0.353, signifying 
it was monodispersed in nature and consisted mostly of singular sized particles. 
Moreover, these results imply that the three individual constituents (ZnPcS4, AuNP-
PEG5000-SH-NH2 and Anti-GCC Ab) were successfully bonded together to form 
one single final actively targeted PS nanoconjugate molecule. 
Zeta potential is a scientific term for electro kinetic potential in a colloidal system 
(Honary et al., 2013). Within the ZP technique the net surface potential charge of 
a NP drug delivery system can be determined (Honary et al., 2013). According to 
studies by Bhattscharjee et al. (2016), these surface net charge ZP values can be 
directly correlated to the colloid steadiness of NP-dispersions and so determine 
the overall stability of a NP drug delivery system. The standard classification 
guidelines for NP-drug delivery dispersion stability classification are as follows: ±0-
10 mV - highly unstable; ±10-20 mV - relatively stable; ±20-30 mV - moderately 
stable; and ±30 mV - highly stable (Patel et al., 2011; Bhattscharjee et al., 2016). 
Moreover, since ZP is a potential charge that exists on the outer parts of a 
molecular compound, it is often used an indicator of electrophoretic mobility of the 
compound (Bhattscharjee et al., 2016). Within an in vivo system a very high 
positive or negative ZP surface net charge can affect a NP drug delivery systems 
distribution and subcellular localization, due to the electrostatic repulsive forces 
that naturally occur on all biomolecules  in vivo surfaces, such as proteins, lipids, 
cell membranes etc. (Bhattscharjee et al., 2016). Moreover, cancer cell surfaces 
are usually more negatively charged than average normal cell surfaces, due to the 
constant translocation of negatively charged constituents from the inner layer of 
the cell membrane (e.g., phosphatidylserine, anionic phospholipids, glycoproteins 
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and proteoglycans) to the outer cancer cells surface (Honary et al., 2013). Hence, 
when considering final NP delivery systems for successful drug subcellular 
localization, a ZP result of near neutral to slightly positive is considered favorable, 
taking into consideration that generally cancer cellular membranes exhibit higher 
negative charges than normal cells (Yu et al., 2016). Studies by Honary et al. 
(2013), have noted that NPs with an overall positive charge are more preferentially 
taken up by the tumours and retained for a longer time span, compared to 
negatively charged or neutral particles. 
Favourably as can be observed in Table 14, the ZP value of the final actively 
targeted PS nanoconjugate was found to be 36.5 ± 2.6 mV, proposing that it is 
highly stable with a slightly positively charge, hinting at the fact that it should remain 
stable within an in vivo environment, as well as be retained within cancer tumour 
cells more selectively for a longer period of time. 
4.2.4  Presumptive ROS Generation  
Since the final actively targeted PS nanoconjugate contained ZnPcS4 PS which 
absorbs at 340 nm (Soret Band) and emits at 583, 634 and 674 nm range (Q band) 
in PBS (Abramczyk et al., 2017; Brozek-Pluska et al., 2016), it should possess the 
ability to generate ROS. However, the ability of a molecular drug conjugate to 
generate ROS can sometimes be affected, due to it becoming quenched with side 
chain conjugates (Brozek-Pluska et al., 2016).  
Thus, in order to presumptively confirm if the final actively targeted PS 
nanoconjugate was capable of ROS generation before conducting PDT 
experiments (in order to observe the cytotoxic ROS effects in cell culture), its UV-
Visible absorption and fluorescent spectra were recorded using the Jenway 
Genova Nano Plus Life Science Spectrophotometer pre- and post-laser irradiation 
exposure within the 198 to 800 nm spectral region. 
The presumptive production of ROS from the final actively targeted PS 
nanoconjugate was determined by comparing the decay in absorbance intensity of 
the UV-Vis Q band in the known 634 and 674 nm range of ZnPcS4, pre- and post-
laser irradiation with that of a previously run control sample of ZnPcS4 alone.  
As can be observed in Figure 27, two strong UV-Vis absorption Q bands in the 634 
and 673 nm range can be observed pre-laser irradiation suggesting that the final 
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actively targeted PS nanoconjugate with ZnPcS4 had photolytic activity within these 
far-red regions of the visible spectrum (Brozek-Pluska et al., 2016). Post laser 
irradiation it can be observed that these two strong absorption bands decayed in 
intensity, suggesting that upon laser light exposure at 673 nm the final actively 
targeted PS nanoconjugate became excited, transferring its energy to surrounding 
oxygen molecules, presumptively generating ROS and so became photobleached 
(Stuchinskaya et al., 2011). These results presumptively confirmed the photolytic 
activity of the final actively targeted PS nanoconjugate, however only additional 
PDT cell culture assays, performed later on in this study could definitively confirm 
if this potential ROS generation was cytotoxic enough to destroy CRC cells. Lastly, 
it must be noted that when comparing the final actively targeted PS nanoconjugate 
UV-Vis absorption Q bands at 520 nm, pre- and post- laser irradiation, a significant 
decay in intensity was also noted. Since the UV-visible absorption spectrum peaks 
at 520 nm demarcate the presence of AuNPs, within the final actively targeted PS 
nanoconjugate, it could be suggested that upon laser light exposure at 673 nm, the 
final actively targeted PS nanoconjugate AuNPs underwent photothermal decay 
and so presumptively could enhance PDT treatment outcomes, due to its 
theranostic properties. 
 
Figure 27 UV-Visible absorption spectra of the final actively targeted PS 
nanoconjugate (ZnPcS4 - AuNP-PEG5000-SH-NH2 - Anti-GCC Ab) pre- 
and post- laser irradiation at 673 nm, recorded within the 400 to 800 
nm spectral region. 
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4.2.5 Photostability Analysis 
The photostability parameter of any potential PS should be monitored overtime as 
to ensure it remains stable in the dark and its absorbance doesn’t decay overtime, 
rendering it ineffective (Rojkiewicz et al., 2013). Only upon light exposure it should 
go into an excited state and so transfer its energy to neighbouring molecules (for 
example oxygen) and then return to a ground state (Rojkiewicz et al., 2013). 
Sometimes PS nano conjugates can degrade overtime and so lose their absorption 
and excitation properties, due to many external properties, such as the solvent they 
suspended in, additional substituents being present or because the compound 
might have started to aggregate (Rojkiewicz et al., 2013). When the final actively 
targeted PS nanoconjugate or its controls were not being utilized in laser irradiation 
exposure experiments or biochemical assays they kept in the dark at 4°C. 
 
Figure 28 UV-Visible absorption photostability spectra of the final actively 
targeted PS nanoconjugate (ZnPcS4 -AuNP-PEG5000-SH-NH2 - Anti-
GCC Ab) recorded within the 300 to 800 nm spectral region over an 
8-week period. 
In order to determine the photostability of the final actively targeted PS 
nanoconjugate its Soret and Q bands values were measured prior to laser light 
irradiation experiments over the duration of experimental assays (8 weeks) with a 
UV-Vis spectrophotometer (Genova Nano Plus Life Science Spectrophotometer - 
Jenway), using the spectrum/purity scan mode within the 198 to 800 nm spectral 
region. The UV spectra results were captured and reported over an 8-week period, 
to note any photostability absorption changes that could have occurred within the 
final actively targeted PS nanoconjugate. With reference to Figure 28, no 
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significant or obvious changes within the UV spectra, were noted suggesting that 
the final actively targeted PS nanoconjugate remained stable and free of 
aggregation. Furthermore, there were no significant shift changes within the high 
absorption (340 nm - Soret Band) and emission (583, 634 and 674 nm - Q band) 
peaks indicating that the ZnPcS4 PS within the final PS nanoconjugate retained to 
photochemical properties and did not quench (Figure 28). 
4.3 Sub-Cellular Localization Confirmation of Final Actively Targeted PS 
Nanoconjugate 
The success of targeted PDT hinges on different dynamics, namely on the efficacy 
of the PS nanocarriers cancer targeting abilities in normal versus cancer tumour 
cells (Mesquita et al., 2018). Immunofluorescent microscopy staining subcellular 
localization studies were performed in order to determine the intracellular 
concentration of ZnPcS4 PS within in vitro cultured CRC cells (CaCo-2) and the 
degree of cellular uptake, when administered alone, versus within a specifically 
active PS nanocarrier system (AuNPEG5000-SH-NH2 + ZnPcS4 + Anti-GCC Ab). 
Additionally, these immunofluorescent stained images were compared to in vitro 
cultured normal human fibroblasts (WS1), which also received the PS alone and 
final actively targeted PS nanoconjugate, in order to assess if the final actively 
targeted PS nanoconjugate demonstrated any improved targeted specify or affinity 
for CRC cells only or indicated any uptake in normal human cells. Images were 
captured at 400x magnification. 
With reference to Table 15, CRC cells note a slight passive subcellular uptake of 
the ZnPcS4 PS when it was administered alone. These results coincided with the 
findings reported by Roguin et al. (2019), highlighting that ZnPc is a stable 
compound, which exhibits selective passive accumulation in tumour tissues. In an 
effort to further augment the passive subcellular localization of the ZnPcS4 PS in 
CRC cells, it was integrated with a gold nanocarrier. Since studies by Hong et al. 
(2016) stated that nanoparticles significantly enhance the solubility of PSs and so 
increases their selective passive localization. 
When looking at the images in Table 15, CRC cells which received the same 
concentration of ZnPcS4 PS, however conjugated to AuNPs (AuNPEG5000-SH-
NH2 - ZnPcS4 AuNPEG5000-SH-NH2) noted an improved PS drug passive uptake, 
with a far more intense red staining.  Several lines of evidence emphasize that 
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when targeting moieties, which correlate with overexpressed cancer cell receptors 
are correctly attached to PS nanocarrier platforms, the PS absorption is selective 
and can be directly up via cell membrane endocytosis into target tumours in higher 
concentrations (Hodgkinson et al., 2017).  With reference to Table 15, the 
experimental group of CRC cells treated with the final actively targeted PS 
nanoconjugate (AuNPEG5000-SH-NH2 + ZnPcS4 + Anti-GCC Ab) noted enhanced 
affinity and active accumulation of the PS. These findings indicate that the final 
targeted PS nanoconjugate facilitated enhanced ZnPcS4 PS retention in CRC cells 
(CaCo-2), via the specific PS nanoconjugates Anti-GCC Ab selective and active 
targeting abilities.   
Table 15 Subcellular localization comparison of ZnPcS4 PS uptake in CaCo-2 
cells, treated with ZnPcS4 PS alone, AuNPEG5000-SH-NH2 - ZnPcS4 
and the final actively targeted PS nanoconjugate. DAPI-stained nuclei 
(Blue), cellular membrane proteins (Green) and ZnPcS4 localization 
(RED). 
 
With reference to Table 16, normal human fibroblasts WS1 cells treated with 
ZnPcS4 alone noted some absorption of the PS, suggesting that within these 
applied conditions, normal human cells would be affected within CRC localized 
PDT treatments and so unwanted side effects could be observed. Whereas, 
normal human fibroblasts WS1 cells treated with AuNPEG5000-SH-NH2 - ZnPcS4 
control conjugate, noted still only slight absorption of the PS at the same 
Description ICAM Green Cellular 
Membrane Protein 
DAPI Blue Nucleus ZNPCS4 Red CY5 for 
PDT 
Overlay Final Image 
CaCO cells only 
  
Received no PS 
 
CaCO cells with 
0.125 µM 
ZnPcS4  
    












NH2 – Anti-GCC 
Ab 
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administered concentration, suggesting that the AuNPs promoted the PS for a 
more passive uptake within cancer tissues and so CRC PDT treatment outcomes 
would have lessened side effects of normal surrounding tissues (Table 16). 
However, experimental normal human fibroblasts WS1 cells treated with the final 
actively targeted PS nanoconjugate, noted no detectable subcellular localization of 
the PS. These findings indicated that the final PS nanoconjugate, has no actively 
specific affinity for healthy cells (such as fibroblasts), suggesting that if was to be 
applied within actively targeted PDT treatment for CRC, the treatment would 
remain localized to CRC only, with no unwanted side effects being induced in 
healthy surrounding tissues.  
Table 16 Subcellular localization comparison of ZnPcS4 PS uptake in WS1 
cells, treated with ZnPcS4 PS alone, AuNPEG5000-SH-NH2 - ZnPcS4 
and the final actively targeted PS nanoconjugate. DAPI-stained nuclei 
(Blue), cellular membrane proteins (Green) and ZnPcS4 localization 
(RED). 
4.4 Photodiagnosis of CRC using the Final Actively Targeted PS 
Nanoconjugate 
PDD is similar to PDT, since it forms a part of photomedicine based diagnostics, 
which also incorporates a PS and light, however it induces no cellular damage - 
due to a shorter purple to blue wavelength of light being applied (Dobson et al.,  
Description ICAM Green Cellular 
Membrane Protein 
DAPI Blue Nucleus ZNPCS4 Red CY5 for 
PDT 
Overlay Final Image 
WS1 cells only 
  
Received no PS 
 
WS1 cells with 









WS1 cells with 




   
WS1 cells with 
0.125 µM ZnPcS4 
– AuNP-
PEG5000-SH-NH2 
– Anti-GCC Ab 




2018). The development of new rapid diagnostic techniques is the basis for modern 
and effective treatments of cancer, as an early diagnosis allows physicians to 
rapidly initiate treatment and so substantially increases the chances of patient 
survival (Dobson et al., 2018). In comparison to PDT, PDD is based on 
fluorescence elicited by shorter purple to blue wavelength light (330 – 400 nm) 
(Oniszczuk et al.,  2016). Available literature indicates that most PDD methods are 
based on precursors of protoporphyrin IX (PpIX) or phthalocyanines (Pc) having a 
Soret band within the 300 – 400nm range (Oniszczuk et al., 2016). The ZnPcS4 
PS which was utilized within this study has a Soret band at 340 nm, suggesting 
that if it selectively and specifically localizes in CRC cells only, it could be 
successfully utilized for PDD applications in order to identify this type of cancer.  
In order to determine if the final actively targeted PS nanoconjugate could be 
successfully absorbed by CRC cells only (and not normal fibroblast cells), as well 
as be utilized for fluorescent PDD of CRC, intercellular cell adhesion molecule-1 
(ICAM-1) immunofluorescent morphological staining and fluorescent microscopy 
imaging assays were performed. ICAM-1 is a cellular surface marker membrane 
protein, which is expressed within almost all in vitro adherent cells, however 
different type of cell lines exhibit different morphological shapes and so this allows 
one to distinguish identify different cell membrane shapes (i.e. fibroblasts – spindle 
shaped versus CRC cells – ovoid shaped) (Jeong et al., 2016). Images were 
captured at 400x magnification. During immunofluorescent studies, it was found 
that ZnPcS4 alone, when bound to AuNPEG5000-SH-NH2 or within its final actively 
targeted PS nanoconjugate form, was able to actively fluoresce and illuminate in 
both WS1 and CRC cells, when blue light filters at 340 nm was applied to stained 
cells.  
In with reference to Table 17, CRC cells note a slight passive subcellular uptake of 
the ZnPcS4 PS when it was administered alone. These results coincided with the 
findings reported by Roguin et al. (2019), highlighting that ZnPc is a stable 
compound, which exhibits selective passive accumulation in tumour tissues. In an 
effort to further augment the passive subcellular localization of the ZnPcS4 PS in 
CRC cells, it was integrated with a gold nanocarrier. Since studies by Hong et al. 
(2016) stated that NPs significantly enhance the solubility of PSs and so increases 
their selective passive localization. When looking at Table 17, CRC cells which 
received the same concentration of ZnPcS4 PS, however conjugated to AuNPs 
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(AuNPEG5000-SH-NH2 - ZnPcS4 AuNPEG5000-SH-NH2) noted an improved PS 
drug passive uptake.  Several lines of evidence emphasize that when targeting 
moieties, which correlate with overexpressed cancer cell receptors are correctly 
attached to PS nanocarrier platforms, the PS absorption is selective and can be 
directly up via cell membrane endocytosis into target tumours in higher 
concentrations (Hodgkinson et al., 2017).  With reference to Table 17, the 
experimental group of CRC cells treated with the final actively targeted PS 
nanoconjugate (AuNPEG5000-SH-NH2 + ZnPcS4 + Anti-GCC Ab) noted enhanced 
affinity and active accumulation of the PS. These findings indicate that the final 
targeted PS nanoconjugate facilitated enhanced ZnPcS4 PS retention in CRC cells 
(CaCo-2), via the specific PS nanoconjugates Anti-GCC Ab active targeting 
abilities and so could be considered for PDD identification, however its selective 
targeting abilities in CRC cells only and not in normal human cells still required 
confirmation below. 
Table 17 PDD comparison of ZnPcS4 PS uptake in CaCo-2 cells, treated with 
ZnPcS4 PS alone, AuNPEG5000-SH-NH2 - ZnPcS4 and the final 
actively targeted PS nanoconjugate. ZnPcS4 fluorescence at 340 nm 
(Blue) and cellular membrane proteins (Green).  




nm  for PDD 
Overlay Final Image 
CaCo-2 cells only 
 
Received no PS  
 
CaCo-2  cells with 0.125 
µM ZnPcS4  
   
CaCo-2  cells with 0.125 
µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 
   
CaCo-2  cells with 0.125 
µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – 
Anti-GCC Ab 
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With reference to Table 18, normal human fibroblasts WS1 cells treated with 
ZnPcS4 alone noted some absorption of the PS, suggesting that within these 
applied conditions, the PS could not be used for CRC PDD, since the PS could not 
specifically distinguish between normal and cancerous cells. Whereas, normal 
human fibroblasts WS1 cells treated with AuNPEG5000-SH-NH2 - ZnPcS4 control 
conjugate, noted a slight absorption of the PS at the same administered 
concentration, suggesting that the AuNPs promoted the PS for a more passive 
uptake within CRC cancer tissues (Table 18). Thus, these results still indicate that 
even when the PS was conjugated to AuNP, its uptake was not specific enough 
and slight absorption was found in WS1 cells and so even within these applied 
conditions, the PS could not be used for CRC PDD, since the PS could not 
specifically distinguish between normal and cancerous cells.  
Table 18 PDD comparison of ZnPcS4 PS uptake in WS1 cells, treated with 
ZnPcS4 PS alone, AuNPEG5000-SH-NH2 - ZnPcS4 and the final 
actively targeted PS nanoconjugate. ZnPcS4 fluorescence at 340 
nm(Blue) and cellular membrane proteins (Green).  
Description ICAM Green Cellular 
Membrane Protein 
ZnPcS4 Blue 
Fluorescence @340 nm  
for PDD 
Overlay Final Image 




WS1 cells with 0.125 
µM ZnPcS4  
   
WS1 cells with 0.125 
µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 
   
WS1 cells with 0.125 
µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – 
Anti-GCC Ab 
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However, experimental normal human fibroblasts WS1 cells treated with the final 
actively targeted PS nanoconjugate, noted no detectable subcellular localization of 
the PS (Table 18). These findings indicated that the final PS nanoconjugate, had 
no actively specific affinity for healthy cells (such as fibroblasts), suggesting that if 
was to be applied within actively targeted CRC PDD detection, the application 
would remain localized to CRC only, and so be able to precisely and highly 
selectively be able to distinguish between normal and cancerous cells. Overall, 
these results confirm that when a ZnPcS4 PS is conjugated to a AuNP carrier, that 
is linked with an active targeting biomolecule (Anti-GCC Ab), the PSs active and 
specific uptake in CRC cells can be attained, in order to accommodate PDD cancer 
detection, due to the PSs highly specific and sensitive absorption in only CRC cells 
(with no affinity for normal human cells) and so can allow for precise identification 
and differentiation of CRC tissues in comparison to normal tissues.  
4.5 CaCo-2 ZnPcS4 PS PDT Dose Response Analysis 
In order to determine the lowest possible concentration of ZnPcS4 PS which could 
be administered to CRC cells to yield 50 % cell viability, as well as induce a 
significant amount of cytotoxicity, in order to establish cell death induction potential, 
but still be able to determine cellular responses, varying concentrations of ZnPcS4 
PS was administered to cultured cells within PDT dose response assays (0.0312, 
0.0625, 0.125 and 0.25 µM). Furthermore, these PDT dose response assays were 
performed in order to determine the ideal ICD50 concentrations at which the ZnPcS4 
PS contained within the final actively targeted PS nanoconjugate, should also be 
administered so that results could be compared in relation to PS PDT treatment 
alone versus PS nanoconjugate actively targeted PDT at the same concentration.  
4.5.1 Cellular Morphological Assessment by Light Microscopy 
The effect of ZnPcS4 PS PDT treatment alone on the various control and 
experimental groups was analysed by viewing the captured inverted microscope 
digital images and comparing them. All images were captured at a 40x 
magnification. The cellular structures of the CRC cells were evaluated based on 
changes in cell shape, size and non-viable cells (Noguchi et al., 2015). Change in 
the microscopic structure of cells and their cellular components is an indication of 
cell damage occurring or having occurred (Noguchi et al., 2015). 
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With reference to Table 19 it can be observed that the control group of CRC cells 
only, demonstrated no changes in morphology and retained their distinctive 
appearance and so this was utilized as a comparative reference of being “normal”, 
when assessing the other various control and experimental groups.  
Table 19 Morphological comparison of various control and experimental 
groups of CaCo-2 CRC cells treated within ZnPcS4 PDT dose 
response assays. 




Cells + Irradiation (10 J/cm2) 
 
Cells + 0.0312 µM ZnPcS4 
 
Cells + 0.0625 µM ZnPcS4 
 
Cells + 0. 125 µM ZnPcS4 
  
Cells + 0. 25 µM ZnPcS4 
PDT Treated Experimental Groups 
 
Cells + 0.0312 µM ZnPcS4 + PDT 
 
Cells + 0.0625 µM ZnPcS4 + PDT 
 
Cells + 0.125 µM ZnPcS4 + PDT 
 
Cells + 0.25 µM ZnPcS4 + PDT 
 
Control group CRC cells treated with 673nm laser irradiation at a fluency of 10 
J/cm2 alone, presented no detectable morphological changes, suggesting that 
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laser irradiation alone has no effect on CRC cells (Table 19). All control groups of 
CRC cells, which received the varying concentrations of PS alone (0.0312, 0.0625, 
0.125 and 0.25 µM) without laser irradiation, noted no significant morphological 
changes or effects when compared to the cells only control. According to Kruger 
et al. (2018), ideally a PS should have no dark toxicity and should only affect cells 
when activated by laser light. These findings indicated that the ZnPcS4 PS at these 
various concentrations, remained inactive within dark conditions and so exerted no 
dark cytotoxicity on CRC cells.  
However, experimental group CRC cells, which received varying concentrations of 
the PS (0.0312, 0.0625, 0.125 and 0.25 µM) and PDT laser irradiation at 673nm 
with a fluency of 10 J/cm2, demonstrated changes in cellular morphology in a dose-
dependent manner. In a dose dependent manner ZnPcS4 PS PDT induced cellular 
damage in CRC cells when compared to the CRC control of cells only. Cells started 
changing their distinctive appearance, in terms of rounding up and detaching from 
cell culture plates. The most significant damage noted in ZnPcS4 PS PDT treated 
CRC cells, were those which received 0.25 µM ZnPcS4, as most cells appeared as 
free-floating structures and the cells which remained attached had irregular nuclear 
fragmentation, as well as reduced nuclear genetic material, suggesting this 
particular dose was lethal. Whereas, ZnPcS4 PS PDT treated CRC cells, which 
received 0.125 µM ZnPcS4, noted a significant amount of morphological damage 
and debris, however at least 50% of the cells appeared functional, suggestive that 
this could perhaps be the ICD50 dose required.   
4.5.2 Cellular Viability Assessment  
The Trypan blue exclusion test was performed to assess the effect ZnPcS4 PS 
PDT dose responses had on the survival of CRC treated cells, since it indicates 
the percentage of viable cells, due to its staining ability to distinguish between 
viable and non-viable cells. Figure 29 showed that the control group of CRC cells 
only had 100% viable cells, indicating that the cells were both normal and healthy. 
This control group of CRC cells only, was utilized for statistically significant 
comparisons of findings against other various control and experimental groups for 
overall result analysis (P˂0.05*) (P˂0.01**) (P˂0.001***). 
It is clearly shown that the control group of CRC cells which received laser 
irradiation at 673 nm and a fluency of 10 J/cm2 noted an insignificant decrease in 
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cell viability when compared to the reference control group of cells only (Figure 
29). This is consistent with literature, as it suggests that laser irradiation at 673 nm 
with a fluency 10 J/cm2, without any addition of a PS, does cause damage to CRC 
cells (Manoto et al., 2012).  
Control culture CRC cells, which received various concentrations of ZnPcS4, with 
no laser irradiation applied to them, were used as comparative controls groups. 
There was a dose dependent decrease in cell viability noted for these control 
groups treated which received the various concentrations of ZnPcS4 only, however 
it was insignificant (Figure 29). This suggests that the ZnPcS4 PS in its inactivated 
form when administered alone, at these varying concentrations, lacks cytotoxicity 
and so does not damage CRC cells, without laser irradiation being applied.  
 
Figure 29 Trypan blue exclusion cell viability assay. Response of CaCo-2 cells 
treated with varying concentrations of ZnPcS4 PS following PDT, 
demonstrating a decrease in cell viability in a dose dependent 
manner. 
The PDT experimental groups which consisted of CRC cells treated with varying 
concentrations of the PS and exposed to 673 nm laser irradiation at 10 J/cm2, noted 
a significant decrease in cellular viability in a dose-dependent manner (Figure 29). 
The most significant decrease in cell viability was 44%*** and this was noted in 
PDT treated experimental groups which received 0.25 µM ZnPcS4 PS, signifying 
that at this particular concentration CRC PDT treatment could obliterate cells 
beyond cellular responses detection, due to severe cell death induction. Within the 
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PDT treated experimental groups whereby CRC cells received 0.125 µM ZnPcS4 
PS, significant cellular damage had occurred, however 54%** of the cells were 
found to be viable and so from this assay the recommended ICD50 concentration 
of the ZnPcS4 PS would be 0.125 µM. Overall these results indicate that ZnPcS4 
is an excellent PS for the use in this type of CRC PDT treatment, since it is capable 
of substantial cell death induction.  
4.5.3 Cellular Proliferation Assessment 
The CellTiter-Glo® luminescent assay (AnaTech: Promega, PRG7571) was used 
to measure cellular proliferation by evaluating the amount of ATP produced from 
metabolically active cells. 
 
Figure 30 ATP luminescence cell proliferation assay. Response of CaCo-2 cells 
treated with varying concentrations of ZnPcS4 PS following PDT, 
demonstrating a decrease in cellular proliferation in a dose 
dependent manner. 
Figure 30 showed that the control group of CRC cells only, had 100% viable cells 
capable of proliferation, indicating that the cells were both normal and healthy. This 
control group of CRC cells only, was utilized for statistically significant comparisons 
of findings against other various control and experimental groups for overall result 
analysis (P˂0.05*) (P˂0.01**) (P˂0.001***). 
The control group of CRC cells which received laser irradiation at 673 nm and a 
fluency of 10 J/cm2, noted no significant decreases in cellular viability when 
compared to the reference control group of cells only (Figure 30). These results 
127 
 
are consistent with studies performed by Manoto et al. (2012) which noted that 
laser irradiation at 673 nm, with a fluency 10 J/cm2, without any addition of a ZnPc 
PS does cause damage to CRC cells. 
Control culture CRC cells, which received various concentrations of ZnPcS4, with 
no laser irradiation applied to them, were used as comparative controls groups. 
There was a slight dose dependent cellular proliferation decrease noted for these 
control groups, which were treated with the various concentrations of ZnPcS4 only, 
however it was insignificant (Figure 30). This suggests that the ZnPcS4 PS in its 
inactivated form when administered alone (without laser irradiation), within these 
particular concertation ranges, lacks cytotoxicity and so does not damage cellular 
proliferation mechanisms within CRC cells.  
The PDT experimental groups which consisted of CRC cells treated with varying 
concentrations of the PS and exposed to 673nm laser irradiation at 10 J/cm2, noted 
a significant decrease in cellular proliferation in a dose-dependent manner (Figure 
30). The most significant decrease in cellular viability was noted in PDT treated 
experimental groups which received 0.25 µM ZnPcS4 PS, signifying that at this 
particular concentration CRC PDT treatment could obliterate cells beyond cellular 
responses detection, due to the severe cellular proliferation damage it induced. 
Within the PDT treated experimental groups, whereby CRC cells received 0.125 
µM ZnPcS4 PS, significant cellular proliferation damage had occurred, however in 
comparison to the CRC cells only control, 4.E+05*** cells were found to be 
metabolically active and capable of cellular proliferation and this concentration 
approximately 50% of the CRC were viable. Hence, these results were suggestive 
that the recommended ICD50 concentration of the ZnPcS4 PS would be 0.125 µM. 
Overall these results indicate that ZnPcS4 is an excellent PS for the use in this type 
of CRC PDT treatment, since it is capable of substantial induction cellular 
proliferation damage. 
4.5.4 Cellular Cytotoxicity Assessment  
The CytoTox 96® Non-Radioactive Cytotoxicity Assay (Anatech: Promega, 
PRG1780), was used to quantitatively measure the amount of LDH released into 
the culture media of the various experimental and control cells to evaluate the 
degree of cytoxicity the ZnPcS4 PS was able to induce in CRC cells.  
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With reference to Figure 31, the LDH positive control signifies 100% cellular 
cytotoxicity in CRC cells (CaCo-2), due to complete cellular lysis and so was used 
as a standard reference to calculate percentage cytotoxicity in all other control and 
experimental groups. The control group of cells only, was used as a standard 
reference for viable CRC cells, which reflects no cellular cytotoxicity, for statistical 
significance comparisons in all other control and experimental groups (P˂0.05*) 
(P˂0.01**) (P˂0.001***). 
The control group of CRC cells which received laser irradiation at 673 nm and a 
fluency of 10 J/cm2, noted no significant increases in cellular cytotoxicity when 
compared to the LDH positive control group of cells only (Figure 31). As previously, 
discussed these results are consistent with studies performed by Manoto et al. 
(2012) which noted that laser irradiation at 673 nm, with a fluency 10 J/cm2, without 
any addition of a ZnPc PS does not induce any cytotoxicity in CRC cells. 
 
Figure 31 Cytotoxicity of control and experimental groups of ZnPcS4 PS drug 
at different concentrations with and without 673 nm laser irradiation 
at 10 J/cm2, using Lactate Dehydrogenase membrane integrity assay. 
Control culture CRC cells, which received various concentrations of ZnPcS4, with 
no laser irradiation applied to them, were used as comparative controls groups. 
There was a slight dose dependent cellular cytotoxicity increase noted for these 
control groups, which were treated with the various concentrations of ZnPcS4 only, 
however it was insignificant (Figure 31). This suggests that the ZnPcS4 PS in its 
inactivated form when administered alone (without laser irradiation), within these 
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particular concertation ranges, lacks cytotoxicity and so does not induce cellular 
damage within CRC cells.  
The PDT experimental groups which consisted of CRC cells treated varying 
concentrations of the PS and exposed to 673nm laser irradiation at 10 J/cm2, noted 
a significant increase in cellular cytoxicity in a dose-dependent manner (Figure 31). 
The most significant increase in cellular cytotoxicity was 67%*** and this was noted 
in PDT treated experimental groups which received 0.25 µM ZnPcS4 PS, signifying 
that at this particular concentration CRC PDT treatment could obliterate cells 
beyond cellular responses detection, due to severe cytotoxicity it induced. Within 
the PDT treated experimental groups, whereby CRC cells received 0.125 µM 
ZnPcS4 PS, significant cytotoxicity had occurred, however it was only 45%** and 
so from this assay the recommended ICD50 concentration of the ZnPcS4 PS would 
be 0.125 µM. Overall these results indicate that ZnPcS4 is an excellent PS for the 
use in this type of CRC PDT treatment, since it is capable of substantial cellular 
cytoxicity induction. 
4.5.5 Summation of ZnPcS4 PS PDT Dose Response Assays 
Analysis in Relation to Final Actively Targeted PS 
Nanoconjugate Correction Factor 
The optimal IDC50 dose response concentration of ZnPcS4 PS after PDT treatment 
that induced approximately 50 % cytotoxicity was found to be 0.125 µM, after 
assessing the above morphological, cellular viability, proliferation and cytotoxicity 
results. 
Therefore, once the above had been established then further final actively targeted 
PS nanoconjugate PDT experiments within in vitro cultured CaCo-2 could be 
conducted utilizing the synthesized ZnPcS4 – AuNP-PEG5000-SH-NH2 - Anti-GCC 
Ab at the recommended and adjust ICD50 ZnPcS4 PS concentration of 0.125 µM. 
This was done for comparative result reporting, in order to compare if the ZnPcS4 
PS PDT induced cytotoxicity alone, induced more or less cytotoxicity versus the 
final actively PDT targeted PS nanoconjugate.  
Since the molecular characterization results in Table 12 and 13 noted that the final 
actively targeted PS nanoconjugate consisted of 30.91 µg/ml of Anti-GCC  Ab, 
which was successfully bound to 0.95 X 1015 AuNP-PEG5000-SH-NH2 particles/ml 
and on average 0.000035 M / 35 uM of ZnPcS4 in 0.001 M PBS (w/v), it meant it 
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required a dilution correction factor to bring the ZnPcS4 PS concentration down to 
recommended ICD50 concentration of 0.125 µM, when being added to the various 
control and experimental culture plates. The calculations showing this dilution 
factor correction have been shown in Appendix E6. 
After diluting the experimental synthesized final actively targeted PS 
nanoconjugate, using a 280-fold dilution factor to contain 0.125 µM ZnPcS4 PS, it 
must be noted that this also affected the final concentration of the AuNP-PEG5000-
SH-NH2 and Anti-GCC Ab. Therefore, within the final actively targeted PS 
nanoconjugate (ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC  Ab) PDT 
response assays, within in vitro cultured CRC and WS1, culture plates received 
0.11 µg/ml Anti-GCC  Ab, which was successfully bound to 3.39 X 1012 AuNP-
PEG5000-SH-NH2 particles/ml conjugated to a 0.125 µM of ZnPcS4 in 0.001 M 
PBS (w/v). Thus, the required 0.125 µM ZnPcS4 PS concentration, corrected 
volumes of final actively targeted PS nanoconjugate that was required to be 
administered to the various control and experimental control groups cell culture 
media within the final PDT PS nanoconjugate assays was indicated in Table 9 
(Section 3.11).  
4.6 Final Actively Targeted PS Nanoconjugate PDT Response Assays in 
CaCo-2 CRC Cells 
4.6.1 Cellular Morphology by Light Microscopy Assessment in CRC Cells  
The effect of the final actively targeted PS nanoconjugate PDT response assays 
on within the various CRC control and experimental groups were analysed by 
viewing the captured inverted microscope digital images and comparing them. All 
images were captured at a 40x magnification. The cellular structures of the CRC 
cells were evaluated based on changes in cell shape, size and non-viable cells 
(Noguchi et al., 2015). Change in the microscopic structure of cells and their 
cellular components is an indication of cell damage occurring or having occurred 
(Noguchi et al., 2015). 
With reference to Table 20, it can be observed that the control group of CRC cells 
only, demonstrated no changes in morphology and retained their distinctive 
appearance and so this was utilized as a comparative reference of being “normal”, 
when assessing the other various control and experimental groups. Control group 
of CRC cells treated with 673nm laser irradiation at a fluency of 10 J/cm2 alone, 
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presented no detectable morphological changes, suggesting that laser irradiation 
alone has no effect on CRC cells (Table 20).  
Non-irradiated control groups of CRC cells, which received 0.125 µM ZnPcS4, 
0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2, 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab, noted slight in significant morphological 
changes of rounding up in comparison to the cells only control, however still 
appeared attached to the cell culture dishes with distinctive viability (Table 20). 
These findings suggest that the ZnPcS4 PS alone, in conjugation with AuNPs or 
when finally bound to the active nanoconjugate exhibited no dark cytotoxicity and 
remained in active without PDT activation. 
Table 20 CaCo-2 CRC cells morphological comparison of various control and 
experimental groups of final actively targeted PS Nanoconjugate PDT 
response assays 
PDT irradiated experimental groups of CRC cells, which received 0.125 µM 
ZnPcS4, 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2, 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab, noted significant morphological changes of 
rounding up, nuclear destruction and detachment from cell culture plates in 
comparison to the cells only control (Table 20). 
Final Actively Targeted PS Nanoconjugate PDT Response Assays in CaCo-2 CRC Cells 
General Control Groups 
Cells only 
 
Cells + Irradiation (10 J/cm2) 
 
Final Actively Targeted PS Nanoconjugate PDT Response Assays in CaCo-2 CRC Cells 
Control Groups 
 
Cells plus 0.125 µM ZnPcS4 
 
Cells plus 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH- NH2 
  
Cells plus 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab 
PDT Treated Experimental Groups 
Cells plus 0.125 µM ZnPcS4 + 
Irradiation  
 
Cells plus 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH- NH2 + Irradiation  
  
Cells plus 0.125 µM ZnPcS4 – AuNP-




However, PDT irradiated experimental groups of CRC cells, which received 0.125 
µM ZnPcS4, did not exhibit as much significant morphological damage, when 
compared to the same groups, which received 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2, and further more when comparing these two groups to the 
experimental group which received 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 
– Anti-GCC Ab, and irradiation, which showed the most significant morphological 
damage (Table 20). These outcomes, can be attributed to the following; second-
generation PSs (such as ZnPcS4) when administered alone are hydrophobic and 
tend to aggregate under physiological conditions, drastically hindering their PDT 
cytotoxic species formation, due to their limited uptake in tumour cells (Kruger and 
Abrahamse, 2018). However, when PSs are combined with AuNPs, their passive 
uptake in tumour cells is improved via the EPR effect and so when activated with 
laser irradiation PDT outcomes are improved (Hong et al., 2016). Additionally, 
AuNPs enhance the overall PDT cytotoxic cellular destruction by contributing 
photothermal destruction (Kruger and Abrahamse, 2018). Nevertheless, the most 
cytotoxic form of PDT tumour cell destruction can be found when bound AuNP-
PSs are conjugated to targeting ligands such as mAbs, since their specific and 
active uptake is localized, with additional photothermal contributions and so this 
form of targeted PDT is often the most effective (Kruger and Abrahamse, 2019). 
Overall, these findings suggest that the final actively targeted PS nanoconjugate 
was the most effective PDT treatment for CRC morphological destruction, due to 
its enhanced passive, as well as actively specific targeted AuNP-PEG5000-SH-
NH2 – Anti-GCC Ab bound constituents for improved ZnPcS4 PS subcellular 
localization.  
4.6.2 Flow Cytometry Annexin V-FITC/PI Cell Death Pathway Detection 
Analysis in CRC Cells 
Annexin V-FITC/PI cell death detection kit (BD Scientific: BD/556570), was used 
for detection and quantitation of cells undergoing early or late apoptosis, cells dying 
from necrosis cells, or cells remaining viable within experimental samples 24 hours 
post laser irradiation, using flow cytometry. This assay was performed in order to 
determine if the final actively targeted PS nanoconjugate (ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC  Ab), was able to enhance PDT treatment, more 
than ZnPcS4 PS administration alone. The CRC cells only control was used to gate 
and statistically compare results of viable cells, whereas the necrosis and 
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apoptosis (early and late) controls were used to gate and statistically compare cells 
undergoing these particular modes of cell death (P˂0.05*) (P˂0.01**) (P˂0.001***). 
With reference to Figure 32, it can be observed that the control group of CRC cells 
only, were found to be 98% viable and so this was utilized as a comparative 
reference of being “normal”, when assessing the other various control and 
experimental groups. Furthermore, the positive control group for necrosis noted 
90% necrosis and the apoptosis positive control group noted 43% early apoptosis 
and 39% late apoptosis and so was utilized for control and experimental groups 
result comparability. 
Figure 32 Percentage of different stages of cell death after flow cytometry 
analysis using Annexin V-FITC/PI staining method on various control 
and experimental groups of CRC cells, within final actively targeted 
PS nanoconjugate PDT response assays. 
Control group of CRC cells treated with 673nm laser irradiation at a fluency of 10 
J/cm2 alone, presented no significant cell death changes, suggesting that laser 
irradiation alone had no effect on CRC cells (Figure 32). 
Non-irradiated control groups of CRC cells, which received 0.125 µM ZnPcS4, 
0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2, 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab, noted slight increases in apoptotic forms of cell 
death, with decreases in cellular viability, however these changes were 
insignificant (Figure 32). These findings suggest that the 0.125 µM ZnPcS4 PS 
alone, in conjugation with AuNPs or when finally bound to the active 
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nanoconjugate, exhibited no dark cytotoxicity and remained in active without PDT 
irradiation. 
PDT irradiated experimental groups of CRC cells, which received 0.125 µM 
ZnPcS4, 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2, 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab, noted significant forms of apoptotic cell death, 
with decreases in cellular viability (Figure 32).  However, PDT irradiated 
experimental groups of CRC cells, which received 0.125 µM ZnPcS4, did not exhibit 
as much significant late apoptotic cell death (15%*), as when compared to the 
same groups, which received 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 
(21%**). Furthermore, when comparing these two groups to the experimental 
group, which received 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC 
Ab, and irradiation, the most significant late apoptotic cell death of 34%*** was 
noted, with a significant increase of 16%* of necrotic cell death.  
Accruing evidence has shown that cells undergoing early apoptosis are often 
autophagic and so have the potential to rejuvenate, thus early phases of apoptotic 
cell death is not ideal in PDT cancer treatments, as cells can recover leading to 
tumour re-occurrence (Noguchi et al., 2015). Thus, the most favourable forms of 
cell death in relation to successful PDT treatment outcomes, is either late apoptotic 
or necrotic cell death modes, whereby cancer cells are destroyed beyond recovery 
(Van Straten et al., 2017; Chilakamarthi and Giribabu, 2017). Since second-
generation PSs (such as ZnPcS4) when administered alone are hydrophobic and 
tend to aggregate under physiological conditions, this drastically hinders their PDT 
cytotoxic species formation, due to their limited uptake in tumour cells (Kruger and 
Abrahamse, 2018), affecting their overall treatment outcomes and so this could 
explain why the 0.125 µM ZnPcS4 PDT treatment did not exhibit as much 
significant late apoptotic cell death (15%*), as when compared to the same groups, 
which received 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 (21%**) (Figure 32). 
Furthermore, since studies by Hong et al., (2016) have also stated that when PSs 
are combined with AuNPs, their passive uptake and solubility in tumour cells is 
improved via the EPR effect and so when activated with laser irradiation, PDT 
outcomes generally produce more favourable late apoptotic forms of cell death. 
Additionally, AuNPs tend to enhance overall PDT cellular destruction outcomes by 
contributing photothermal destruction (Kruger and Abrahamse, 2018) and so all of 
this could have also attributed to the higher late apoptotic cell death of 21%** being 
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noted in the PDT irradiated experimental groups of CRC cells, which received 
0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 (Figure 32). 
Nevertheless, the most favorable and cytotoxic form of PDT tumour cell death was 
found within the PDT experimental groups, which received 0.125 µM ZnPcS4 – 
AuNP-PEG5000-SH-NH2 – Anti-GCC Ab, and irradiation, whereby the most 
significant decrease in cellular viability was found, with the most favorable 
significantly late apoptotic cell death of 34%*** and an increase of 16%* of necrosis 
(Figure 32). These favorably enhanced forms of induced PDT cell death was 
probably due to the fact that the PS nanoconjugate had an actively selective 
targeting mAb attached to it, which promoted PS localization in CRC cells and so 
improved overall treatment outcomes, with significant cell death induction. This 
statement can be supported by studies conducted by Kruger and Abrahamse, 
(2019), whereby the most significant PDT apoptotic and necrotic cellular 
destruction can be found when bound AuNP-PSs are conjugated to targeting 
ligands such as mAbs, since their specific and active uptake is localized, with 
additional photothermal contributions and so this form of targeted PDT is often the 
most effective in cancer cell obliteration.  
4.7 Final Actively Targeted PS Nanoconjugate PDT Response Assays in WS1 
Normal Human Fibroblast Cells 
The comparisons of the final actively targeted PS Nanoconjugate PDT response 
assays was evaluated within in vitro cultured normal human WS1 fibroblast cells, 
since it was desirable to evaluate the safety, tolerability and effective targeting 
abilities profiles of the PDT treatments, as to ensure they had negligible effects no 
surrounding healthy tissues 
4.7.1 Cellular Morphology by Light Microscopy Assessment in WS1 Cells 
The effect of the final actively targeted PS nanoconjugate PDT response assays 
within the various WS1 control and experimental groups were analysed by viewing 
the captured inverted microscope digital images and comparing them. All images 
were captured at a 40x magnification. The cellular structures of the WS1 cells were 
evaluated based on changes in cell shape, size and non-viable cells (Noguchi et 
al., 2015). Change in the microscopic structure of cells and their cellular 
components is an indication of cell damage occurring or having occurred (Noguchi 
et al., 2015).  
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With reference to Table 21, it can be observed that the control group of WS1 cells 
only, demonstrated no changes in morphology and retained their distinctive 
appearance and so this was utilized as a comparative reference of being “normal”, 
when assessing the other various control and experimental groups. Control group 
of WS1 cells treated with 673nm laser irradiation at a fluency of 10 J/cm2 alone, 
presented no detectable morphological changes, suggesting that laser irradiation 
alone has no effect on WS1 cells (Table 21).  
Table 21 WS1 normal human cells morphological comparison of various 
control and experimental groups of final actively targeted PS 
Nanoconjugate PDT response assays 
 
Non-irradiated control groups of WS1 cells, which received 0.125 µM ZnPcS4, 
0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2, 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab, no significant morphological changes were 
observed (Table 21). These findings suggest that the ZnPcS4 PS alone, in 
conjugation with AuNPs or when finally bound to the active nanoconjugate 
exhibited no dark cytotoxicity and remained in active without PDT activation. 
PDT irradiated experimental groups of WS1 cells, which received 0.125 µM 
ZnPcS4 alone, did note significant morphological changes of rounding up, nuclear 
Final Actively Targeted PS Nanoconjugate PDT Response Assays in WS1 Human Fibroblast Cells 




Cells + Irradiation (10 J/cm2) 
 
Final Actively Targeted PS Nanoconjugate PDT Response Assays in  WS1 Human Fibroblast Cells 
Control Groups 
 
Cells plus 0.125 µM ZnPcS4 
 
Cells plus 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH- NH2 
  
Cells plus 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab 
PDT Treated Experimental Groups 
 
Cells plus 0.125 µM ZnPcS4 + 
Irradiation  
 
Cells plus 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH- NH2 + Irradiation  
  
Cells plus 0.125 µM ZnPcS4 – AuNP-




destruction and detachment from cell culture plates in comparison to the cells only 
control (Table 21). Whereas, PDT irradiated experimental groups of WS1 cells 
which received 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab, 
reported no significant morphological changes (Table 21).  
These findings suggest that the administration of 0.125 µM ZnPcS4 alone with laser 
irradiation does cytotoxically affect normal human cells, whereas when 
administered with either a AuNP carrier and / or active targeting mAb, it does not. 
These results are probably attributed to the fact that conventional administrations 
of PS alone, without any further functionalization for enhanced passive or active 
targeting, are generally inadequately absorbed by tumour cells and so the PS can 
accumulate within these surrounding healthy tissues, inducing unwanted effects 
within them when laser irradiation is applied (Hong et al., 2016). Furthermore, 
these results coincided with studies conducted by Nombona et al., (2012) which 
reported that ZnPcS linked to AuNPs or bound to liposomes, exerted a significant 
PDT phototoxic effect on cancer cells, due to improved PS passive absorption and 
so negligible phototoxicity on normal human fibroblast cells was found.  
Additionally, studies by Kruger and Abrahamse (2019), reported that non-targeted 
standard PS delivery systems yield relatively poor PDT clinical outcomes, since 
only negligible amounts of the PS are taken up by cancer cells and the remainder 
of the PS induces unwanted PDT phototoxic damage in normal cells. This study 
went on further to state that the only way to overcome PS dispersion in normal 
cells, was to enhance their concentrated and localized uptake in tumour cells only, 
through further functionalizion delivery mechanisms, such as nanoconjugate 
platforms or active targeting with biomarkers.  
Overall, these findings suggest that the final actively targeted PS nanoconjugate 
was probably the most effective PDT treatment for CRC, as it indicated no photo 
toxic side effects on normal human cells, due to its enhanced passive, as well as 
actively specific targeted AuNP-PEG5000-SH-NH2 – Anti-GCC Ab bound 
constituents for improved ZnPcS4 PS subcellular localization in tumor tissues only.   
4.7.2 Flow Cytometry Annexin V-FITC/PI Cell Death Pathway Detection 
Analysis in WS1 Cells 
Annexin V-FITC/PI cell death detection kit (BD Scientific: BD/556570), was used 
for detection and quantitation of cells undergoing early or late apoptosis, cells dying 
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from necrosis cells, or cells remaining viable within experimental samples 24 hours 
post laser irradiation, using flow cytometry. This assay was performed in order to 
determine if the final actively targeted PS nanoconjugate (ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab), induced any unwanted side- effects on normal 
human WS1 cells. The WS1 cells only control was used to gate and statistically 
compare results of viable cells, whereas the necrosis and apoptosis (early and late) 
controls were used to gate and statistically compare cells undergoing these 
particular modes of cell death (P˂0.05*) (P˂0.01**) (P˂0.001***). 
With reference to Figure 33, it can be observed that the control group of WS1 cells 
only, were found to be 93% viable and so this was utilized as a comparative 
reference of being “normal”, when assessing the other various control and 
experimental groups. Furthermore, the positive control group for necrosis noted 
89% necrosis and the apoptosis positive control group noted 49% early apoptosis 
and 37% late apoptosis and so was utilized for control and experimental groups 
result comparability. 
 
Figure 33 Percentage of different stages of cell death after flow cytometry 
analysis using Annexin V-FITC/PI staining method on various control 
and experimental groups of WS1 cells, within final actively targeted 
PS nanoconjugate PDT response assays. 
Control group of WS1 cells treated with 673nm laser irradiation at a fluency of 10 
J/cm2 alone, presented no significant cell death changes, suggesting that laser 
irradiation alone had no effect on WS1 cells (Figure 33). 
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Non-irradiated control groups of WS1 cells, which received 0.125 µM ZnPcS4, 
0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2, 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab, noted slight increases in early apoptotic forms 
of cell death, however these changes were insignificant (Figure 33). These findings 
suggest that the 0.125 µM ZnPcS4 PS alone, in conjugation with AuNPs or when 
finally bound to the active nanoconjugate, exhibited no dark cytotoxicity and 
remained in active without PDT irradiation within normal cells.  
PDT irradiated experimental groups of WS1 cells, which received 0.125 µM 
ZnPcS4 – AuNP-PEG5000-SH-NH2 and 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-
NH2 – Anti-GCC Ab, also only noted slight increases in early apoptotic forms of cell 
death, however these changes were insignificant (Figure 33). However, PDT 
irradiated experimental groups of WS1 cells, which received 0.125 µM ZnPcS4, 
noted a significant decrease in cellular viability (73%**) and significant increases 
in early apoptosis (12%*) and late apoptosis (10%*).  
These findings suggest that the administration of 0.125 µM ZnPcS4 with laser 
irradiation, does cytotoxically affect normal human cells, whereas when 
administered with either a AuNP carrier and / or active targeting mAb, it does not. 
Since studies by Nombona et al. (2012) have reported that ZnPcS when 
administered alone, does exert PDT cytotoxic effect on normal fibroblast cells, due 
to its lack of functionalization for enhanced passive or active targeting, these 
results were probable. Thus, it can be stated that the administration of 0.125 µM 
ZnPcS4 alone within PDT studies for CRC cancer, unwanted normal healthy cell 
damage would be observed.  
Therefore, these findings suggest that the final actively targeted PS nanoconjugate 
was probably the most effective PDT treatment for CRC, as it indicated no photo 
toxic side effects on normal human cells, due to its enhanced passive, as well as 
actively specific targeted AuNP-PEG5000-SH-NH2 – Anti-GCC Ab bound 
constituents for improved ZnPcS4 PS subcellular localization in tumor tissues only. 
4.8 Nuclear DNA Damage Examination by Hoechst 33258 Analysis in Final 
Actively Targeted PS Nanoconjugate PDT Response Assays in CRC 
Cells 
Hoechst 33258 bisbenzimide derivate fluorescent stain is a nuclear DNA staining 
method which is used for the detection and assessment of cellular nuclear DNA 
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damage. It can seek out and place itself within the minor grooves of the double-
stranded DNA with binding affinity within the A-T rich regions of the DNA, allowing 
for the detection of nuclei cell damage (Chen et al., 2016). Hoechst 33258 is a blue 
fluorescent dye that is excited by ultraviolet light at a wavelength of 352 nm and 
has maximum fluorescence at 461 nm in the violet-blue region. Hoechst 33258 is 
a cell permeable nucleic acid stain and according to Chen et al. (2016) it can 
differentiate between live, necrotic and apoptotic cell stages, due to the degree of 
nuclear damage that is caused by DNA conformation and chromatin state of the 
cell and the stains sensitivity.  
Thus, in order to confirm if the final actively targeted PS nanoconjugate was able 
to induce more notable PDT induced cellular DNA nuclear damage in CRC CaCo-
2 cells, than when compared to the administration of ZnPcS4 PS alone, ZnPcS4 – 
AuNP-PEG5000-SH-NH2 alone or ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC 
Ab alone, Hoechst 33258 bisbenzimide derivate fluorescent stain was performed 
and images were captured at 400x magnification.  
With reference to Table 22, the Hoechst blue stained nuclei noted no cellular 
damage in control groups of CRC cells only or those that just received laser 
irradiation at 673 nm with a fluence of 10 J/cm2. The cellular nuclei appeared 
prominent and round in shape and so these images were used as reference 
comparisons against the PDT experimental groups. 
Within experimental PDT groups, which received 0.125 µM ZnPcS4 alone and 
irradiation, most of the cellular nuclei appeared prominent and round in shape, with 
very slight fragmentation in comparison to the CRC group of cells only (Table 22). 
These findings suggested that 0.125 µM ZnPcS4 PDT treatment alone, does not 
induce significant DNA damage, as most of the cellular nuclei remained intact and 
appeared viable. These outcomes, can be attributed to the following; second-
generation PSs (such as ZnPcS4) when administered alone are hydrophobic and 
tend to aggregate under physiological conditions, drastically hindering their PDT 
cytotoxic species formation, due to their limited uptake in tumour cells and so 




Table 22 Hoechst 33258 CRC cells nuclear DNA damage examination in final 
actively targeted PS nanoconjugate PDT response assays 
Within experimental PDT groups, which received 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2, and laser irradiation, it can be observed that the CRC nuclei 
began changing shape, as some were irregularly swollen and fragmented in shape 
(Table 22). Studies by Manoto et al. (2012) linked morphological shrinkage and 
swelling of the Hoechst stained nuclei in CRC cells treated with 10 µM PDT 
photoactivated ZnPcSmix to signify apoptotic cell death. The DNA damage findings 
within this experimental group can also be linked to apoptotic cell death, since the 
flow cytometry cell death results for this same experimental group noted  a 
significant 21%** of late apoptotic cell death (Figure 32). This improved DNA 
damage in comparison to 0.125 µM ZnPcS4 PDT treatment alone, can be attributed 
to the fact that in this experimental group the PS was combined with a AuNP, which 
promoted its solubilization and passive uptake in CRC cells and so the PDT 
cytotoxic cellular destruction was improved upon (Kruger and Abrahamse, 2018). 
Additionally, AuNPs enhance the overall PDT cytotoxic cellular destruction by 
contributing photothermal destruction (Kruger and Abrahamse, 2018). 
In comparison to the above two discussed groups, the experimental PDT groups, 
which received 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab, and 
irradiation, the nuclei displayed prominent shrinkage and fragmentation (Table 22). 
Studies by Balusamy et al. (2018) have reported that when Hoechst stained nuclei 
present shrinkage with fragmentation the DNA chromatin state of the cell is 
Final Actively Targeted PS Nanoconjugate PDT Response Assays in CaCo-2 CRC Cells 




Cells + Irradiation (10 J/cm2) 
 
 
Final Actively Targeted PS Nanoconjugate PDT Response Assays in CaCo-2 CRC Cells 
PDT Treated Experimental Groups 
 
Cells plus 0.125 µM ZnPcS4 + 
Irradiation  
 
Cells plus 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH- NH2 + Irradiation  
   
Cells plus 0.125 µM ZnPcS4 – 
AuNP-PEG5000-SH- NH2 – Anti-
GCC Ab + Irradiation  
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becoming disrupted and it is usually indicative of late apoptotic forms of cell death, 
whereby cells are unable to recover. The DNA damage findings within this 
experimental group can also be linked to late forms of apoptotic cell death, since 
the flow cytometry cell death results for this same experimental group noted a 
significant 34%** of late apoptotic cell death, with a significant increase of 16%* of 
necrotic cell death (Figure 32). This improved DNA damage in comparison to 0.125 
µM ZnPcS4 – AuNP-PEG5000-SH-NH2 PDT treatment alone, can be attributed to 
the fact that in this experimental group the PS was bound to AuNP which was 
conjugated to targeting mAb biomarker and so its cellular uptake was far more 
concentrated and actively localized in CRC, with additional photothermal 
contributions and so this form of targeted PDT is often more lethal (Kruger and 
Abrahamse, 2018). Overall, these results suggested that the final actively targeted 
PS nanoconjugate had indeed enhanced the PDT treatment of CRC cells in vitro, 
by selectively and actively targeting tumour cells in comparison to ZnPcS4 PDT 
treatment alone, with far more significant forms of late apoptotic cell death being 
observed. 
Conclusively, these results are suggestive that irradiated experimental groups, 
which received the combined PDT therapy of final actively targeted PS 
nanoconjugate (0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab) 
were unlikely to recover post-PDT, due to their severe nuclear damage and so this 
implies that this active PS drug targeting form of PDT was the most efficacious 















CONCLUSION AND FUTURE DIRECTIVES 
5.1 Conclusion 
5.1.1 Study Overview 
CRC remains among the most lethal malignancies worldwide and the conventional 
diagnostic and therapeutic modalities still bring about unsuccessful results and are 
well known to cause side effects such as invasiveness, toxic distribution to healthy 
tissues (Broekgaarden, 2016; Zhang et al., 2018). According to studies, early 
diagnosis of CRC offers the probability of selecting an effective treatment modality 
and could increase the patients’ survival rate to approximately 90 %, however, due 
to limited early diagnostic and typical shortfalls of traditional diagnosis modalities; 
the prognosis of CRC is relatively poor (Simon, 2016). These adverse effects such 
as poor tumour selectivity, non-specificity, as well as the lack of target drug 
distributions, have been major challenges presented in classical diagnostic and 
treatment strategies (Sansaloni-Pastor et al., 2019; Xu et al., 2020). Hence, 
research is focused on alternative modalities that are believed to have advantages 
such as more specificity, repeatability, and negligible side effects that can offer 
better diagnosis outcome, as well as monitor therapy strategies (Natasha 
Hodgkinson et al., 2017; Sansaloni-Pastor et al., 2019). Along this line, 
unconventional diagnostic and treatment strategies such as PDD and PDT have 
attracted attention, since they possess clear advantages over classical modalities, 
such as minimal invasiveness, high selectivity towards cancerous tissue, with 
fewer side effects after treatment (Li et al., 2018). 
PDD and PDT are photochemistry‐based, minimally invasive, modalities that have 
potential applications in the early diagnosis and treatment of cancer (Santos et al., 
2019). PDD is a light-mediated intervention for the diagnosis of cancer that involves 
the activation of fluorescent PS moiety, after absorption of light at appropriate 
wavelength usually shorter purple to blue wavelength light (330 – 400 nm) to evoke 
fluorescence, that can be used to detect cancer, without the induction of cellular 
damage (Oniszczuk et al., 2016). Notably, some PSs that are utilized for 
fluorescent diagnostics, have also been shown to be suitable PSs within PDT 
treatments (Oniszczuk et al., 2016). Thus, when additionally excited within the PDT 
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red wavelength region they can generate cytotoxic species to destroy cancer cells 
after diagnosis, and this could be an extremely feasible combinative strategy (He 
et al., 2017; Naidoo et al., 2019). PDT is an emerging treatment approach that 
relies on the synergistic activity of a photoactivated non-toxic PS after local 
exposure of the affected cancerous tissue to a light source (near-infrared light) and 
subsequent generation of cytotoxic ROS and 1O2 species, which have lethal effects 
on tumour (Zhou et al., 2016). PDD and PDT have emerged as novel diagnostic 
and therapeutic strategies owing to the preferential passive accumulation of PSs, 
non-invasiveness nature, and the allowance of further active targeting PS 
functionalization with biomarkers and NPs, in order to increase tumour selectivity 
and specific cancer tissue targeting, thus enhanced photoactivity outcomes 
(Baskaran et al., 2018). 
Pcs are widely used second generation PSs in PDD and PDT treatments (Yalazan 
et al., 2019). According to Brozek-Pluska et al., (2020), Pcs are endowed with 
unique chemical and physical properties, such as their resemblance to biomolecule 
structures (haemoglobin, chlorophyll), high extinction coefficients and a diverse 
chemical structure (central atoms), which allow for chemical modification 
enhancements. ZnPcS4 PSs have three major Q bands of emission: 583, 634, 674 
nm, within the far-red spectral range for maximum tissue depth penetration and PS 
excitation for effective PDT outcomes applications (Abramczyk et al., 2017). 
Whereas, other studies have also noted that ZnPcS4 PSs have an additional short-
blue absorption B band, between 330 to 350 nm, which is ideal for PDD 
applications (Brozek-Pluska 2015). Brozek-Pluska and colleagues also noted that 
metallated Pcs demonstrate more improved chemical and photochemical stability, 
which elicit high triplet quantum yields and long triplet lifetimes.  
Within studies by Brozek-Pluska et al. (2020) utilizing Raman imaging and 
spectroscopy to characterize and differentiate normal and cancerous colon tissues, 
based on ZnPcS4 PS vibrational features, they found that ZnPcS4 PS noted a 
higher affinity subcellular localization uptake in CRC cells and reported excitation 
wavelengths at 340 nm and 689 nm, suggesting that this PS could possibly be 
successfully applied in PDT and PDD applications for the successful CRC photo- 
diagnosis and treatment, however further investigation was required (Brozek-
Pluska et al., 2020). Studies conducted by Mfouo-Tynga and Abrahamse, (2015) 
reported that a mixed sulfonated metallophthalocyanine (ZnPcSmix) containing zinc 
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as the central atoms, effectively enters cancer cells and accumulates in pivotal 
organelles, like the mitochondria, lysosomes and Golgi apparatus, which in turn 
trigger favorable apoptotic cell death. Furthermore, studies by Sekhejane et al. 
(2014) reported notable zinc phthalocyanine sulfonated mix (ZnPcSmix) PS PDT 
induced apoptotic cell death (40%) within in vitro treated CRC cell lines (DLD-1 
and CaCo-2). However, studies by Broekgaarden et al. (2016) suggested that this 
PS should be further modified within its sulphide groups for improved solubilisation, 
as well as be considered for targeted cellular uptake and absorption to possibly 
enhance PDD-PDT applications. Such enhancements could include its conjugation 
to NPs, which could further augment solubility and passive cellular uptake 
(Hodgkinson et al., 2017).  Studies by Chiarante et al. (2017) have shown the 
successful PDT treatment of 2D and 3D CRC cell cultures, when ZnPcS PSs were 
encapsulated into poloxamine polymeric NPs. Thus, ZnPcS4 seemed to be an ideal 
PS for chemical modification into an active targeting nano drug delivery system for 
CRC PDD diagnosis and simultaneous PDT treatment. 
Studies by Hodgkinson et al. (2017) have reported the enhanced passive uptake 
of PSs can be improved upon when they are conjugated to NPs, since NP carriers 
promote solubility, stability, as well as limit non-specific toxicity of PSs and so photo 
chemical diagnostic and treatment applications can be boosted. Studies by Singh 
et al., (2018) have reported that AuNPs have exceptional tuneable optical 
properties, due to their surface plasmon resonance, which is beneficial in PS light 
activation within the visible to NIR range. In addition, the surface plasmon 
resonance of AuNPs that are attached to PSs, has been associated with increased 
oxygen molecules upon PDT laser light exposure, which is a beneficial aspect for 
effective ROS generation and 1O2 production (Mesquita et al., 2018; Montaseri et 
al., 2020). Furthermore, studies by Abrahamse et al. (2017) have noted that AuNPs 
conjugated to PSs tend to promote PDT treatment outcomes in cancer cells, since 
their metallic centre Au core, releases photothermal heat upon PDT red laser 
irradiation activation and so assists in tumour cell destruction.  
However, in an effort to circumvent the non-specificity of PSs and enhance their 
cellular accumulation, considerable efforts have been devoted towards the 
synthesis and characterization of bio-conjugate markers, which can increase host 
PS accumulation specificity, in targeted cancer tumours (Hong et al., 2016). 
Studies by Calavia et al. (2018) reported the improved PDT treatment of in vitro 
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cultured CRC cells, when a combination of ZnPcS PS conjugated to AuNPs was 
administered, due to improved PSs passive uptake. Studies by Sehgal et al. (2013) 
investigated the conjugation of ZnPcS PS to a monoclonal antibody directed 
against carcinoembryonic antigen (CEA) to improve targeted PS uptake within 
CRC cells. Their results showed that the CRC cell uptake of the bioconjugate was 
37 times higher than compared to free ZnPcS administration. Furthermore, there 
was intense fluorescence, as well as high selectivity within CRC cells with 
negligible phototoxicity, when light excitation at 550 nm was applied to the co-
culture (Sehgal et al., 2013). Thus, this study evaluated selective targeting of ZnPc-
anti-CEA PS conjugate in CEA overexpressed CRC, suggesting that it could be 
particularly useful for PDT treatment, as well as be utilized as a PDD agent for the 
fluorescent surveillance of CRC cells (Sehgal et al., 2013). Studies by Danaee et 
al. (2017) noted that CRC tumour receptors tend to specifically overexpress the 
GUCY2C protein gene and stated that Anti-GCC mAbs could be bound to NP-PS 
molecules, in order to enhance the selective active targeting of CRC cells for 
improved PDT treatment.  
Thus, the aim of this study was to combine an efficient cytotoxic oxygen generating 
hydrophilic tetra sulphonated metal based PS known as ZnPcS4, with CRC specific 
targeting antibodies – Anti-Guanylate Cyclase Ab (Anti-GCC) on the surface of 
heterobifunctional PEG amine stabilized AuNPs, in order to enhance the active PS 
uptake specifically in CRC cells, so the PDD and PDT treatment of CRC tumours 
could be improved, with negligible effect on healthy tissues, since it has not been 
accomplished to date. 
5.1.2 Construction and Characterization of Final Actively Targeted 
PS Nanoconjugate 
Once the final actively targeted PS nanoconjugate (ZnPcS4 – AuNP-PEG5000-SH-
NH2 – Anti-GCC) was successfully constructed a number of characterization 
assays were employed to validate the efficient binding and conjugation of the mAbs 
and PS to the surface of these functionalized AuNPs. These molecular 
characterization studies were also used to identify the final actively targeted PS 




Molecular characterization UV spectra and FTIR assays confirmed that ZnPcS4 PS  
was successfully conjugated onto the AuNPPEG5000 surface, via ligand 
absorption and exchange methods with strong Au-S and weak di-sulphide bonds. 
Furthermore, these assays confirmed that the Anti-GCC mAbs were successfully 
conjugated on the amine functionalized AuNP-PEG5000-SH-NH2 via amide 
bonding. ZP results noted that the final actively targeted PS nanoconjugate had a 
mean Z-average diameter of 57.18 ± 3.04 nm, indicating that it was small enough 
to be considered as an active nano drug carrying system, with the definitive 
possibility of cellular uptake and absorption (Yu et al., 2016). Additionally, The ZP 
value of the final actively targeted PS nanoconjugate was found to be 36.5 ± 2.6 
mV, proposing that it is highly stable with a slightly positively charge, hinting at the 
fact that it should remain stable within an in vivo environment, as well as be 
retained within tumour cells more selectively (Bhattscharjee et al., 2016; Honary et 
al., 2013). DLS measurements noted that the final actively targeted PS 
nanoconjugate was homogenously pure, remained spherical in shape, reported no 
aggregation, with a PDI value of 0.353, signifying it was monodispersed in nature 
and consisted mostly of singular sized particles (Bhattscharjee et al., 2016). 
Moreover, these results suggested that the three individual constituents (ZnPcS4, 
AuNP-PEG5000-SH-NH2 and Anti-GCC Ab) were successfully bonded together to 
form one single molecule (Bhattscharjee et al., 2016). Lastly, within UV spectra 
assays the final actively targeted PS nanoconjugate confirmed UV-Vis absorption 
Soret bands with the 340 nm wavelength region and Q bands within the 520, 634 
and 674 nm wavelength regions, showing it retained its photo diagnostic, 
photodynamic and photothermal properties, as well as  remained photostable. 
Furthermore, these results showed the final actively targeted PS nanoconjugate 
did not undergo much aggregation, and so presumptively had the ability to 
generate cytotoxic species. 
5.1.3 Dose Responses Outcomes of Final Actively Targeted PS 
Nanoconjugate in CRC Cells 
In order to determine the optimal dosing of ZnPcS4 PS within the final actively 
targeted PS nanoconjugate PDT mediated assays, individual dose response 
studies were performed. Various control and experimental groups of CRC cells 
were treated with varying concentrations of ZnPcS4 PS for 20 hrs, after which some 
were irradiated at 673nm with a fluency of 10 J/cm2 and incubated for another 24 
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hrs. Cellular biological responses were used to determine the lowest possible 
concentration of ZnPcS4 PS which could be administered to in vitro cultured CaCo-
2 to yield 50% cell viability, as well as induce a significant amount of cytotoxicity, 
in order to establish ICD50, but still allow cellular biological responses post-PDT 
treatment to be determined. The optimal ICD50 dose response concentrations of 
ZnPcS4 post-PDT treatment that induced approximately 50 % cytotoxicity was 
found to be 0.125 µM ZnPcS4, after observing morphological changes, cellular 
viability, cellular proliferation and cellular cytotoxicity damage. Furthermore, the 
CRC control groups from these assays noted no significant cellular cytoxicity in 
relation to laser irradiation alone, suggesting that laser irradiation at 673 nm with a 
fluence of 10 J/cm2, had no contributing external factors to CRC cells destruction.  
Once the above had been achieved, final actively targeted PS nanoconjugate PDT 
experiments were performed within in vitro cultured CRC and WS1 cells, by 
adjusting the ZnPcS4 – AuNP-PEG5000-SH-NH2 - Anti-GCC Ab concentrations 
that were administered to the recommended ICD50 of 0.125 µM for the ZnPcS4 PS. 
Therefore, within the final actively targeted PS nanoconjugate (ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC  Ab) PDT response assays, cell culture plates 
received 0.11 µg/ml Anti-GCC  Ab, which was successfully bound to 3.39 X 1012 
AuNP-PEG5000-SH-NH2 particles/ml conjugated to a 0.125 µM of ZnPcS4 in 0.001 
M PBS (w/v).  
This was performed in order to compare the PDT phototoxicity of ZnPcS4 PS alone 
versus the final actively targeted PS nanoconjugate, in order to observe if the final 
PS nanoconjugate was able to improve the PDT treatment outcomes of CRC, as 
well as be selective and sensitive enough to diagnose CRC.  
5.1.4 Subcellular Localization and PDD of Final Actively Targeted PS 
Nanoconjugate in CRC and WS1 Cells  
Within subcellular localization studies, equal concentrations of the final actively 
targeted PS nanoconjugate were administered to in vitro cultured human CRC cells 
(CaCo-2) and fibroblasts (WS1) cells. CRC control groups which received ZnPcS4 
alone noted a poor cellular uptake of the PS, whereas CRC control groups which 
received ZnPcS4 – AuNP-PEG5000-SH-NH2 noted an improved passive 
absorption of the PS. However, the most improved subcellular localization was 
found in CRC experimental groups which received the final actively targeted PS 
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nanoconjugate. These findings confirmed that the final actively targeted PS 
nanoconjugate was able to actively and specifically localize within in vitro cultured 
human CRC cells. In relation to WS1 control groups which received ZnPcS4, minor 
amounts of the PS were found within the cells, suggesting that when this PS is 
administered alone it can be absorbed by surrounding healthy tissues and so when 
activated with PDT can induce unwanted side-effects. WS1 control groups which 
received ZnPcS4 – AuNP-PEG5000-SH-NH2 noted only slight increments of the 
PS within the cells. Whereas, WS1 experimental groups which received the final 
actively targeted PS nanoconjugate, noted no subcellular localization whatsoever 
of the PS. These findings confirmed that the final actively targeted PS 
nanoconjugate demonstrate no affinity for in vitro cultured WS1 cells, suggesting 
that its selective targeting affinity was specifically directed at CRC cells only and 
so when administered with PDT the treatment should remain localized to CRC cells 
only, leaving healthy tissues unharmed. These findings coincided with studies 
conducted by Gao et al. (2017) which reported that PSs when encapsulated into 
an active targeting moiety are more effectively taken up by CRC cells, which in turn 
exerted appreciable anti-proliferative effects within in vivo tumour models, with 
negligible effects on normal tissues. Overall, these results indicated that the final 
actively targeted PS nanoconjugate demonstrated enhanced retention and specific 
localization of the ZnPcS4 PS within cellular membrane proteins and cytoplasm of 
the CRC cells, which is indicative of efficient subcellular organelle absorption for 
enhanced PDD diagnosis, as possible effective PDT cytotoxic species production, 
with no effects on healthy tissues. Thus, the final actively targeted PS 
nanoconjugate should be considered as a more efficient PS delivery system in 
relation to the administration of ZnPcS4 PS drug alone for improved PDD 
diagnostic and PDT treatment outcomes.  
Within photo diagnosis studies, equal concentrations of the final actively targeted 
PS nanoconjugate were administered to in vitro cultured human CRC cells (CaCo-
2) and fibroblasts (WS1) cells. During immunofluorescent studies, it was found that 
ZnPcS4 alone, when bound to AuNPEG5000-SH-NH2 or within its final actively 
targeted PS nanoconjugate form, was able to actively fluoresce and illuminate in 
both WS1 and CRC cells, when blue light filters at 340 nm was applied to stained 
cells. CRC cells noted a slight passive subcellular uptake of the ZnPcS4 PS when 
it was administered alone. These results coincided with the findings reported by 
Roguin et al. (2019), highlighting that ZnPc is a stable compound, which exhibits 
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selective passive accumulation in tumour tissues. CRC cells which received the 
same concentration of ZnPcS4 PS, however conjugated to AuNPs (AuNPEG5000-
SH-NH2 - ZnPcS4 AuNPEG5000-SH-NH2) noted an improved PS drug passive 
uptake. These findings suggested that the gold nanocarrier enhanced the passive 
subcellular localization of the ZnPcS4 PS in CRC cells. Studies by Hong et al. 
(2016) support these findings, as they stated that NPs significantly enhance the 
solubility of PSs and so increases their selective passive localization. However, 
when assessing CRC cells treated with the final actively targeted PS 
nanoconjugate and enhanced affinity and active accumulation of the PS was 
observed. These findings indicate that the final targeted PS nanoconjugate 
facilitated enhanced ZnPcS4 PS retention in CRC cells (CaCo-2), via the specific 
PS nanoconjugates Anti-GCC Ab active targeting abilities (Hodgkinson et al., 
2017) and so could be considered for PDD identification, however its selective 
targeting abilities in CRC cells only and not in normal human cells still required 
confirmation. Normal human fibroblasts WS1 cells treated with ZnPcS4 alone noted 
some absorption of the PS, suggesting that within these applied conditions, the PS 
could not be used for CRC PDD, since the PS could not specifically distinguish 
between normal and cancerous cells. Whereas, normal WS1 cells treated with 
AuNPEG5000-SH-NH2 - ZnPcS4 control conjugate, noted a slight absorption of the 
PS at the same administered concentration, suggesting that the AuNPs promoted 
the PS for a more passive uptake within CRC cancer tissues. Thus, these results 
still indicate that even when the PS was conjugated to AuNP, its uptake was not 
specific enough and slight absorption was found in WS1 cells and so even within 
these applied conditions, the PS could not be used for CRC PDD, since the PS 
could not specifically distinguish between normal and cancerous cells. However, 
WS1 cells treated with the final actively targeted PS nanoconjugate, noted no 
detectable subcellular localization of the PS. These findings indicated that the final 
PS nanoconjugate, had no actively specific affinity for healthy cells (such as 
fibroblasts), suggesting that if was to be applied within actively targeted CRC PDD 
detection, the application would remain localized to CRC only, and so be able to 
precisely and highly selectively be able to distinguish between normal and 
cancerous cells. Overall, these results confirm that when a ZnPcS4 PS is 
conjugated to a AuNP carrier, that is linked with an active targeting biomolecule 
(Anti-GCC Ab), the PSs active and specific uptake in CRC cells can be attained, 
in order to accommodate PDD cancer detection, due to the PSs highly specific and 
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sensitive absorption in only CRC cells (with no affinity for normal human cells) and 
so can allow for precise identification and differentiation of in vitro CRC cells in 
comparison to normal tissues. 
5.1.5 PDT Cell Death Effect of Final Actively Targeted PS 
Nanoconjugate in Normal Human Fibroblast WS1 Cells  
Flow cytometric cellular death analysis was performed on WS1 cells in order to 
determine if the final actively targeted PS nanoconjugate, induced any unwanted 
side effects on normal human tissues. Within assays investigating the PDT effects 
of the final actively targeted PS nanoconjugate and its individual control 
components in WS1 cells, it was found that the 0.125 µM ZnPcS4 PS alone, in 
conjugation with AuNPs or when finally bound to the active nanoconjugate, 
exhibited no dark cytotoxicity and remained in active without PDT irradiation. PDT 
irradiated experimental groups, which received 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 and 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC 
Ab, also only noted slight increases in early apoptotic forms of cell death, however 
these changes were insignificant. Whereas, PDT irradiated experimental groups, 
which received 0.125 µM ZnPcS4, noted a significant decrease in cellular viability 
(73%**) and significant increases in early apoptosis (12%*) and late apoptosis 
(10%*). These findings suggested that the administration of 0.125 µM ZnPcS4 
alone with laser irradiation, does cytotoxically affect normal human cells, whereas 
when administered with either a AuNP carrier and / or active targeting mAb, it does 
not. Studies by support these findings Nombona et al., (2012) since they reported 
that ZnPcS when administered alone, does exert PDT cytotoxic effect on normal 
fibroblast cells, due to its lack of functionalization for enhanced passive or active 
targeting and so these results were probable. Thus, it can be stated that the 
administration of 0.125 µM ZnPcS4 alone within PDT studies for CRC cancer, 
unwanted normal healthy cell damage would be observed. Overall, results 
indicated that the final actively targeted PS nanoconjugate was probably the most 
effective PDT treatment for CRC, as it indicated no photo toxic side effects on 
normal human cells, due to its enhanced passive, as well as actively specific 
targeted AuNP-PEG5000-SH-NH2 – Anti-GCC Ab bound constituents for improved 




5.1.6 PDT Cell Death Effect of Final Actively Targeted PS 
Nanoconjugate in Human CRC Cells 
Then flow cytometric cellular death analysis was performed on CRC cells in order 
to determine if the final actively targeted PS nanoconjugate, was able to enhance 
PDT treatment, more than ZnPcS4 PS drug administration alone. Within assays 
investigating just the PDT effects of the final actively targeted PS nanoconjugate 
and its individual control components in CRC cells, it was found that non-irradiated 
control groups, which received 0.125 µM ZnPcS4, 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2, 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab, 
noted slight increases in apoptotic forms of cell death, with decreases in cellular 
viability, however these changes were insignificant. These findings suggested that 
the 0.125 µM ZnPcS4 PS alone, in conjugation with AuNPs or when finally bound 
to the active nanoconjugate, exhibited no dark cytotoxicity and remained in active 
without PDT irradiation. PDT irradiated experimental groups, which received 0.125 
µM ZnPcS4, 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2, 0.125 µM ZnPcS4 – 
AuNP-PEG5000-SH-NH2 – Anti-GCC Ab, noted significant forms of apoptotic cell 
death, with decreases in cellular viability.  However, PDT irradiated experimental 
groups, which received 0.125 µM ZnPcS4, did not exhibit as much significant late 
apoptotic cell death (15%*), as when compared to the same groups, which 
received 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 (21%**). Furthermore, 
when comparing these two groups to the experimental group, which received 0.125 
µM ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab, and irradiation, the most 
significant late apoptotic cell death of 34%*** was noted, with a significant increase 
of 16%* of necrotic cell death. Accruing evidence has shown that cells undergoing 
early apoptosis are often autophagic and so have the potential to rejuvenate, thus 
early phases of apoptotic cell death is not ideal in PDT cancer treatments, as cells 
can recover leading to tumour re-occurrence (Noguchi et al., 2015). Thus, the most 
favourable forms of cell death in relation to successful PDT treatment outcomes, 
is either late apoptotic or necrotic cell death modes, whereby cancer cells are 
destroyed beyond recovery (Van Straten et al., 2017; Chilakamarthi and Giribabu, 
2017). Since second-generation PSs (such as ZnPcS4) when administered alone 
are hydrophobic and tend to aggregate under physiological conditions, this 
drastically hinders their PDT cytotoxic species formation, due to their limited uptake 
in tumour cells (Kruger and Abrahamse, 2018), affecting their overall treatment 
outcomes and so this could explain why the 0.125 µM ZnPcS4 PDT treatment did 
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not exhibit as much significant late apoptotic cell death (15%*), as when compared 
to the same groups, which received 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 
(21%**). Furthermore, since studies by Hong et al., (2016) have also stated that 
when PSs are combined with AuNPs, their passive uptake and solubility in tumour 
cells is improved via the EPR effect and so when activated with laser irradiation, 
PDT outcomes generally produce more favourable late apoptotic forms of cell 
death. Additionally, AuNPs tend to enhance overall PDT cellular destruction 
outcomes by contributing photothermal destruction (Kruger and Abrahamse, 2018) 
and so all of this could have also attributed to the higher late apoptotic cell death 
of 21%** being noted in the PDT irradiated experimental groups of CRC cells, 
which received 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2. Nevertheless, the 
most favourable and cytotoxic form of PDT tumour cell death was found within the 
PDT experimental groups, which received 0.125 µM ZnPcS4 – AuNP-PEG5000-
SH-NH2 – Anti-GCC Ab, and irradiation, whereby the most significant decrease in 
cellular viability was found, with the most favourable significantly late apoptotic cell 
death of 34%*** and an increase of 16%* of necrosis. These favourable enhanced 
forms of induced PDT cell death were probably due to the fact that the PS 
nanoconjugate had an actively selective targeting mAb attached to it, which 
promoted PS localization in CRC cells and so improved overall treatment 
outcomes, with significant cell death induction. This statement can be supported 
by studies conducted by Kruger and Abrahamse, (2019), whereby the most 
significant PDT apoptotic and necrotic cellular destruction can be found when 
bound AuNP-PSs are conjugated to targeting ligands such as mAbs, since their 
specific and active uptake is localized, with additional photothermal contributions 
and so this form of targeted PDT is often the most effective in cancer cell 
obliteration.  
5.1.7 PDT Induced Cellular DNA Effect of Final Actively Targeted PS 
Nanoconjugate in Human CRC Cells 
Finally, in order to confirm if the final actively targeted PS nanoconjugate was able 
to induce more notable PDT induced cellular DNA nuclear damage in CRC CaCo-
2 cells, than when compared to the administration of ZnPcS4 PS alone, ZnPcS4 – 
AuNP-PEG5000-SH-NH2 alone or ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC 
Ab alone, Hoechst 33258 bisbenzimide derivate fluorescent stain was performed. 
Within experimental PDT groups, which received 0.125 µM ZnPcS4 alone and 
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irradiation, most of the cellular nuclei appeared prominent and round in shape, with 
very slight fragmentation in comparison to the CRC group of cells only. These 
findings suggested that 0.125 µM ZnPcS4 PDT treatment alone, did not induce 
significant DNA damage. Since second-generation PSs (such as ZnPcS4) when 
administered alone are hydrophobic and tend to aggregate under physiological 
conditions, drastically hindering their PDT cytotoxic species formation, due to their 
limited uptake in tumour cells and so often minimal cellular destruction is often 
observed (Kruger and Abrahamse, 2018). Within experimental PDT groups, which 
received 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2, and laser irradiation, CRC 
nuclei began changing shape, as some were irregularly swollen and fragmented. 
Studies by Manoto et al., (2012) linked morphological shrinkage and swelling of 
the Hoechst stained nuclei in CRC cells treated with 10 µM PDT photoactivated 
ZnPcSmix to signify apoptotic cell death. This improved DNA damage in comparison 
to 0.125 µM ZnPcS4 PDT treatment alone, was attributed to the fact that in this 
experimental group the PS was combined with a AuNP, which promoted its 
solubilization and passive uptake in CRC cells and so the PDT cytotoxic cellular 
destruction was improved upon (Kruger and Abrahamse, 2018). Additionally, 
AuNPs enhance the overall PDT cytotoxic cellular destruction by contributing 
photothermal destruction (Kruger and Abrahamse, 2018). In comparison to the 
above two discussed groups, the experimental PDT groups, which received 0.125 
µM ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab, and irradiation, the nuclei 
displayed prominent shrinkage and fragmentation. Studies by Balusamy et al., 
(2018) have reported that when Hoechst stained nuclei present shrinkage with 
fragmentation the DNA chromatin state of the cell is becoming disrupted and it is 
usually indicative of late apoptotic forms of cell death, whereby cells are unable to 
recover. This improved DNA damage in comparison to 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 PDT treatment alone, was attributed to the fact that in this 
experimental group the PS was bound to AuNP which was conjugated to targeting 
mAb biomarker and so its cellular uptake was far more concentrated and actively 
localized in CRC, with additional photothermal contributions and so this form of 
targeted PDT is often more lethal (Kruger and Abrahamse, 2018). Overall, these 
results suggested that the final actively targeted PS nanoconjugate had indeed 
enhanced the PDT treatment of CRC cells in vitro, through significant cellular 
damage and DNA destruction, by selectively and actively targeting tumour cells in 
comparison to ZnPcS4 PDT treatment alone.  
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5.1.8 Final Conclusion 
Overall, these findings coincided with the studies conducted by Kruger and 
Abrahamse, (2019) which emphasis that incorporating NP-PS drug carrier systems 
with specific targeting moieties, complementary to receptors overexpressed on 
cancer cells, allows for more efficient and active accumulation of PSs in cancer 
cells due to their targeting abilities and so improves the overall efficacy of PDD-
PDT applications, with negligible damage to healthy tissues. Thus, these results 
suggest that the Anti-GCC Ab, which was linked to the ZnPcS4 – AuNP-PEG5000-
SH-NH2 actively enhanced PS uptake in CRC cells and so allowed for specific CRC 
diagnosis, with drastically amplified overall PDT treatment outcomes, in 
comparison to ZnPcS4 administration alone. Lastly, these results imply that the 
PDT treatment of CRC cells with the final actively targeted PS nanoconjugate was 
superior at inducing cell death and DNA destruction (due to its enhance targeted 
specificity) and so would undoubtedly eradicate in vitro CRC tumours. Thus, the 
simultaneous PDD and PDT-mediated treatment of in vitro cultured CRC cells is 
possible when utilizing the final actively targeted PS nanoconjugate that was 
developed within this study. 
5.2 Future Directives 
In relation to molecular conjugate characterization for effective immobilization of 
mAb to the nano-PS drug surface, additional techniques could be employed to 
validate the binding affinity of Anti-GGC to ZnPcS4 – AuNP-PEG5000-SH-NH2 
(Zaltariov et al. 2014). A well-established technique for simultaneous analysis of 
particle size and concentration number still needs to be explored, as studies by 
Tarik et al., (2017) observed that inductively coupled plasma mass spectrometry 
(ICPMS) is a method of choice for determining the concentration number of each 
individual element within a molecular component, as it has the ability to detect and 
quantify more than one volatile compound simultaneously. This single particle 
ICPMS could also be coupled with dynamic light scattering (DLS) to further 
functionalize and characterize the bonding concentration number of each 
component on the nano bioconjugate (Stuchinskaya et al. 2011). Additionally, 
nanoparticle tracking analysis (NTA), which is a highly precise and reproducible 
technique for determining nanoparticle size could be utilized in the future study to 
address challenges faced by DLS (Hoover et al. 2020). Furthermore, due to the 
complexity and inherent heterogeneity of mAb and antibody-related products, an 
156 
 
ELISA assay would be highly recommended for further quantification and 
characterization of the nano bioconjugates targeting abilities, in order to determine 
the antigenic functionality and activity of the bound Abs (Zhang et al. 2020). 
According to Hong and Rao, (2019) AuNPs have exceptional stability, high 
scattering energy, high surface area, biocompatibility, strong absorption within the 
NIR region, and easy surface functionalization. Therefore, for the physical 
characterization of the final actively targeted PS nanoconjugate, thermal 
gravimetric analysis (TGA) coupled with Transmission electron microscopy (TEM) 
assay could be used to further corroborate the properties of multicomponent 
nanoparticle based system in relation to the AuNPs’ thermal stability and structural 
configuration respectively (Crouse and Abrahamse, 2020). Several lines of 
evidence indicate that ROS is closely connected to numerous biological processes 
and defence mechanisms, cells rely on it for survival; such as immune defence, 
antimicrobial activity, cell cycle and signal transduction mechanisms (He et al. 
2017). However, at high concentrations ROS can induce autophagy, apoptosis and 
necrosis (He et al., 2017). These molecules are activated by various mechanisms 
including PDT and can be assessed using various spectrophotometry techniques, 
such electron spin resonance (ESR/EPR), chemiluminescence and fluorescence 
(Zhang et al. 2018).  
Furthermore, this study warrants further investigation into the therapeutic efficacy 
of this final actively targeted PS nanoconjugate, using reliable models that 
resemble in vivo conditions of CRC cells. Virtually all in vitro PDD-PDT experiments 
are performed on monolayer cultures and the cellular environments of these 
models do not emulate that of in vivo models. Therefore, tumour spheroids will 
serve as excellent models in cancer research for the assessment of diagnostic and 
therapeutic mediations, since they precisely mimic different features of solid 
tumours (Costa et al. 2016). Additionally, one could recommend co-culturing Caco-
2 and WS1 cells together in vitro with regards to subcellular localization PDD 
experiments, in order to more effectively explore the direct specificity of this final 
actively targeted PS nanoconjugate, in relation to specific cellular organelle 
localization and its definitive ability to precisely distinguish the difference between 
normal and cancerous CRC cells. 
Lastly, the final actively targeted PS nanoconjugate and PDT laser irradiation 
within this study exerted a remarkable cytotoxicity and cell death in CRC. 
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Therefore, this merits further investigation in relation to the particular signalling 
pathways it either activates or inactivates, in order to fully understand cellular death 
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Appendix A: Characterization of Final Targeted PS Nanoconjugate 










































Appendix C: List of Consumables 
Product Catalogue no. Company/Supplier 
0.1 mM nonessential amino acids  M7145 Sigma Aldrich 
1.0 mM sodium pyruvate  S8636 Sigma Aldrich 
35mm x 10mm Style Treated Polystyrene 
Cell Culture Dish 
430165 Corning Incorporated 
5 ml Disposable pipette BD357543 Beckson Dickinson 
10 ml Disposable pipette BD357551 Beckson Dickinson 
4 % Paraformaldehyde P6148 Sigma Aldrich 
4’6-diamidine-2-phenylindole (DAPI) D9564 Sigma Aldrich 
50% w/v hydroxylamine 438227 Sigma- Aldrich 
672.3 nm Laser  National Laser Centre 
CaCo-2 Cell line  SS1402 CCAC-FL; 
CCAC-C 
Cellonex 
Amphotericin B A2942 Sigma Aldrich 
Azide S8032 Sigma Aldrich 
Anti-GCC  antibody  122404 Abcam 
Anti-ICAM1 antibody  [MEM-111] AB2213 AC Abcam 
Annexin V/PI apoptosis detection kit 556570 BD Pharmigen 
Biofreezing medium 25 Ml F2270 Biochrom AG 
BSA A2153 Sigma Aldrich 
CellTitreGlo ATP kit G7573 Promega 
Centrifuge tube, 50 mL, PP flat top, sterile, 
bulk 
CR430489 Corning Incorporated 
Coverslips CG88 Lasec 
CytoTox 96® Non-Radioactive Cytotoxicity 
Assay 
G1780 Promega 
Dulbecco’s Modified Eagle Medium D5796 Sigma Aldrich 
EDC N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride ≥99.0%  
03449 Sigma Aldrich 
Eppendorf®, Microtubes Z666521 Sigma Aldrich 
Eppendorf®, Microtubes Z666505 Sigma Aldrich 
Eppendorf®, Microtubes Z666515 Sigma Aldrich 
Ethanol absolute 99.99% 32221 Sigma Aldrich 
Falcon (5ml) Polystyrene round bottom tube BD352054 Beckson Dickinson 
Fluoromount™ Aqueous Mounting Medium  F4680 Sigma Aldrich 
Foetal Bovine Serum 10499-044 Thermo Fisher Scientific 
Formaldehyde Solution  F8775 Sigma Aldrich 
Goat Anti-Mouse IgG H&L (FITC) AB6785 AC Abcam 
Gold nanoparticles AUNPPEG5000-SH-NH MKCB6206 Sigma Aldrich 
Hanks Balances Salt Solution (HBSS) 55021C Sigma Aldrich 
Heavy tin foil 5m x 45 cm 6009652290191 Pick n’ Pay 
Hoechst 33258 Pentahydrate (bis-
benzimide) 10mg 
H211491 Thermo Fisher Scientific 
Latex Gloves large powder free EV/55620 Thermo Fisher Scientific 
L-Glutamine G7513 Sigma Aldrich 
Minimum Essential Medium Eagle with 
Earle’s Salts and sodium bicarbonate, 
without L-glutamine, liquid, sterile filtered, 
suitable for cell culture 
RNBG8606 Sigma Aldrich 
Microplate, 96 well, F-Bottom clear, sterile 
2pcs/bag 
655161 Sigma Aldrich 
Microplate, 96 well, F-Bottom (Chimney 
well), white, lumitrac, high binding, sterile 
10pcs/bag 
665074 Sigma Aldrich 
Microscope slides, frosted one end size 25 
mm x 75 mm 
S8400 Sigma Aldrich 
Mounting medium 10 Ml M1289 Sigma Aldrich 
Sulfo-NHS,  56485 Sigma- Aldrich 
Paraformaldehyde (4%) P6148 Sigma Aldrich 
PBS P4417 Sigma Aldrich 
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Penicillin/Streptomycin P4333 Sigma Aldrich 
Phosphate buffered saline P5493 Sigma Aldrich 
Tissue culture flask 25 cm2, angled neck, 
vent, sterile 
CR/423052 Corning Incorporated 
Tissue culture flask 75 cm2, angled neck, 
vent, sterile 
CR/430641U Corning Incorporated 
Tissue culture flask 175 cm2, angled neck, 
vent, sterile 
CR/431080 Corning Incorporated 
Triton X-100 T9284 Sigma Aldrich 
TrypLETM Select (500 mL) 12563-029 Gibco Invitrogen 
Trypan Blue stain 0.4% T10282 Invitrogen 
Universal fit pipette tips,100-1000 µl,Bulk CR4868 Corning 
WS-1 Cell line Normal Human 
Fibroblasts (WS1 ATCC 
CRL-1502) 
ATCC 
Zinc sulfo tertra phthalocyanine (ZnPcS4) 
powder 
Purchased from Santa Cruz® Biotechnology (sc-





















Appendix D: List of Chemicals, Solutions and Media 
Chemicals, Solutions and Media 
D1 70% (v/v) Ethanol (100 ml) Absolute Ethanol  70 ml 
Distilled Water  30 ml 
D2 200 µg/mL Anti-GCC  (working solution) Anti-GCC  457.7ug/ml  300ul 
0.001 M PBS D3 0.69ml 
D3 0.001 M PBS (1 L) 10 x 0.1 M PBS  1 ml 
Sterilized Distilled water  99 ml 
D4 Suspension Stock 0.0005 M ZnPcS4 
• Weigh off 0.0006g of ZnPcS4 
powder (or 0.0012g) 
• Add 1.25ml of 0.001M PBS and mix 
well (or 2.5ml) 
• Store at room temp. and wrap in tin 
foil due to light sensitivity = ZnPcS4 
Stock of 0.0005M (E6) 
ZnPcS4 powder 
molar mass: 898.15 g/mol 
 0.0006 g 
0.001 M PBS  D3 1.25 ml 
D5 Working Stock 0.000125 M or 125 µM 
ZnPcS4 
• Take 1ml of ZnPcS4 Stock of 
0.0005M and add 4ml 0.001M PBS 
and mix well to make 0.000125 M or 
125 µM 
• The following calculation was done: 
C1V1 = C2V2 
(X) (4ml) = (0.0005 M of ZnPcS4) (1 ml) 
X = 0.000125 M = 125 µM (E6) 
Suspension Stock 0.0005 
M ZnPcS4 
 1ml 
0.001 M PBS  D3 4ml 
D6 50% (w/v) Hydroxylamine Quencher Hydroxylamine  5 µg 
0.001 M PBS D3 10 µl 
D7 Complete CaCo-2 Cell Growth Medium 
(500 ml) 
DMEM - Dulbecco’s 
Modified Eagle Medium 
 500 ml 
15% Foetal Bovine Serum  75 ml 
0.1% Penicillin-
Streptomysin 
 500 µl 
0.1% Amphotericin β  500 µl 
D8 Complete WS1 Cell Growth Medium 
(500 ml) 
MEM- Minimum Essential 
Media   
 500 ml 
10% Foetal Bovine Serum  50 ml 
1% Penicillin-Streptomysin  5 ml 
1% Amphotericin β  5 ml 
2% L-glutamate  10 ml 
1% Sodium pyruvate  5 ml 
1% Non-essential amino 
acids 
 5 ml 
D9 0.01 M PBS (100 ml) 10 x 0.1 M concentrate 
PBS 
 10 ml 
Sterilized Distilled water  90 ml 
D10 3.7% Formaldehyde Solution  Formalin  3.7 ml 
Sterilized Distilled water  96.3 ml 
D11 PBS BSA Sodium Azide Buffer (100 ml) 0.01 M PBS D9 100 ml 
Bovine Serum Albumin 
(BSA) 
 1 g 
Sodium Azide  0.01 g 
Note: filter sterilize   
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D12 2 µg/ml ICAM -1 Mouse Monoclonal 
IgG1 Antibody (working solution of 
1:500 dilution)   
 
1000 µg/ml ICAM -1 
Mouse Monoclonal IgG1 
Antibody (ab2213) 
 1 µl 
PBS BSA Sodium Azide 
Buffer 
D9 499 µl 
D13 5 µg/ml Goat Anti-Mouse IgG Antibody 
(working solution of 1:400 dilution) 
2000 µg/ml Goat Anti-
Mouse IgG Antibody 
(ab6785) 
 1 µl 
PBS BSA Sodium Azide 
Buffer 
D9 399 µl 
D14 Stock Solution: 1.0 mg/ml 40-6-




 0.001 g 
Sterilized Distilled water  1 ml 
Note: light sensitive   
D15 Working solution: 1 µg/ml 40-6-
Diamidino-2-phenylindole (DAPI) 
1.0 mg/ml 40-6-Diamidino-
2-phenylindole (DAPI) or 
1000 µg/ml 
D14 1 µl 
Sterilized Distilled water  1 ml 
Note: light sensitive   
D16 20% Fluoromount® Aqueous Mounting 
Medium (10 ml) 
Fluoromount® Aqueous 
Mounting Medium 
 2 ml 
Distilled water  8 ml 
D17 ATP CellTiter-Glo® Luminescent 
Solution 
CellTiter-Glo® Buffer  10 ml 
CellTiter-Glo® Substrate  0.07 g 
Note: this is enough 
solution to run 200 assays 
  
D18 LDH CytoTox 96® Non-Radioactivity 
Solution 
CytoTox 96® Substrate mix  0.012 g 
CytoTox 96® Assay buffer  1.2 ml 
Note: this is enough 
solution to run 20 assays 
  
D19 1x (v/v) Binding Buffer (18.7 ml) 10 x concentrated Binding 
Buffer 
 1.7 ml 
Sterilized Distilled water  17 ml 
D20 Reconstituted Propidium Iodide Staining 
Solution (1 ml) 
Powdered Propidium 
Iodide  
 250 µg 
1 x (v/v) Binding buffer D19 1 ml 





 0.001 g 













Appendix E: Calculations 
E.1 Calculation of Inoculum for Cell Culture Flasks  
• For instance if the Countess II FL Automated Cell Counter (E8) identified a total of 5.0 
x 105 viable cells/ml from the cell pellet resuspended in 10 ml of complete cell culture 
media, and perhaps the recommended inoculum for CaCo-2 cells is 1x105 viable 
cells/ml in a 75 cm2 cell culture, the following calculation would be performed: 
• Viable cells (cells/ml) x re-suspension volume = Total viable cells 
• Seeding Ratio ÷ Total viable cells = cellular re-suspension  
• Cellular re-suspension x flask size = total cellular re-suspension  
• 500000cells/ml x 10 ml = 5000000 cells / 10ml 
• 1x 105 cells/ml ÷ 50000000 cells / 10ml = 0.02 ml 
• 0.02 ml x 75 cm2 = 1.5 ml 
• Therefore, you would remove 1.5 ml from the 10 ml of cellular re-suspension, and 
inoculate it into the 75 cm2 cell culture flask that contains freshly prepared cell culture 
media to cover the surface area of the base of the flask, to attain a 1x 105 cells/ml 
seeding ratio. 
E.2 Calculation for Seeding of Cell Culture Plates   
The seeding density of cells in a cell culture plate prior to PDT experimentations differs with 
cell lines. An optimum seeding density is always calculated as to ensure specific number 
of cells was available for biochemical assays after irradiation. The amount used to seed 
colon cancer (CaCo-2) cells was 6 x 105 cells/ ml in a 3.4 cm diameter cell culture dish, 
which contained 3ml culture media. 
The calculation is illustrated below: 
o Total viable cells (E9) 5 x 107/ 6x 105 = 83 
o Cell suspension of 10 ml/ 83 = 0.120 ml 
Therefore 0.120 ml of the cells were removed and inoculated into a culture plate and 
enriched with 2.88 ml of complete media (D6), to make the total volume of complete culture 
media 3 ml.  
E.3  Calculation of Cell Seeding for Cryopreservation  
• For instance If the Countess II FL Automated Cell Counter (E8) reported that the total 
viable cells was 5.2 x 106 cells/ml, after re-suspending the cell pellet in 2 ml of complete 
cell culture media and you wanted to cryopreserve cells with a seeding ratio of 2 x 106 
cells per 2 ml, the following calculation would be performed: 
o Viable cells (cells/ml) x re-suspension volume = Total viable cells 
o Total viable cells ÷ Seeding Ratio = amount of cryovials that can be made  
o Re-suspension ÷ amount of cryovials = cellular re-suspension per vial 
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o 5200000 cells/ml x 2ml = 10400000 cells / 2 ml 
o 10400000 cells / 2 ml ÷ 2x 106 cells/ 2 ml = 5.2 cryovials 
o 2 ml ÷ 5.2 = 0.385 ml of re-suspension per vial 
Therefore, from the cellular re-suspension, you would remove 0.385 ml and pipette it 
into a cryovial that contains 1.615 ml of cell freezing medium to obtain a 2 x 106 cells 
per 2 ml seeding ratio. 
E.4  Laser Irradiation Duration of Exposure Calculation for Diode Laser 
• The laser parameters of the 673 nm diode laser are listed below: 
Name and Type Semiconductor (Diode) 
Wavelength 673 nm 
Spectrum Red (Visible) 
Pulsed or Continuous Continuous wave (CW) 
Average Output 75 mW 
Spot Area 36.31681001 cm2 
Spot Radius 3.39999995 cm2 
Energy Density 10 J/cm2 
Number of exposures 1 exposure 24 hours after seeding plates 
Duration of exposure 16 minutes and 8 seconds 
 
• The average output power of the 673 nm diode laser was measured using a power 
meter. 
• The output power of the 673 nm diode laser ranged from 70 mW to 80 mW, thus the 
average output power was determined to be 70 mW 
• The following formula was used to calculate laser irradiation time:  
 
• Therefore, to determine the laser irradiation time for the 673 nm diode laser the 
fluence that was used was 10 J/cm2 and the output power of the laser on the day of 
irradiation was 75 mW, this output was then multiplied by 1.25 as this is specific to 
the laser, the following example was used. 
(93.75 mW x 4) ÷ 36.31681 = 10.3257968 mW/cm2 
10.3257968 mW/cm2 ÷ 1000 = 0.0103257968 W/cm2 
10 J/cm2 ÷ 0.0103257968 W/cm2 = 968.448 seconds 
968.448 seconds ÷ 60 = 16 minutes 
16 minutes x 60 = 960 seconds 
968.4 – 960 = 8 seconds   
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Therefore, the average laser time was 16 minutes and 8 seconds. 
E.5  Preparation & Calculation of Photosensitizer Volume ZnPcS4 
Preparation  
• ZnPcS4 suspension concentration: 0.0005 M (D4): 
o Molar Mass = 898.15g/mol 
o n = m/M = 0.0006g / 898.15g/mol = 0.0000006mol 
o C = n/V = 0.0000006mol / 0.00125L (1.25ml 0.001M PBS) = 0.00048M = 
0.0005M (stock) 
o Thus, to make up 0.0005M ZnPcS4 solution, weigh off 0.0006g of ZnPcS4 
powder  and add 1.25ml of 0.001M PBS and mix well  
o Store at room temp. and wrap in tin foil due to light sensitivity 
• ZnPcS4 working stock concentration: 0.000125 M or 125 µM (D5): 
o Dilute 0.0005 M ZnPcS4 stock solution to utilize at different concentrations i.e. 
using C1V1 = C2V2 formula 
o The following calculation was done: 
o C1V1 = C2V2 
o (X) (4ml) = (0.0005 M of ZnPcS4) (1 ml) 
o X = 0.000125 M = 125 µM 
o Take 1ml of 0.0005 M ZnPcS4 stock and add 4ml 0.001M PBS and mix well to 
make 0.000125 M or 125 µM 
• Calculation of Required ZnPcS4 PS Concentrations for PDT Dose Response Assays: 
o ZnPcS4 PDT dose response concentrations to add to CRC cells: 0.0312, 0.0625, 
0.125 and 0.25 µM 
o Eg: ZnPcS4 working stock concentration: 0.000125M and you want a concentration 
of 0.125 µM in 3ml cell culture media. 
o C1V1 = C2V2 
o (125 µM of ZnPcS4) (X) = (0.125 µM of ZnPcS4) (3 ml of growth medium) 
o X = 0.003 ml x 1000 = 3 µl 
o Therefore 3 µl of the stock solution of 125 µM ZnPcS4 PS was added to the cell 
culture plate which contained 2997ul of relevant complete growth culture medium 
to make the final volume of 3ml. 
PS Conc (M) PS Conc (uM) *Vol PS to 3 ml culture media 
0.000 0000312M 0.0312 µM 0.75 µl of PS to 2999.25 µl culture media 
0.000 0000625M 0.0625 µM 1.5 µl of PS to 2998.5 µl culture media 
0.000 000125M 0.125 µM 3 µl of PS to 2997 µl culture media 
0.000 00025M 0.25 µM 6 µl of PS to 2994 µl culture media 
E.6 Final Targeted PS Nanoconjugate Calculation 
The molecular characterization results noted that the final actively targeted PS 
nanoconjugate (ZnPcS4 – AuNP-PEG5000-SH-NH2 - Anti-GCC Ab) consisted of 30.91 
µg/ml of Anti-GCC Ab, which was successfully bound to 0.95 X 1015 AuNP-PEG5000-SH-
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NH2 particles/ml and on average 0.000035 M / 35 uM of ZnPcS4 in 0.001 M PBS (w/v) 
(Section 4.5.5). Therefore, the ZnPcS4 PS drug concentration of 0.000035 M / 35 uM, when 
bound to control ZnPcS4 -AuNP-PEG5000-SH-NH2 and the experimental synthesized final 
molecular drug conjugate (ZnPcS4 – AuNP-PEG5000-SH-NH2 - Anti-GCC Ab) needed to 
be adjusted to a 0.125 µM ZnPcS4 PS PDT (IC50) concentration, with cell culture media 
volume adjustment, when being added to cell culture plates for consistency as shown in 
below. 
Description  Conc (M) Conc (µM) *Vol PS conjugate added to 3 ml culture 
media 
ZnPcS4 PS IC50 0.000 00125M 0.125 µM • C1V1 = C2V2 
• (125 µM of ZnPcS4) (X) = (0.125 µM of 
ZnPcS4) (3 ml of growth medium) 
• X = 0.003 ml x 1000 = 3 µl 
• Therefore 3 µl of the stock solution of 125 
µM ZnPcS4 PS was added to the culture 
plate which contained 2997ul of relevant 
complete growth culture medium in order 
to acquire a working concentration of 
0.125 µM of ZnPcS4 PS. 
ZnPcS4 - AuNP 0.000 00125M 0.125 µM ZnPcS4 bound to AuNPs synthesized stock 
concentration was 0.0000555 M / 56 uM and a 
concentration of 0.000 00125M / 0.125 uM in 3 
ml cell culture media was needed to meet IC50 
criteria; 
• C1V1 = C2V2 
• (0.125uM final) (3 ml) = (56uM stock) (X) 
• X = 0.0067 ml x 1000 = 6.7 µl 
• Thus add 6.7 µl of 0.0000555 M / 56 uM of 
ZnPcS4 bound to AuNPs synthesized stock 
concentration to 2993.3 ul of cell culture 




0.000 00125M 0.125 ZnPcS4 final molecular conjugate or just bound 
to AuNPs synthesized stock concentration was 
0.000035 M / 35 uM and a concentration of 
0.000 00125M / 0.125 uM in 3 ml cell culture 
media was needed to meet IC50 criteria: 
• C1V1 = C2V2 
• (0.000 00125 M final) (3 ml) = (0.000035 M 
stock) (X) 
• X  = 0.0107 ml x 1000 = 10.71 µl 
• Thus add 10.71 µl of 0.000035 M / 35 uM 
ZnPcS4 final molecular conjugate stock to 
2989.29 ul of cell culture media to get 
0.125 µM IC50 concentration. 
Note: ZnPcS4 final molecular conjugate synthesized stock concentration was 0.000035 M / 35 uM 
and a concentration of 0.000 00125M / 0.125 uM of ZnPcS4 in 3 ml cell culture media was needed 
to meet IC50 criteria; 
• 35uM / 0.125uM = 280-fold dilution 
• ZnPcS4 final molecular conjugate synthesized stock concentration was 0.000035 M of 
ZnPcS4  bound to 30.91 µg/ml of Anti-GCC Ab, which was successfully bound to 0.95 X 
1015 AuNP-PEG5000-SH-NH2 particles/ml and this 280 fold affects diluted Anti-GCC Ab 
to 0.11 µg/ml bound to 3.39 X 1012 AuNP-PEG5000-SH-NH2  
E.7 Calculation of Working Concentration of 20 µg/ml Hoechst Working 
Solution from Stock Concentration of 1.0 mg/ml Hoechst 33258 Dye 
• A stock solution of 1.0 mg/ml of Hoechst 33258 Fluorescent Dye was made (D18).  
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• The culture plate contained 1 ml of relevant complete growth media depending on the 
type of cell culture contained within. 
• Therefore, if you wanted to add a working concentration of 20 µg/ml of Hoechst 
Working Solution Stain to this culture plate the Hoechst 33258 Fluorescent Dye Stock 
Solution of 1.0 mg/ml, which is equivalent to 1000 µg/ml, it would have to be diluted. 
o The following calculation was done: 
o C1V1 = C2V2 
o (1000 µg/ml)(X) = (20 µg/ml) (1 ml of growth medium) 
o X = 0.02 ml x 1000 = 20 µl 
• Therefore 20 µl of 1.0 mg/ml Hoechst 33258 Fluorescent Dye Stock Solution was 
added to the culture plate which contained 1 ml of relevant complete growth culture 
medium in order to acquire a working concentration of 20 µg/ml of Hoechst Working 
Solution Stain 
E.8 Cell Viability Calculation 
The formula below was utilized to calculate the percentage % of viable cells for all 
experimental or control groups: 
• Following the addition of 10 µl of suspended cells to 10 µl of 0.4% trypan blue 
solution in 0.5ul eppendorf tube, cells are gently mixed (briefly) and placed in a 
disposable slide for counting on the Countess II FL Automated Cell Counter. The 
Countess II FL Automated Cell Counter has advanced autofocusing and counting 
algorithms which allow quick and accurate cells counts within a population.  
• The amount of dead and alive cells were then calculated automatically per ml using 
this formula: 
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑐𝑐𝑐𝑐𝑇𝑇𝑇𝑇𝑐𝑐 = 𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑐𝑐𝑛𝑛 𝑇𝑇𝑜𝑜 𝑇𝑇𝑙𝑙𝑙𝑙𝑐𝑐 𝑐𝑐𝑐𝑐𝑇𝑇𝑇𝑇 + 𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑐𝑐𝑛𝑛 𝑇𝑇𝑜𝑜 𝑑𝑑𝑐𝑐𝑇𝑇𝑑𝑑 𝑐𝑐𝑐𝑐𝑇𝑇𝑇𝑇𝑐𝑐 
 
𝑃𝑃𝑐𝑐𝑛𝑛𝑐𝑐𝑐𝑐𝑛𝑛𝑇𝑇𝑇𝑇𝑃𝑃𝑐𝑐 𝑉𝑉𝑙𝑙𝑇𝑇𝑛𝑛𝑙𝑙𝑇𝑇𝑙𝑙𝑇𝑇𝑉𝑉 =  
𝑇𝑇𝑙𝑙𝑙𝑙𝑐𝑐 𝑐𝑐𝑐𝑐𝑇𝑇𝑇𝑇𝑐𝑐
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑐𝑐𝑐𝑐𝑇𝑇𝑇𝑇𝑐𝑐





Appendix F: Publication from Study 
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Appendix G: Simiarity Report Index from Turn It  
 
 
 
 
 
 
